timolol profile

(S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	33624
CHEMBL ID	499
CHEBI ID	9599
SCHEMBL ID	4912
MeSH ID	M0021546

Synonym
BIDD:GT0073
AB00513729-17
BRD-K08806317-050-03-6
gtpl565
PRESTWICK2_000948
BPBIO1_001008
(2s)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
hsdb 6533
timolol gfs
timoptic-xe
timopic
2-propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (s)-
einecs 248-032-6
2-propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (2s)-
NCGC00016038-01
cas-26921-17-5
lopac-t-6394
NCGC00016798-01
tocris-0649
NCGC00022033-02
BSPBIO_000916
PRESTWICK3_000948
LOPAC0_001189
AB00513729
C07141
timolol ,
26839-75-8
(2s)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(s)-1-tert-butylamino-3-(4-morpholin-4-yl-[1,2,5]thiadiazol-3-yloxy)-propan-2-ol
1-(tert-butylamino)-3-[4-(1,4-oxazinan-4-yl)-1,2,5-thiadiazol-3-yloxy]-(2s)-propan-2-ol
(s)-1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol
(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
s-(-)-3-(3-tert-butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole
(2s)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(s)-timolol (anhydrous)
CHEBI:9599 ,
(s)-1-(1,1-(dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(s)-timolol
DB00373
(s)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
timolol anhydrous
NCGC00022033-05
PRESTWICK1_000948
PRESTWICK0_000948
SPBIO_003075
OPREA1_640981
NCGC00022033-04
NCGC00016038-02
HMS2089I11
NCGC00016798-07
CHEMBL499 ,
D08600
timolol (tn)
timolol (inn)
bdbm50292219
NCGC00016798-06
HMS3259C20
(2s)-3-[(tert-butyl)amino]-1-(4-morpholin-4-yl(1,2,5-thiadiazol-3-yl)oxy)propa n-2-ol
tox21_110614
dtxcid203674
dtxsid4023674 ,
cas-26839-75-8
AKOS015969764
NCGC00016798-03
NCGC00016798-09
NCGC00016798-02
NCGC00016798-08
NCGC00016798-05
5jky92s7br ,
unii-5jky92s7br
timololum
timolol [usan:inn]
timolol [mi]
timolol [who-dd]
timolol [hsdb]
timolol [inn]
(s)-1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
2-propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2s)-
NC00592
SCHEMBL4912
tox21_110614_1
NCGC00016798-11
W-107148
Q413994
BRD-K08806317-103-02-5
NCGC00016798-20
EN300-17982937
(2s)-1-(tert-butylamino)-3-{[4-(morpholin-4-yl)-1,2,5-thiadiazol-3-yl]oxy}propan-2-ol
HY-17494
CS-0009238

Excerpt	Reference	Relevance
"5% appeared to be an effective and safe ocular hypotensive agent."	( Timolol maleate: efficacy and safety. Becker, B; Kass, MA; Yablonski, ME; Zimmerman, TJ, 1979)	0.26
" The drug was well tolerated and without serious adverse effects."	( [Efficacy and safety of long-term maintenance treatment with timolol ophthalmic solution in chronic open-angle glaucoma (author's transl)]. Katz, IM, 1979)	0.26
" Double-masked studies will be necessary to clarify the relationship of these adverse effects to the use of timolol."	( Adverse effects experienced by patients taking timolol. Hetherington, J; Hoskins, HD; McMahon, CD; Shaffer, RN, 1979)	0.26
" In this longest chronic administration study to date, MK-927 did not cause adverse ocular or systemic side effects."	( Six week safety study of 2% MK-927 administered twice daily to ocular hypertensive volunteers. Camras, CB; Deasy, D; Framm, L; Lippa, EA; Lustgarten, J; Payne, JE; Podos, SM; Serle, JB, 1992)	0.28
"5% timolol administered once daily are effective and safe in lowering IOP in most patients with ocular hypertension or open-angle glaucoma."	( Efficacy and safety of once-daily levobunolol for glaucoma therapy. Almog, Y; Friedland, BR; Kelley, EP; Lazar, M; LeBlanc, RP; Lee, PF; Mann, C; Novack, GD; Orr, A; Rakofsky, SI, 1989)	0.28
" Adverse experiences requiring cessation of therapy occurred in an additional 10% of patients."	( Levobunolol. A four-year study of efficacy and safety in glaucoma treatment. The Levobunolol Study Group. , 1989)	0.28
" Levobunolol and timolol were similarly effective and safe in reducing intraocular pressure in patients with chronic open-angle glaucoma and those with ocular hypertension."	( [Comparison of the effectiveness and safety of levobunolol and timolol in ocular hypertension and chronic open-angle glaucoma]. Batoosingh, AL; Freyler, H; Menapace, R; Mordaunt, J; Novack, GD; Skorpik, C, 1988)	0.27
" Data submitted to the National Registry of Drug-Induced Ocular Side Effects appear to indicate similar adverse reactions secondary to topical ophthalmic timolol."	( Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. Fraunfelder, FT; Meyer, SM; Shore, JH, 1987)	0.27
" The ocular drugs causing serious adverse ocular or systemic side effects in children include glaucoma medications, corticosteroids, phenylephrine, and the anticholinergic cycloplegics."	( How safe are ocular drugs in pediatrics? Palmer, EA, 1986)	0.27
" The adverse effects of timolol maleate during 6 months of treatment were of transient nature and generally mild."	( A study of the efficacy of two commercial preparations of timolol maleate with special reference to side effects. Palkama, A; Stjernschantz, J; Uusitalo, RJ, 1985)	0.27
"A review of current literary sources disclosed a host of adverse reactions which may potentially be associated with the topical administration of timolol maleate."	( Potential systemic and ocular side effects associated with topical administration of timolol maleate. Trawick, AB, 1985)	0.27
"Timolol maleate, a nonselective beta blocker, has been associated with adverse reactions when administered topically or systemically."	( Side effects of timolol. Baumann, JD; Hetherington, J; Zimmerman, TJ, 1983)	0.27
" Careful selection of patients will reduce the frequency of adverse effects due to beta-receptor inhibition."	( Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta-adrenoreceptor blocking agent. Dunn, FG; Frohlich, ED, )	0.13
"A double-blind crossover study in seven patients with glaucoma and obstructive lung disease revealed a considerable and significant bronchoconstrictive side effect on topically administered timolol maleat."	( [Bronchoconstrictive side effects of timolol eye drops in patients with obstructive lung disease]. Bachofen, H; Flammer, J; Landolt, M; Vonwil, A, 1981)	0.26
" Most adverse effects occurred with levels much higher than would be expected after the topical use of timolol to control glaucoma."	( Potential side effects of timolol therapy in the treatment of glaucoma. Golob, DS; Leader, BJ; Zimmerman, TJ, 1981)	0.26
" Adverse event were reported by 70 out of 89 patients by the end of 2 weeks, but were severe enough only in 11 for the treatment to be discontinued."	( Efficacy and safety of timolol/pilocarpine combination drops in glaucoma patients. Palkama, A; Uusitalo, RJ, 1994)	0.29
"While adverse effects are uncommon in patients who are otherwise fit and well, doctors should be aware of the implications of the systemic effects of these drugs, particularly the non-selective types, and particularly in the elderly."	( The safety of topical beta-blockers in glaucoma treatment. Goldberg, I, 1996)	0.29
" The most significant ocular side effect was increased pigmentation of the iris observed in five and suspected in seven more latanoprost-treated eyes."	( Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Alm, A; Stjernschantz, J, 1995)	0.29
"The review is based on a survey of studies on adverse reactions related to topical administration of beta-blockers for glaucoma."	( [Adverse effects of local use of beta-blockaders in glaucoma. A literature review and a survey of reports to the adverse drug reaction authority 1986-95]. Høvding, G; Nygaard, HA, 1997)	0.3
" It was concluded that switching from timolol maleate to timolol hemihydrate is safe and effective in maintaining control of the intraocular pressure."	( The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. Cate, EA; Mundorf, TK; Otero, DW; Sine, CS; Stewart, JA; Stewart, WC, 1998)	0.3
" Burning and/or stinging on instillation were the only adverse experiences that affected significantly more of the patients receiving 2% dorzolamide twice or three times daily than those receiving placebo."	( The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group. Adamsons, I; Clineschmidt, C; Laibovitz, R; Polis, A; Shedden, A; Taylor, J, 1998)	0.3
" Monotherapy with xalathane is safe sufficiently effective, and comparable to combined therapy with timolol and pilocarpine."	( [Xalathane: comparative assessment of efficacy and safety in hypotensive therapy of glaucoma]. Erichev, VP; Iakubova, LV, )	0.13
" The treatment groups were generally comparable in terms of adverse events, symptoms, ocular signs, visual acuity, visual fields, physical examination, and laboratory measures."	( The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Adamsons, I; DuBiner, H; Snyder, E; Strohmaier, K, 1998)	0.3
" The incidence of the most common drug-related adverse experiences in the first year was compared with that in the second year using McNemar's test."	( Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. Adamsons, IA; Boyle, JE; Ostrov, CS; Polis, A, 1998)	0.3
" Of the patients who received dorzolamide as monotherapy, drug-related adverse events occurred more frequently during the first year (29."	( Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. Adamsons, IA; Boyle, JE; Ostrov, CS; Polis, A, 1998)	0.3
" Drug-related adverse events were less frequent during the second year of monotherapy than during the first year."	( Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. Adamsons, IA; Boyle, JE; Ostrov, CS; Polis, A, 1998)	0.3
" Both combination and concomitant therapy were well tolerated and few patients discontinued due to adverse effects."	( Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Adamsons, I; Hutzelmann, J; Owens, S; Shedden, A; Vargas, E, 1998)	0.3
" The treatment groups were generally comparable in terms of adverse events, symptoms, ocular signs, visual acuity, visual fields, physical examination, and laboratory measures."	( The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Adamsons, I; DuBiner, H; Snyder, E; Strohmaier, K, 1999)	0.3
" No differences were observed between treatments in visual acuity, anterior segment findings, or adverse events."	( Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Day, DG; Dubiner, HB; Holmes, KT; Sharpe, ED; Stewart, JA; Stewart, WC, 1999)	0.3
" in vitro toxic effects of antiglaucoma drugs could, in part, explain some ocular surface disorders in long-term treated patients."	( Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Baudouin, C; Brignole, F; De Saint Jean, M; Debbasch, C; Rat, P; Warnet, JM, 2000)	0.31
" One hundred forty-four patients were discontinued from the study after randomization with the most common reasons being the occurrence of an adverse event (46), inadequate intraocular pressure control (23), patient decision unrelated to study medication (11), lost to follow-up (16), and noncompliance (9)."	( The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March, WF; Ochsner, KI, 2000)	0.31
" Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort."	( The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March, WF; Ochsner, KI, 2000)	0.31
" Both drug regimens appeared to be safe and were well tolerated."	( Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. David, R; Melamed, S, 2000)	0.31
" In vitro toxic effects of antiglaucoma drugs could, in part, explain some ocular surface disorders in long-term treated patients."	( [Toxicity of preserved and unpreserved beta-blocker eyedrops in an in vitro model of human conjunctival cells]. Baudouin, C; Brignole, F; de Saint Jean, M; Debbasch, C; Rat, P; Warnet, JM, 2000)	0.31
" Study subjects within medication treatment groups were classified as to their use or nonuse of concurrent systemic beta-blockers, and mean intraocular pressure (IOP) reduction, adverse events, heart rate, and blood pressure were compared."	( Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Schuman, JS, 2000)	0.31
" Adverse events and mean changes in heart rate and blood pressure from baseline were the primary safety variables."	( Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Schuman, JS, 2000)	0.31
" The majority of adverse events during both treatments were judged as mild."	( Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group. García Sanchez, J, )	0.13
" Safety parameters included adverse events, hyperemia grading, laser flare meter analysis, heart rate, and blood pressure."	( Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Batoosingh, A; Cheetham, J; David, R; Felix, C; Laibovitz, RA; Rosenthal, A; VanDenburgh, AM, 2001)	0.31
" All treatment regimens were safe and well tolerated, with no clinically significant effects on heart rate or blood pressure and no between-group differences in the incidence of adverse events."	( Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Batoosingh, A; Cheetham, J; David, R; Felix, C; Laibovitz, RA; Rosenthal, A; VanDenburgh, AM, 2001)	0.31
" AGN 192024 was safe and well tolerated, and it provided superior ocular hypotensive efficacy and diurnal IOP control compared with timolol in patients with ocular hypertension and glaucoma."	( Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Batoosingh, A; Cheetham, J; David, R; Felix, C; Laibovitz, RA; Rosenthal, A; VanDenburgh, AM, 2001)	0.31
" The side effect profile of unoprostone appears to be comparable to other established IOP-lowering agents."	( A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Kapik, B; Mertz, B; Nordmann, JP; Schwenninger, C; Shams, N; Yannoulis, NC, 2002)	0.31
"From this preliminary study, immediate paracentesis seems to be safe and effective in controlling the intraocular pressure and eliminating symptoms in acute PACG."	( Efficacy and safety of immediate anterior chamber paracentesis in the treatment of acute primary angle-closure glaucoma: a pilot study. Chua, JK; Lai, JS; Lam, DS; Tham, CC, 2002)	0.31
"25% drops in twice daily dosage and does not result in any significant ocular and systemic adverse effects."	( A prospective, long-term, randomized study of the efficacy and safety of the drug combination pilocarpine 1% with clonidine 0.06% or clonidine 0.125% versus timolol 0.25%. Agarwal, H; Rajashekhar, YL; Sihota, R; Venkatesh, P, 2002)	0.31
" Both treatments were well tolerated with no statistically significant difference between the groups in the occurrence of ocular or systemic adverse events."	( Timolol 0.1% gel (Nyogel 0.1% once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Elena, PP; Morel-Mandrino, P; Polzer, H; Rouland, JF; Sunder Raj, P, )	0.13
" Most adverse effects associated with IOP-lowering medications are mild and ocular in nature; however, several of them are associated with systemic risks as well as serious ocular effects, especially following chronic use."	( Short- and long-term safety of glaucoma drugs. Schuman, JS, 2002)	0.31
" Demographic data, reduction of IOP, safety and adverse events were obtained and analyzed."	( The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. Chen, MJ; Chou, JC; Hsu, WM; Liu, JH, 2003)	0.32
"0% patients in timolol group reported mild adverse events."	( The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. Chen, MJ; Chou, JC; Hsu, WM; Liu, JH, 2003)	0.32
" It has a safe systemic profile with minimum effect on the heart."	( The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. Chen, MJ; Chou, JC; Hsu, WM; Liu, JH, 2003)	0.32
" Safety evaluation was carried out, and number of adverse events in each treatment group did not differ substantially."	( A six-week, parallel, randomized, double-blind study comparing the efficacy and safety of the 0.5% timolol/2.0% MK-507 combination b.i.d. to the concomitant administration of 0.5% timolol b.i.d. and 2.0% MK-507 b.i.d. Chen, YF; Hung, PT; Yang, CH, 2003)	0.32
" Adverse events were recorded at each visit."	( Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Feldman, RM; Sheu, WP; Shin, DH, 2004)	0.32
" The study medications were generally well tolerated and no serious adverse reactions occurred during the 6-week study period."	( Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. Chen, YF; Huang, JY; Hung, PT; Shieh, JW; Wang, TH, 2004)	0.32
" The most common reason to discontinue therapy was lack of efficacy (n = 70, 4%) and adverse event (n = 17, 1%)."	( Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Beausencourt, E; Hamacher, T; Jütte, M; Lorger, C; Maier, H; Neff, HM; Schinzel, M; Schlaffer, G; Scholz, R; Schölzel-Klatt, A; Stewart, WC, 2004)	0.32
" Adverse events were recorded at each visit."	( Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Castillo, A; Fernandez-Vidal, A; Garcia-Feijoo, J; Garcia-Sanchez, J; Martinez-de-la-Casa, JM; Mendez-Hernandez, C, 2004)	0.32
" The most common adverse event with LTFC was conjunctival hyperemia, which occurred in patients not previously treated with latanoprost therapy (N=16, 10%)."	( Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. Bányai, L; Blask, KD; Konstas, AG; Kozobolis, VP; Maloutas, S; Stewart, WC; Teus, MA; Trüb, PR; Tsironi, S; Väth, J, 2004)	0.32
" The adverse event profile for Trav/Tim was comparable to Trav or Tim alone."	( The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Barnebey, HS; Bergamini, MV; Flowers, BE; Landry, TA; Mallick, S; Orengo-Nania, S; Samples, J, 2005)	0.33
" The clinical results that Trav/Tim was safe and well tolerated with an incidence of adverse events was comparable to the results of Trav or Tim alone."	( The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Barnebey, HS; Bergamini, MV; Flowers, BE; Landry, TA; Mallick, S; Orengo-Nania, S; Samples, J, 2005)	0.33
" The most frequent ocular adverse event was hyperemia that occurred in 14."	( Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Bergamini, MV; Henry, JC; Katz, GJ; Landry, TA; Lewis, RA; Mallick, S; Robertson, SM; Schuman, JS; Sullivan, EK; Wells, DT, 2005)	0.33
" The most important adverse events for the prostaglandin derivatives were conjunctival hyperemia, eyelashes pigmentation and growth, iris pigmentation."	( Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Antohi, I; Chiseliţă, D; Danielescu, C; Medvichi, R, 2005)	0.33
"To assess in vivo the corneal epithelial damage caused by a topical toxic medication using a 60-MHz ultrasound device."	( [In vivo assessment of corneal epithelial toxicity of timolol with benzalkonium chloride using very-high-frequency ultrasound imaging]. Arbeille, B; Denoyer, A; Fetissof, F; Ossant, F; Patat, F; Pisella, PJ, 2006)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Both volunteered and elicited reports of adverse events were collected; all patients who were randomized and received > or =1 dose of study drug were included in the safety analysis."	( A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Cunliffe, IA; Franks, WA; Renard, JP; Rojanapongpun, P, 2006)	0.33
" Adverse events related to therapy were mild in nature, and there were no statistically significant differences between the 2 treatment groups."	( A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Cunliffe, IA; Franks, WA; Renard, JP; Rojanapongpun, P, 2006)	0.33
" There was no significant difference for any adverse event between groups (p>0."	( The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Berta, A; Chiselita, D; Cvenkel, B; Holló, G; Izgi, B; Liehneova, I; Petkova, N; Stewart, WC; Szaflik, J; Turacli, E, )	0.13
" Treatment-related adverse events were mild in both groups."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.13
"5% fixed combination ophthalmic solution is an effective treatment for reducing IOP and it is safe and well-tolerated in patients with OAG or OH."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.13
"Cataract surgery with PPCCC was safe in terms of the postoperative IOP course."	( Intraocular pressure rise after primary posterior continuous curvilinear capsulorhexis with a fixed dorzolamide-timolol combination: randomized safety study with intraindividual comparison using an angulated and a nonangulated intraocular lens. Buehl, W; Georgopoulos, M; Heinzl, H; Menapace, R; Rainer, G; Wirtitsch, MG, 2007)	0.34
" There were 116 predominantly mild, nonserious adverse events attributed to the study drugs, reported by 86 (24."	( Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Bastien, NR; Koulis, T; Lesk, MR; Sampalis, F; Sampalis, JS, 2008)	0.35
"In patients with primary open-angle glaucoma or ocular hypertension and elevated IOP while on monotherapy with latanoprost, switching to dorzolamide-timolol or combining dorzolamide-timolol with latanoprost are effective and safe treatment options for reducing IOP and achieving therapeutic response."	( Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Bastien, NR; Koulis, T; Lesk, MR; Sampalis, F; Sampalis, JS, 2008)	0.35
" As systemic adverse events, there was one instance of malar flushing after brinzolamide addition and episodes of chest discomfort after timolol addition in 1 patient."	( Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. Ito, K; Matsunaga, K; Miura, K; Okawa, C; Sugimoto, K; Uji, Y, )	0.13
"VHF ultrasound imaging allowed quantitative measurement of corneal epithelium thickness and qualitative imaging of toxic epithelial damage."	( Very-high-frequency ultrasound corneal imaging as a new tool for early diagnosis of ocular surface toxicity in rabbits treated with a preserved glaucoma drug. Arbeille, B; Denoyer, A; Fetissof, F; Ossant, F; Patat, F; Pisella, PJ; Pourcelot, L, 2008)	0.35
" There was no statistical difference for any individual adverse event between treatments (p>0."	( Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. Ahmad, A; Mulaney, J; Sonty, S; Stewart, JA; Stewart, WC, )	0.13
" Safety measures included adverse events, biomicroscopy, ophthalmoscopy, visual acuity and visual field."	( Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Batoosingh, AL; Cohen, JS; Gross, RL; Liu, CC; Safyan, E; Williams, RD, 2008)	0.35
" No safety concerns developed during long-term bimatoprost treatment; two patients in the timolol treatment group discontinued after month 36 because of adverse events."	( Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Batoosingh, AL; Cohen, JS; Gross, RL; Liu, CC; Safyan, E; Williams, RD, 2008)	0.35
"We review available evidence regarding the efficacy and side effect profile of brimonidine as well as its role in glaucoma management."	( Efficacy, safety, and current applications of brimonidine. Batiste, C; Fudemberg, SJ; Katz, LJ, 2008)	0.35
"Latanoprost is safe and equally effective to a fixed combination of dorzolamide and timolol in the treatment of uveitic glaucoma."	( Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Chalkidou, S; Georgopoulos, G; Halkiadakis, I; Kostakou, A; Markomichelakis, NN; Papakonstantinou, D, 2009)	0.35
" Tolerability was measured using a 4-step scale (excellent, good, moderate, poor) and all adverse events were recorded."	( Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Buchholz, P; Feuerhake, C; Kimmich, F, 2009)	0.35
" Few adverse events occurred during the treatment period."	( Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Buchholz, P; Feuerhake, C; Kimmich, F, 2009)	0.35
"5% was effective, well tolerated, and safe in a broad patient population."	( Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Buchholz, P; Feuerhake, C; Kimmich, F, 2009)	0.35
" Adverse events were recorded at each visit."	( Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Grunden, JW; Kwok, K; Miglior, S, 2010)	0.36
" Ocular and systemic adverse events were recorded."	( Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. Alm, A; Grunden, JW; Kwok, KK, )	0.13
"1% experienced a serious adverse event."	( Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. Alm, A; Grunden, JW; Kwok, KK, )	0.13
" The fixed combination is safe and well tolerated for long-term treatment in patients with open-angle glaucoma or ocular hypertension."	( Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. Alm, A; Grunden, JW; Kwok, KK, )	0.13
" The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11."	( Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Bae, K; Iwamoto, Y; Kitazawa, Y; Kotake, S; Sasaki, N; Smith, P, 2011)	0.37
"To evaluate whether transformation of the naso-lacrimal passage as happens after dacryocystorhinostomy (DCR) operation has any effect on the systemic adverse effects of topically administered timolol maleate."	( Effect of dacryocystorhinostomy on systemic adverse effects of topical timolol maleate. Baral, BK; Biswas, S; Chakraborty, S; Mondal, KK; Ray, B; Roy, K, )	0.13
"001% BAC) was the least toxic in our experimental conditions."	( Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets. Aihara, M; Amano, S; Araie, M; Kimakura, M; Miyata, K; Mori, Y; Nakagawa, S; Omichi, S; Usui, T; Yokoo, S, 2012)	0.38
"001% or lower or non-BAC preservative sofZia was suggested to be the least toxic to the ocular surface."	( Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets. Aihara, M; Amano, S; Araie, M; Kimakura, M; Miyata, K; Mori, Y; Nakagawa, S; Omichi, S; Usui, T; Yokoo, S, 2012)	0.38
" The most frequent treatment-related adverse events were conjunctival hyperemia in the travoprost/timolol group, and dry eye and foreign body sensation in the dorzolamide/timolol group."	( Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension. Andreić, V; Babić, N; Grković, D; Jovanović, P; Miljković, A, )	0.13
" Adverse events were collected and slit-lamp examinations were performed to assess safety."	( Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chen, X; Dong, Y; Fang, A; Hu, Y; Ling, Z; Liu, D; Sun, W; Sun, X; Wang, Y; Xing, Y; Ye, J; Yin, Z; Zhang, M, 2014)	0.4
" Adverse events occurred in 26."	( Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chen, X; Dong, Y; Fang, A; Hu, Y; Ling, Z; Liu, D; Sun, W; Sun, X; Wang, Y; Xing, Y; Ye, J; Yin, Z; Zhang, M, 2014)	0.4
" Patients with ocular adverse events were evenly distributed in both groups."	( Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. Antón López, A; Holló, G; Hommer, A; Ropo, A, 2014)	0.4
" However, its improved adverse effect profile seems to be beneficial in patients sensitive to preservatives."	( Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Lorenz, K; Pfeiffer, N, 2014)	0.4
"7 ng/ml, which can cause systemic adverse effects in patients at risk."	( Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops. Backman, JT; Kautiainen, H; Mäenpää, J; Neuvonen, M; Neuvonen, PJ; Niemi, M; Volotinen-Maja, M, 2014)	0.4
" In the TS, related ocular adverse events (AEs) were more frequent for patients treated with FC compared to TIM (16."	( A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Astakhov, Y; Boiko, E; Liinamaa, J; Lorenz, K; Pfeiffer, N; Ropo, A; Saarela, V; Traverso, CE; Uusitalo, H, 2014)	0.4
" Overall, the study treatments were safe and well tolerated."	( A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Astakhov, Y; Boiko, E; Liinamaa, J; Lorenz, K; Pfeiffer, N; Ropo, A; Saarela, V; Traverso, CE; Uusitalo, H, 2014)	0.4
" Intraocular pressure (IOP), adverse events, and ocular/systemic safety variables were also evaluated."	( Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Ikäheimo, K; Kaarniranta, K; Mannermaa, E; Ropo, A, 2016)	0.43
" There were no serious adverse effects."	( Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. Cheng, C; Gong, H; Li, G; Li, YX; Wang, XK; Xu, DP, 2015)	0.42
" Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70%."	( Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients. Kim, CY; Kim, HK; Kim, JM; Kim, TW; Park, KH, 2016)	0.43
"Both LT and TT are safe and effective for the treatment of OHT associated with uveitis and greater IOP reduction may be achieved by TT than by LT treatment."	( Evaluation of Efficacy and Safety of Latanoprost/Timolol versus Travoprost/Timolol Fixed Combinations for Ocular Hypertension Associated with Uveitis. Kanda, T; Mine, I; Sakurai, Y; Shibata, M; Taguchi, M; Takeuchi, M, 2017)	0.46
" Ophthalmic timolol may cause serious adverse effects such as symptomatic bradycardia, various conduction disorders in the heart, orthostatic hypotension, syncope and falls."	( Cardiac safety of ophthalmic timolol. Mäenpää, J; Pelkonen, O, 2016)	0.43
" Safety was assessed based on the documentation of adverse events."	( Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma. Bell, K; Keicher, A; Lorenz, K; Pfeiffer, N; Renieri, G; Ruckes, C; Thieme, H; Wasielica-Poslednik, J, 2017)	0.46
" Safety was assessed with adverse event rates, ocular discomfort score, blur scale, blood pressure and heart rates, best-corrected visual acuity (BCVA) and slit lamp examinations."	( Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Adachi, M; Aihara, M; Fukuchi, T; Matsuo, H; Sasaki, N; Togano, T, 2017)	0.46
" Thus, BTFC can be considered as a safe and effective agent for glaucoma treatment."	( Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Adachi, M; Aihara, M; Fukuchi, T; Matsuo, H; Sasaki, N; Togano, T, 2017)	0.46
" The most common treatment-related adverse events for the travoprost group were ocular hyperemia and eyelash growth."	( A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension. Aljasim, LA; Bradfield, Y; Dixon, ER; Feldman, R; Gustafson, N; Landry, T; Salem, C; Venkataraman, S, 2017)	0.46
" Travoprost was well-tolerated, and no treatment-related systemic adverse events were reported."	( A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension. Aljasim, LA; Bradfield, Y; Dixon, ER; Feldman, R; Gustafson, N; Landry, T; Salem, C; Venkataraman, S, 2017)	0.46
" The present study assessed the response rate and adverse events of topical timolol in the treatment of infantile hemangioma."	( Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. Li, Y; Zheng, L, 2018)	0.48
" Adverse reactions and decreased effectiveness were examined."	( Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil. Inoue, K; Ishida, K; Tomita, G, 2018)	0.48
"0%) participants experienced adverse reactions at 1 and 3 months, respectively."	( Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil. Inoue, K; Ishida, K; Tomita, G, 2018)	0.48
"Treatment changes involving either switching from a PG analog to PG/timolol fixed combination eye drops or adding ripasudil to PG analog therapy were equally safe and effective in reducing IOP."	( Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil. Inoue, K; Ishida, K; Tomita, G, 2018)	0.48
"Uveitis due to brimonidine is a rare adverse effect, but it must be known."	( Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine. Arciniegas-Perasso, CA; Clemente-Tomás, R; Duch-Samper, AM; García-Ibor, F; Hervás-Hernandis, JM; Ruiz-Del Río, N, 2018)	0.48
" The most frequently reported adverse events (AEs) were ocular, with the most frequent ocular AE being conjunctival hyperemia, with an incidence of 61%, 66%, and 14%, respectively."	( Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Heah, T; Kahook, MY; Kim, T; Kopczynski, CC; Mah, FS; Novack, GD; Raizman, MB; Ramirez-Davis, N; Serle, JB; Usner, DW, 2019)	0.51
", tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells."	( Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol. Akaishi, T; Fuwa, M; Kato, M; Mieda, M; Shimazaki, A; Taniguchi, T; Yamashita, N, 2019)	0.51
" Among the reported adverse events, the neuropsychiatric spectrum has been cited, albeit for a small proportion of those treated."	( Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol. Cimolai, N, 2019)	0.51
" We included trials comparingdifferent treatments and reported response or adverse events rate in IH patients."	( The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis. Chen, JJ; Guo, XD; Hu, DL; Shu, Q; Wu, XJ; Xu, S; Xuan, XX; Yang, H; Zhang, H, 2020)	0.56
"5%, with minimal treatment-related serious or systemic adverse events (AEs)."	( Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. Fechtner, RD; Heah, T; Kim, T; Kopczynski, CC; Lewis, RA; McKee, H; Myers, JS; Sheng, H; Singh, IP; Usner, DW, 2020)	0.56
" There are no published guidelines or protocols for use in these indications in adults, and the dermatologic community may not be familiar with adverse events that have been extensively documented relating to its ophthalmic use."	( Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events. Dahle, SE; Gallegos, A; Isseroff, RR; Kaur, R; Schaefer, S; Tchanque-Fossuo, C; West, K; Yang, H; Yoon, DJ, 2021)	0.62
" All treatments had some common adverse ocular effects."	( Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma. Liao, Y; Nie, X; Wang, Y, 2020)	0.56
" Ocular treatment-emergent adverse events occurred in 42."	( Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma. Kim, JM; Lee, JW; Maglambayan, J; Park, KH; Park, SW; Simonyi, S, 2021)	0.62
" Vital signs and adverse effects were recorded at each visit."	( Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial. Baselga, E; Bernabeu-Wittel, J; Gich, I; Montserrat-García, MT; Muñoz-Garza, FZ; Puig, L; Ríos, M; Roé-Crespo, E, 2021)	0.62
" An improvement in color was observed at week 4 in the timolol group, and timolol was well tolerated with no systemic adverse effects."	( Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial. Baselga, E; Bernabeu-Wittel, J; Gich, I; Montserrat-García, MT; Muñoz-Garza, FZ; Puig, L; Ríos, M; Roé-Crespo, E, 2021)	0.62
"Preservative-free topical medications have been introduced for glaucoma care to reduce ocular adverse events associated with preservatives."	( Comparative efficacy and safety of preserved versus preservative-free beta-blockers in patients with glaucoma or ocular hypertension: a systematic review. Azuara-Blanco, A; Freiberg, J; Kolko, M; Rives, AS; Skov, AG; Virgili, G, 2022)	0.72
" Subgroup analysis of adjunctive RKI efficacy and additional review of its major ocular adverse events (AE) were also performed."	( Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials. Chang, SN; Kuo, BI; Lin, JW; Nishida, T; Wu, JH, 2022)	0.72
" Most adverse events (AEs) were mild, and no serious treatment-related AEs were reported."	( Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. Aihara, M; Iwata, A; Kawata, H; Lu, F; Odani-Kawabata, N, 2021)	0.62
" Changes in color, size, bleeding tendency, physicians' and patients' global assessments and adverse events were assessed."	( Effectiveness and safety of 0.5% timolol solution in the treatment of pyogenic granuloma: A randomized, double-blind and placebo-controlled study. Ahmed, SS; Das, NK; Datta, A; Dogra, S; Hazra, A; Kaliyadan, F; Khandpur, S; Mondal, N; Panda, S; Patra, AC; Rahaman, S; Roy, S; Setia, MS; Sil, A, )	0.13
" Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD)."	( Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2). Bacharach, J; Bejanian, M; Belalcázar, S; Chen, MY; Ferguson, G; Goodkin, ML; Guo, Q; Liu, J; Robinson, MR; Tatham, A; Thieme, H; Wirta, DL, 2021)	0.62
"Brimonidine had a similar side effect profile to the fix combination."	( Comparing the effects and safety of dorzolamide hydrochloride + timolol maleate versus brimonidine after neodymium-doped yttrium aluminium garnet laser capsulotomy posterior capsule opacification. Çakmak, K; Erbil, H; Korkmaz, Ş; Mesci, C, 2022)	0.72
" A more conservative random effect model meta-analysis technique was used to analyze the efficacy and adverse reactions of timolol and lasers."	( Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies. Cai, B; Chen, X; Huang, H; Wang, B; Yu, J, 2022)	0.72
" PF FC therapies, such as PF tafluprost/timolol FC, avoid ocular surface exposure to toxic preservative agents and reduce the required number of treatment administrations."	( Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability. Oddone, F, 2022)	0.72

Excerpt	Reference	Relevance
" Applying a theory for translating the pharmacokinetics to the duration-action course of drug, pharmacokinetic t1/2 was proven to be much shorter than pharmacological t1/2."	( Pharmacokinetic differences between single and multiple oral dosing with the guidance for beta-adrenoceptor blockade assessment. Ishizaki, T; Tawara, K, 1979)	0.26
" The poor metaboliser phenotype is associated with increased plasma drug concentrations, a prolongation of elimination half-life and more intense and sustained beta-blockade."	( The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Lennard, MS; Tucker, GT; Woods, HF, )	0.13
"The pharmacokinetic profiles of transdermal timolol 6 and 24 mg (as 5 and 20% w/v patches) was studied in four healthy young volunteers."	( Pharmacokinetics and beta-blocking effects of transdermal timolol. Ishizaki, T; Kikuchi, K; Koyama, E; Kubota, K; Yamada, T, 1993)	0.29
"To develop methods for constructing a pharmacokinetic model to predict the time course of aqueous humor and plasma drug concentrations after topical dosage in rabbits using the simulation program iThink (formerly STELLA; High Performance Systems, Lyme, NH)."	( A model to predict aqueous humor and plasma pharmacokinetics of ocularly applied drugs. Grass, GM; Lee, VH, 1993)	0.29
" A two-compartment pharmacokinetic model was used to fit the aqueous humor level for determining the drainage (kd) and absorption rate constants (ka) in the precorneal area as well as the elimination rate constant (ke) of timolol in aqueous humor."	( Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. Chen, JL; Chiang, CH; Ho, JI, 1996)	0.29
" The Cmax of carteolol (4."	( Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method. Fukuda, S; Kanda, Y; Kiuchi, Y; Koide, R; Oguchi, K; Ohtori, R; Sato, H; Ueda, T, 1998)	0.3
" On the basis of these results, an in vivo pharmacokinetic model was developed for estimation of penetration parameters."	( Characterization of ocular pharmacokinetics of beta-blockers using a diffusion model after instillation. Ichikawa, M; Mukai, T; Nakamura, J; Nakashima, M; Nishida, K; Sasaki, H; Yamamura, K, 1999)	0.3
"The ocular absorption of timolol and tilisolol was characterized using an in vivo pharmacokinetic model and in vivo penetration parameters."	( Characterization of ocular pharmacokinetics of beta-blockers using a diffusion model after instillation. Ichikawa, M; Mukai, T; Nakamura, J; Nakashima, M; Nishida, K; Sasaki, H; Yamamura, K, 1999)	0.3
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
"25%) in terms of in vitro release and IOP lowering pharmacodynamic effect."	( Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Aggarwal, D; Kaur, IP, 2005)	0.33
" Although in the initial 15 min the drug concentrations in AH were comparable to that of the timolol solution, increased Cmax and significantly improved ocular bioavailability were obtained for the gel."	( Pharmacokinetics of timolol in aqueous humor sampled by microdialysis after topical administration of thermosetting gels. Ding, PT; Lu, WY; Wei, G; Zheng, JM, 2006)	0.33
" The correlation between the calculated occupancy of beta-adrenergic receptors and the systemic side effects after instillation could be successfully analyzed with a pharmacokinetic and pharmacodynamic model, showing the predictability of the model for the systemic side effects of timolol."	( Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). Araie, M; Iga, T; Nagahara, M; Ohno, Y; Takayanagi, R; Yamada, Y, 2005)	0.33
" In vitro kinetics and in vivo pharmacokinetic profiles after oral administration of timolol, metoprolol, and propranolol, were investigated in rats using the depletion assay."	( Application of substrate depletion assay for early prediction of nonlinear pharmacokinetics in drug discovery: assessment of nonlinearity of metoprolol, timolol, and propranolol. Iwaki, M; Kawase, A; Komura, H, 2005)	0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"We have constructed a new ocular pharmacokinetic pharmacodynamic (PK/PD) model for anti-glaucoma drugs to describe ocular hypotensive effects on intraocular pressure (IOP) after instillation of a combination of an alpha(1)-adrenergic antagonist, bunazosin, and a beta-adrenergic antagonist, timolol, into rabbits."	( Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs. Higuchi, S; Kawazu, K; Kitahara, T; Nakamura, J; Nakashima, M; Nishida, K; Sakanaka, K; Sasaki, H; Tomonari, M, 2008)	0.35
" Comparative pharmacokinetic-pharmacodynamic studies with four beta blockers were performed in conscious rats, using heart rate under isoprenaline-induced tachycardia as a pharmacodynamic endpoint."	( Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach. Boralli, VB; Danhof, M; de Lange, EC; Freijer, J; Krekels, EH; Slijkerman, P; van Steeg, TJ, 2009)	0.35
"The aim of the present study was to assess the pharmacodynamic equivalence (lowering of intraocular pressure) of two preparations of eye drops containing 20 mg dorzolamide (CAS 120279-96-1) and 5 mg timolol (CAS 26839-75-8)."	( Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers. Demircheva, I; Gatchev, E; Hristova, R; Kolev, E; Koytchev, R; Petrov, A; Richter, W; Tegel, F; Thyroff-Friesinger, U, 2011)	0.37
" In order to investigate the pharmacodynamic equivalence of both products, the two-sided 95% confidence interval was calculated for the difference of the primary target parameter (absolute decrease in IOP 2 h post dose), by means of a parametric (ANOVA) statistical method."	( Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers. Demircheva, I; Gatchev, E; Hristova, R; Kolev, E; Koytchev, R; Petrov, A; Richter, W; Tegel, F; Thyroff-Friesinger, U, 2011)	0.37
"PF FDC demonstrated good IOP-lowering efficacy and displayed similar pharmacokinetic characteristics to the monotherapy agents."	( Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Ikäheimo, K; Kaarniranta, K; Mannermaa, E; Ropo, A, 2016)	0.43
" In vivo pharmacokinetic studies indicated that TM-TSG could enhance absorption of TM in aqueous humor and improve the ocular bioavailability in comparison of commercial TM eyedrops."	( Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study. Chen, J; Huang, J; Huang, Y; Huang, Z; Li, Y; Pan, X; Wu, C; Zeng, Y, 2018)	0.48
" Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6."	( Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. Del Amo, EM; Fayyaz, A; Gardner, I; Heikkinen, EM; Jamei, M; Ranta, VP; Reinisalo, M; Ricci, GD; Toropainen, E; Urtti, A; Vellonen, KS, 2020)	0.56
"Ocular bioavailability after eye drops administration is an important, but rarely determined, pharmacokinetic parameter."	( Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. Del Amo, EM; Fayyaz, A; Gardner, I; Jamei, M; Puranen, J; Ranta, VP; Ruponen, M; Toropainen, E; Urtti, A; Valtari, A; Vellonen, KS, 2020)	0.56

Excerpt	Reference	Relevance
" The effects of timolol alone and in combination with a fixed dose of hydrochlorothiazide and amiloride have been studied in a double-blind, controlled study in fifty-four patients with mild to moderate essential hypertension."	( Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study. Agabiti-Rosei, E; Alicandri, C; Ambrosioni, E; Magnani, B; Miele, N; Muiesan, G, 1976)	0.26
"In 39 selected patients with open-angle glaucoma, in whom pressure regulation with Timolol alone was inadequate, success was achieved by using this drug in combination with various other glaucoma drugs over treatment periods of 12 to 18 months."	( [Timolol in combination with other glaucoma drugs (author's transl)]. Merkle, W, 1981)	0.26
"Once-daily latanoprost treatment provides uniform circadian (around-the-clock) IOP reduction by itself, or in combination with timolol."	( Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Bito, LZ; Gaygi, Z; Nagy, ZT; Rácz, P; Ruzsonyi, MR, 1996)	0.29
"Topically applied 4% timolol, 4% timolol combined with 2% pilocarpine, 6% timolol, and 6% timolol combined with 2% pilocarpine were evaluated in clinically normal Beagles and Beagles with glaucoma."	( Evaluation of multiple doses of 4 and 6% timolol, and timolol combined with 2% pilocarpine in clinically normal beagles and beagles with glaucoma. Gelatt, JK; Gelatt, KN; Larocca, RD; MacKay, EO; Strubbe, DT, 1995)	0.29
"5%, or oral acetazolamide 250 mg when used alone or when dorzolamide is combined with either timolol or acetazolamide."	( Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide. Camras, CB; Toris, CB; Yablonski, ME; Zhan, GL, 2004)	0.32
"5% alone or combined with latanoprost in reducing IOP in a real-world setting."	( Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Bastien, NR; Koulis, T; Lesk, MR; Sampalis, F; Sampalis, JS, 2008)	0.35
"A Snovel method for the simultaneous separation and determination of two antiglaucoma drugs namely, dorzolamide hydrochloride (DOR) and timolol maleate (TIM) in aqueous humor samples (AH) was developed by using salting-out assisted liquid-liquid microextraction (SALLME) combined with HPLC-UV method."	( Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. Abdel-Wadood, HM; Mohamed, AM; Mousa, HS, 2014)	0.4
" However, no studies have evaluated ripasudil combined with β-blockers and prostaglandin analogues."	( Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. Abe, H; Araie, M; Inoue, T; Kuwayama, Y; Suganami, H; Tanihara, H; Yamamoto, T, 2015)	0.42
"These clinical trials found additive IOP-lowering effects of ripasudil from placebo at trough and peak levels in combination with timolol and at peak level in combination with latanoprost."	( Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. Abe, H; Araie, M; Inoue, T; Kuwayama, Y; Suganami, H; Tanihara, H; Yamamoto, T, 2015)	0.42
" Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment."	( Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. Ge, J; Yuan, W; Zhang, L; Zhao, H; Zheng, J, 2016)	0.43
"To examine the relevance of concentration of benzalkonium chloride (BAK) on the cornea, we investigated the effects of latanoprost containing BAK alone and in combination with other antiglaucoma drug classes on corneal epithelium in vitro in a cultured rabbit corneal cell line (SIRC) and in vivo, using a corneal resistance device (CRD)."	( In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide. Fukuda, M; Sasaki, H; Shibata, N; Shibata, S; Shibata, T; Sugiyama, K; Takeda, N, 2016)	0.43
" The proposed methods were applied to two pharmaceutical formulations; the method for HCT and AMH has proven as reliable assaying method, whereas the method for TML, when combined with HCT, is applicable to screening semi-quantitative analyses."	( Simultaneous spectrofluorometric analysis of tablets containing hydrochlorothiazide combined with timolol maleate or amiloride hydrochloride. Lataifeh, A; Mohammed, MS; Wedian, F, 2020)	0.56
"The aim of study was to understand anti-glaucoma fixed dose drug combination use in real-world settings, focussing on drug selection, repeated prescription of the same active ingredient, and administration of fixed dose combinations, thus providing a reference for doctors during prescription and pharmacists during prescription review, ultimately educating patients on medication."	( The use of fixed dose drug combinations for glaucoma in clinical settings: a retrospective, observational, single-centre study. Huang, T; Shen, J; Xiong, X; Yan, J, 2022)	0.72

Excerpt	Reference	Relevance
" Bioavailability was reduced by 25% when the drug was taken orally."	( Plasma timolol levels after oral and intravenous administration. Edwards, IR; Else, OF; Sorenson, H, 1978)	0.26
" This leads to in situ formation of a super-saturated ME that possesses a particularly high absorption rate due to the enhanced diffusion pressure of the drug."	( Pharmacodynamic effects of transdermal bupranolol and timolol in vivo: comparison of microemulsions and matrix patches as vehicle. Kemken, J; Müller, BW; Ziegler, A, 1991)	0.28
" D-Timolol was well absorbed across the cornea as L-timolol and produced the duration of action as long as L-timolol."	( Development of D-timolol for the treatment of glaucoma and ocular hypertension. Chiou, GC, 1990)	0.28
" The bioavailability of timolol from the microemulsion and the ion-pair solution was higher than that obtained from timolol alone."	( Microemulsions as topical delivery vehicles: ocular administration of timolol. Bauchiero, L; Chiappero, O; Gallarate, M; Gasco, MR; Gremmo, E; Trotta, M, 1989)	0.28
" In terms of topical ophthalmic drug delivery, the noncorneal absorption route may be important for drugs that are poorly absorbed across the cornea due to their physical-chemical properties."	( Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Ahmed, I; Patton, TF, 1985)	0.27
"Nasolacrimal occlusion (NLO) and eyelid closure are simple techniques that not only increase the ocular bioavailability of topically applied ocular drugs but also reduce the probability of adverse systemic effects."	( Improving the therapeutic index of topically applied ocular drugs. Kandarakis, AS; Kooner, KS; Ziegler, LP; Zimmerman, TJ, 1984)	0.27
"The systemic bioavailability of timolol, a beta-adrenergic receptor blocking agent, was calculated from published data in normal volunteers and uremic patients after oral doses."	( Estimation of the systemic bioavailability of timolol in man. El-Rashidy, R, )	0.13
" The systemic bioavailability ranged from 61% for atenolol to 100% for timolol."	( Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit. Kompella, UB; Lee, VH; Lee, YH, 1993)	0.29
" Ocular bioavailability is determined by the ability of drug to penetrate through the cornea and conjunctiva/sclera, and on the other hand, by its elimination from the conjunctival sac."	( Delivery of antiglaucoma drugs: ocular vs systemic absorption. Urtti, A, 1994)	0.29
" A better understanding of the mechanisms involved in transcorneal permeation could lead to improvements in drug dosage forms or the development of drug delivery devices which enhance the ocular bioavailability of drugs."	( Theoretical corneal permeation model for ionizable drugs. Cheng, YL; Friedrich, SW; Saville, BA, 1993)	0.29
" When the 20% (w/v) timolol patch was applied, the mean bioavailability was 74."	( Pharmacokinetics and beta-blocking effects of transdermal timolol. Ishizaki, T; Kikuchi, K; Koyama, E; Kubota, K; Yamada, T, 1993)	0.29
" Ocular bioavailability as well as toxicity for timolol hemihydrate is similar to that which has been shown previously for timolol maleate."	( Timolol hemihydrate: a new formulation of timolol for the treatment of glaucoma. Stewart, WC, 1996)	0.29
"The new vehicle obviously improves the bioavailability of topically applied timolol."	( How can the bioavailability of timolol be enhanced? A pharmacokinetic pilot study of novel hydrogels. Brewitt, H; Mayer, H; Stark, M; von der Ohe, N, 1996)	0.29
" A two-compartment pharmacokinetic model was used to fit the aqueous humor level for determining the drainage (kd) and absorption rate constants (ka) in the precorneal area as well as the elimination rate constant (ke) of timolol in aqueous humor."	( Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. Chen, JL; Chiang, CH; Ho, JI, 1996)	0.29
"This pilot suggests that need for a longer-term study with larger numbers of subjects to evaluate the potential role of silicone punctal plugs to enhance the ocular bioavailability of topically applied antiglaucoma medications."	( Efficacy of silicone punctal plugs as adjuncts to topical pharmacotherapy of glaucoma--a pilot study. Punctal Plugs in Glaucoma Study Group. Bartlett, JD; Boan, K; Corliss, D; Gaddie, IB, 1996)	0.29
"To improve the bioavailability of the ocular drug timolol by facilitating its transport through the cornea, an amphiphilic prodrug was synthesized via the addition of a palmitic chain by esterification."	( Tensioactivity and supramolecular organization of the palmitoyl prodrug of timolol. Benoit, JP; Bouligand, Y; Pech, B; Proust, JE, 1997)	0.3
"A new formulation (HYA) based on timolol hyaluronate and pilocarpine hyaluronate salts has been shown to improve the bioavailability of the drugs and to extend the duration of their action."	( Pharmacological evaluation of a new timolol/pilocarpine formulation. Bucolo, C; Mangiafico, S; Spadaro, A, 1998)	0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" This information may serve as a basis for optimizing the intraocular delivery of drugs that are poorly absorbed across the cornea due to their physicochemical properties."	( Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. Ahmed, I; Gokhale, RD; Patton, TF; Shah, MV, 1987)	0.27
"Under the present experimental conditions (including concentration and bioavailability of the drugs used), topical application of the NOS inhibitors 7-NI, L-NAME, and AMT does not prevent an IOP increase induced by water intake in rabbits."	( Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressure in rabbits. Elena, PP; Flammer, J; Fleischhauer, JC; Haefliger, IO; Liu, R, 2001)	0.31
"This paper describes a graphical model for simplifying in vitro absorption, metabolism, distribution, and elimination (ADME) data analysis through the estimation of oral bioavailability (%F) of drugs in humans and other species."	( Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. Hwang, KK; Mandagere, AK; Thompson, TN, 2002)	0.31
" The absorption rate of latanoprost and timolol into the aqueous humor was similar after administration of the FC compared to the two drugs given separately."	( Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. Calissendorff, B; Grunge-Lowerud, A; Högberg, G; Sjöquist, B, 2002)	0.31
" The systemic bioavailability (F) of the eyedrop was 78."	( Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Kaila, T; Korte, JM; Saari, KM, 2002)	0.31
" Clinicians should pay attention to the high systemic bioavailability of ophthalmic timolol, because intensive systemic beta-blockade can be highly hazardous to aged patients suffering from cardiopulmonary diseases."	( Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Kaila, T; Korte, JM; Saari, KM, 2002)	0.31
" The results of this study suggest that PS could be regarded as a potential corneal enhancer to increase the intraocular bioavailability of AC and TM."	( Enhancer effects on in vitro corneal permeation of timolol and acyclovir. Bucolo, C; Montenegro, L; Puglisi, G, 2003)	0.32
"The ocular bioavailability of timolol increased in sorbic acid solution due to ion pair formation."	( Improvement of the ocular bioavailability of timolol by sorbic acid. Higashiyama, M; Inada, K; Ohtori, A; Tojo, K, 2004)	0.32
" A new timolol maleate solution has been formulated that contains potassium sorbate (timolol-LA [TLA; Istalol(R)]) to enhance the ocular bioavailability of timolol instilled into the eye, as well as half the benzalkonium chloride preservative found in timolol maleate."	( A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Crockett, RS; Mundorf, TK; Naka, H; Novack, GD; Ogawa, T, 2004)	0.32
" In the present study, we desired to evaluate the ocular comfort and systemic bioavailability of TLA in healthy volunteers in comparison to standard timolol maleate ophthalmic solution (TIM)."	( Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers. Crockett, RS; Inui, N; Mundorf, TK; Naka, H; Novack, GD; Ogawa, T, 2005)	0.33
" Although in the initial 15 min the drug concentrations in AH were comparable to that of the timolol solution, increased Cmax and significantly improved ocular bioavailability were obtained for the gel."	( Pharmacokinetics of timolol in aqueous humor sampled by microdialysis after topical administration of thermosetting gels. Ding, PT; Lu, WY; Wei, G; Zheng, JM, 2006)	0.33
"The lower timolol concentration in the hydrogel vehicle and its better bioavailability resulted in reduced systemic absorption and side-effects without loss of efficacy."	( Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Kähönen, M; Niño, J; Ropo, A; Tahvanainen, K; Tuominen, J; Turjanmaa, V; Uusitalo, H, 2005)	0.33
" Poor ocular bioavailability of drugs (< 1%) from conventional eye drops is due mainly to the precorneal loss factors that include rapid tear turnover, nonproductive absorption, transient residence time in the cul-de-sac, and the relative impermeability of the drugs to corneal epithelial membrane."	( Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Gupta, H; Jain, S; Mathur, R; Mishra, AK; Mishra, P; Velpandian, T, 2007)	0.34
" The extent of absorption of TM-SE patch expressed by AUC was 64% larger as compared to the oral solution with steady plasma concentration over 18 h and relative bioavailability (F(rel)) of 163%."	( Novel transdermal delivery of Timolol maleate using sugar esters: preclinical and clinical studies. El-Laithy, HM, 2009)	0.35
"In situ gel-forming systems have drawn much attention of current researchers to overcome the poor bioavailability from the conventional eye drops."	( Development and characterization of 99mTc-timolol maleate for evaluating efficacy of in situ ocular drug delivery system. Ali, A; Aqil, M; Bhatnagar, A; Gupta, H; Jain, S; Khar, RK; Mittal, G, 2009)	0.35
"Surface-modified solid lipid nanoparticles could provide an efficient way of improving ocular bioavailability of timolol hydrogen maleate."	( Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Attama, AA; Müller-Goymann, CC; Reichl, S, 2009)	0.35
" However, low drug-contact time and poor ocular bioavailability of drugs due to drainage of solution, tear turnover and its dilution or lacrimation limits its uses."	( Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. Paliwal, R; Paliwal, SR; Vyas, SP; Wadhwa, S, 2010)	0.36
"Poor bioavailability (<1%) of drugs from conventional eye drops is mainly due to the various precorneal loss factors which include rapid tear turnover, systemic drug absorption through naso-lachrymal duct, transient residence time of the drug solution in the cul-de-sac and the relative impermeability of the drugs to corneal epithelial membrane."	( Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery. Gupta, H; Jain, S; Velpandian, T, 2010)	0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" pH, in the cul-de-sac of the eye for providing a prolonged effect and increased bioavailability with reduction in frequency of administration."	( Stimuli-sensitive hydrogels: a novel ophthalmic drug delivery system. Appala, R; Bushetti, SS; Imam, SS; Shareef, A; Singh, M; Singh, V, )	0.13
" Precorneal retention study in vivo indicated that the optimal liposomal-hydrogel formulation had improved bioavailability and its retention time on rabbit corneal surface were significantly longer than that of pure liposomes or eye-drops."	( Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo. Luo, QH; Nie, SF; Pan, WS; Yang, ZJ; Zhang, HH, )	0.13
"Ophthalmic drug delivery through eye drops is inefficient because of low corneal bioavailability and short residence time in tears."	( Temperature sensitive contact lenses for triggered ophthalmic drug delivery. Chauhan, A; Jung, HJ, 2012)	0.38
" In addition, lenses with one-third of the drug loading as eye drops resulted in the similar IOP reduction, suggesting higher bioavailability for contact lenses compared to eye drops."	( Drug delivery by contact lens in spontaneously glaucomatous dogs. Ben-Shlomo, A; Chauhan, A; Mackay, EO; Peng, CC; Plummer, CE, 2012)	0.38
"Ophthalmic drug delivery through contact lenses increases bioavailability and reduces systemic drug uptake."	( Drug delivery by contact lens in spontaneously glaucomatous dogs. Ben-Shlomo, A; Chauhan, A; Mackay, EO; Peng, CC; Plummer, CE, 2012)	0.38
" The in vivo studies showed that IOP reduction from baseline by pure contact lens on daily basis was comparable with that by eye drops but with only 20% of drug dose, which suggested higher drug bioavailability for contact lenses."	( Extended drug delivery by contact lenses for glaucoma therapy. Burke, MT; Carbia, BE; Chauhan, A; Peng, CC; Plummer, C, 2012)	0.38
" We propose to develop drug-eluting contact lenses for managing glaucoma with increased bioavailability and improved compliance."	( Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy. Carbia, BE; Chauhan, A; Hsu, KH; Plummer, C, 2015)	0.42
" In conclusion, resins have great potential as effective ocular drug delivery carriers to increase ocular bioavailability of timolol while simultaneously reducing systemic drug absorption."	( Preparation and evaluation of a timolol maleate drug-resin ophthalmic suspension as a sustained-release formulation in vitro and in vivo. Cao, J; Liu, W; Qin, F; Wang, X; Zeng, L; Zhu, Y, 2016)	0.43
" From in vitro permeation studies, we can conclude that TM-loaded transfersomes may enhance the corneal transmittance and improve the bioavailability of conventional TM delivery."	( Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process. Arroyo, CM; Calle, M; Canca, D; Cózar-Bernal, MJ; González-R, PL; González-Rodríguez, ML; León, JM; Rabasco, AM, 2016)	0.43
" Current ocular drug delivery in treating glaucoma is confronting a variety of challenges, such as low corneal permeability and bioavailability due to the unique anatomical structure of the human eye."	( Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation. Huang, J; Huang, Y; Li, Y; Pan, X; Peng, T; Wu, C; Wu, CY; Zeng, Y; Zhan, Z, 2017)	0.46
" Ocular pharmacokinetic study performed in normotensive rabbits showed that HyNa-TM complex exhibited attractive bioavailability properties in the aqueous humor (AUC and Cmax significantly higher and later Tmax) compared to commercial TM eye-drops."	( The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case. Allemandi, DA; Battistini, FD; Boiero, C; Guzmán, ML; Luciani-Giaccobbe, LC; Manzo, RH; Olivera, ME; Palma, SD; Tártara, LI, 2017)	0.46
"Contact lenses are receiving significant attention for delivering ophthalmic drugs with higher bioavailability compared to eye drops."	( Effect of the surface layer on drug release from delefilcon-A (Dailies Total1 Chauhan, A; Dixon, P, 2017)	0.46
"The poor retention and penetration are the major issues in the bioavailability of drugs through ocular route."	( Development of Timolol Maleate Loaded Chitosan Nanoparticles For Improved Ocular Delivery. Kaushik, D; Pandey, P; Saroha, A, 2017)	0.46
" It is possible that the co-instillation of MH nanoparticles may provide a useful way to improve the bioavailability of water-soluble drugs in the ophthalmic field."	( Co-instillation of nano-solid magnesium hydroxide enhances corneal permeability of dissolved timolol. Kanai, K; Kawasaki, N; Nagai, N; Nakazawa, Y; Ogata, F; Okamoto, N; Otake, H; Shimomura, Y, 2017)	0.46
" Poor bioavailability of ophthalmic solutions can be overcome by using smart ophthalmic drug-delivery systems."	( Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma. Ashtari, K; Ilka, R; Kianirad, M; Mehravi, B; Mohseni, M; Naseripour, M, 2018)	0.48
" However, the conventional formulation of TM and BRZ exhibits sub optimal therapeutic effects attributable to the poor ocular bioavailability of these drugs."	( Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery. Ali, J; Baboota, S; Khan, S; Shrivastava, N, 2018)	0.48
"Rapid clearance and low ocular bioavailability are drawbacks of conventional ophthalmic eye drops."	( In situ formation of injectable chitosan-gelatin hydrogels through double crosslinking for sustained intraocular drug delivery. Abe, T; Kaji, H; Nagai, N; Nishizawa, M; Saijo, S; Song, Y, 2018)	0.48
" These data indicate that the prepared GNPs possessed all needed qualities of a successful ocular system; corneal affinity, suitable particle size, high entrapment efficiency, sustained release, good stability, efficient lowering of intraocular pressure, high drug bioavailability and lack of irritancy."	( Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: Augmented in-vivo efficacy and safe histological profile. Hathout, RM; Mansour, S; Shokry, M, 2018)	0.48
" Rapid clearance and low ocular bioavailability are drawbacks of conventional ocular treatments."	( Chitosan-Gelatin Hydrogel Crosslinked With Oxidized Sucrose for the Ocular Delivery of Timolol Maleate. Alsharif, FM; El-Feky, GS; Elshaier, YAMM; Zayed, GM, 2018)	0.48
" The present study was aimed to develop a timolol maleate loaded thermo-sensitive gel (TM-TSG) with improved bioavailability to treat glaucoma."	( Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study. Chen, J; Huang, J; Huang, Y; Huang, Z; Li, Y; Pan, X; Wu, C; Zeng, Y, 2018)	0.48
" In vivo pharmacokinetic studies indicated that TM-TSG could enhance absorption of TM in aqueous humor and improve the ocular bioavailability in comparison of commercial TM eyedrops."	( Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study. Chen, J; Huang, J; Huang, Y; Huang, Z; Li, Y; Pan, X; Wu, C; Zeng, Y, 2018)	0.48
"2-fold) and bioavailability (2."	( Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma. Bu, R; Feng, S; Ge, Y; Gou, J; He, H; Tang, X; Wang, J; Xu, J; Yin, T; Zhang, A; Zhang, Y, 2019)	0.51
"Thin and erodible polymeric films were developed as potential ocular drug delivery systems to increase drug retention on the eye with the aim of improving bioavailability and achieving controlled drug release."	( Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma. Boateng, JS; Mitchell, JC; Tighsazzadeh, M, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"To enhance bioavailability of timolol (TML) and utilize alternatives for traditional eye drops for more patient compliance, this study was aiming to develop biodegradable orally dissolving strips (ODSs) of TML for treatment of primary open-angle glaucoma (POAG)."	( Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits. Ahmed, KA; Al-Sawahli, MM; Alolayan, EM; El-Feky, YA; El-Telbany, DFA; El-Telbany, RFA; Fayez, AM; Mostafa, DA; Zakaria, S, 2020)	0.56
"Ocular bioavailability after eye drops administration is an important, but rarely determined, pharmacokinetic parameter."	( Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. Del Amo, EM; Fayyaz, A; Gardner, I; Jamei, M; Puranen, J; Ranta, VP; Ruponen, M; Toropainen, E; Urtti, A; Valtari, A; Vellonen, KS, 2020)	0.56
" This device can provide a simple, noninvasive, extended drug release up to 45 days with higher bioavailability and lower risk for adverse effects."	( Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment. Ben-Shlomo, G; Ding, X; Que, L, 2020)	0.56
" However, the bioavailability of eye drops is low (<5%)."	( Lollipop-Inspired Multilayered Drug Delivery Hydrogel for Dual Effective, Long-Term, and NIR-Defined Glaucoma Treatment. Huang, J; Ma, F; Pang, Y; Song, Y; Wang, F; Wang, X; Wang, Y; Wu, B; Zhang, W; Zhang, X; Zhu, Z, 2021)	0.62
" Low bioavailability and high frequency of administration in eye drops are major challenges in ocular pharmacotherapy."	( Synthesis and evaluation of modified lens using plasma treatment containing timolol-maleate loaded lauric acid-decorated chitosan-alginate nanoparticles for glaucoma. Alemezadeh, SA; Bagherzadeh, K; Hosseini, MS; Mehravi, B; Mirzaei, M; Mohseni, M; Naseripour, M, 2023)	0.91

Excerpt	Relevance	Reference
" Both timolol and acebutolol had a significant hypotensive effect at 24 hours and a low incidence of side effects, suggesting that further increases in dosage might be effective and well tolerated."	( Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. Wilcox, RG, 1978)	0.26
" Heart rates at rest were 91 and 98 beats/min in the patients with low and high digoxin dosage and rose to 135 and 139 beats/min, respectively, during exercise."	( Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. David, D; Kaplinsky, E; Klein, HO; Segni, ED, 1979)	0.26
" The dosage regimen calculations for patients indicated to receive the treatment for certain chronic diseases, should be determined by utilizing the disposition data obtained in steady-state conditions."	( Pharmacokinetic differences between single and multiple oral dosing with the guidance for beta-adrenoceptor blockade assessment. Ishizaki, T; Tawara, K, 1979)	0.26
"21 patients with essential sustained mild or moderate hypertension were treated with timolol for an average of 6 months at a mean dosage of 3,14 tablets per day."	( [A treatment of mild and moderate hypertension with timolol (author's transl)]. Fritel, D, )	0.13
"001), but a major determinant of the magnitude of the decrease was the dosage change of the timolol."	( Serum potassium and uric acid changes during treatment with timolol alone and in combination with a diuretic. Mikkelsen, E; Pedersen, OL, 1979)	0.26
" Propranolol and timolol produced a dose-dependent increase of atrial and atrioventricular nodal refractory periods; dose-response curves were parallel."	( Effects of the beta-adrenergic blocking agents propranolol and timolol on canine cardiac refractory periods. Cheymol, G; Heckle, J; Jaillon, P; Weissenburger, J, 1979)	0.26
"A single-dose kinetic study of oral timolol, 20 mg, was undertaken in 3 groups of volunteers with varying degrees of renal function--(1) 10 normal subjects (N); (2) 9 patients with moderate chronic renal insufficiency (MCRI; C cr, 20 to 50 ml/min); (3) 4 patients with end-stage renal disease (ESRD)--to assess the need for dosage modification as renal function diminishes."	( Timolol kinetics in chronic renal insufficiency. Affrime, MB; Busby, P; Kim, KE; Lowenthal, DT; Nancarrow, J; Onesti, G; Pitone, JM; Shirk, J; Swartz, CD, 1978)	0.26
" Although the range of mean timolol concentrations at steady state varies to a certain extent among different patients, the dosage regimens for patients who will receive treatment for certain chronic disease states (e."	( Clinical pharmacologic observations on timolol. II. Antihypertensive effect and kinetic disposition on twice-daily dosing in patients with mild or moderate hypertension. Ishizaki, T; Nakaya, H; Oyama, Y; Tawara, K, )	0.13
" The average total daily dosage schedule for timolol ranged between 15 and 20 mg, with the same blood pressure lowering effect whether the divided dose was given twice or three times."	( [The anti-hypertensive effect of timolol maleate (blocadren) in gradated combination with a diuretic]. Vorburger, C, 1976)	0.26
" The optimal dose should be determined on a case-by-case basis, by increasing the daily dosage gradually."	( [Beta-blockers and migraine]. Bousser, MG; Massiou, H, 1992)	0.28
" Airway response was measured as change in FEV1 and sGaw and dose-response curves to timolol, BPPA and placebo were performed."	( Assessment of bronchial effects following topical administration of butylamino-phenoxy-propanol-acetate, an oculoselective beta-adrenoceptor blocker in asthmatic subjects. Bauer, KG; Binkowitz, B; Brunner-Ferber, F; Distlerath, LM; Kaik, GA; Lippa, EA; Till, P, 1992)	0.28
" More patients on hydrochlorothiazide attained a diastolic blood pressure of less than 90 mmHg while less patients required doubling of dosage compared to timolol and enalapril."	( The efficacy of hydrochlorothiazide, timolol and enalapril in Ethiopians with essential hypertension. Habte, B, 1992)	0.28
" For timolol, nasolacrimal occlusion collapsed the dose-response curve and extended the duration of action."	( Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Fuqua, M; Nardin, GF; Sharir, M; Zimmerman, TJ, 1992)	0.28
" Moreover, the possible influence of dosing time on the extent of ocular and systemic drug absorption must be considered when planning dosing schedules for topically applied ophthalmic drugs."	( Improving the ocular to systemic ratio of topical timolol by varying the dosing time. Grass, GM; Lee, VH; Ohdo, S, 1991)	0.28
"In an attempt to increase patient compliance with a dosing regimen, prescriptions for topical solutions of glaucoma medication were refilled using the C Cap, a memory aid designed to help patients to remember to instill the medication as prescribed."	( Effectiveness of the C Cap in promoting prescription refill compliance among patients with glaucoma. Chin, A; Gill, MA; Nakahiro, RK; Okamoto, MP; Sclar, DA; Skaer, TL, )	0.13
" Whether dose reduction will lead to reduced corneal toxicity in glaucoma filtration surgery following topical or subconjunctival dosing is an interesting therapeutic opportunity that remains to be determined."	( Corneal penetration of 5-fluorouracil and its improvement by prodrug derivatization in the albino rabbit: implication in glaucoma filtration surgery. Bundgaard, H; Buur, A; Lee, VH; Wang, W, 1991)	0.28
"The ratio between ocular and systemic drug concentrations describes the relative safety of ophthalmic dosage forms of the same drug in terms of its systemic side effects."	( Effects of epinephrine pretreatment and solution pH on ocular and systemic absorption of ocularly applied timolol in rabbits. Kyyrönen, K; Urtti, A, 1990)	0.28
" A dose-response relationship for D-timolol could be established."	( Effects of D-timolol and L-timolol eye drops on intraocular pressure and aqueous flow. A dose-response study in normal eyes. Alm, A; Koskela, T; Taarnhøj, J, 1990)	0.28
" The dose-response curves of the strips from both strains for alpha-adrenoceptor stimulation with NA determined after pretreatment with CTX were comparable to those determined in the absence of timolol."	( Role of stimulatory GTP-binding protein (Gs) in reduced beta-adrenoceptor coupling in the femoral artery of spontaneously hypertensive rats. Asano, M; Masuzawa, K; Matsuda, T, 1988)	0.27
" Based on the amount of timolol in the residual ointment, 50-60% of the original timolol dosage was delivered from the patch."	( Initial evaluation of transdermal timolol: serum concentrations and beta-blockade. Bondi, JV; Dunlay, MC; Ferguson, RK; Hichens, M; Loper, AE; Ribeiro, LG; Rotmensch, HH; Vlasses, PH, )	0.13
" Dose-response relationships of pilocarpine and timolol to lower intraocular pressure were demonstrated with this model."	( Microvascular access to the uveal tract in the rabbit eye for ocular pharmacologic studies. Chiou, FY; Chiou, GC; Li, BH; Ruiz-Razura, A, 1989)	0.28
"The classical approach of displacing the dose-response curve by an alpha adrenoceptor blocker has most often failed to demonstrate a contribution of an alpha adrenoceptor-mediated component in the final inotropic response to norepinephrine unless the beta adrenoceptors are extensively blocked."	( Both alpha and beta adrenoceptor-mediated components contribute to final inotropic response to norepinephrine in rat heart. Osnes, JB; Schiander, IG; Skomedal, T, 1988)	0.27
" If standard doses of beta-blockers are used in PM subjects, they may be susceptible to concentration-related adverse reactions and they may also require lower and less frequent dosing for control of angina pectoris."	( Oxidation phenotype and the metabolism and action of beta-blockers. Lennard, MS, 1985)	0.27
" The extent of bronchial beta-adrenoceptor blockade following one eyedrop in each eye of timolol 1% and L-714,465 1% was compared in six normal subjects, by measuring the displacement of the bronchodilator dose-response curve to isoprenaline following each drug compared to the isoprenaline dose-response curve after placebo eyedrops (methyl-cellulose)."	( Bronchial beta-adrenoceptor blockade following eyedrops of timolol and its isomer L-714,465 in normal subjects. Richards, R; Tattersfield, AE, 1985)	0.27
" If standard doses of beta-blockers are used in poor metabolisers, these subjects may be susceptible to concentration-related adverse reactions and they may also require less frequent dosing for control of angina pectoris."	( The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Lennard, MS; Tucker, GT; Woods, HF, )	0.13
" If standard doses of some beta-blockers are used in poor metabolizers, these patients may be susceptible to concentration-related adverse reactions and they may also require lower and less frequent dosing for control of angina pectoris."	( Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Lennard, MS; Silas, JH; Tucker, GT; Woods, HF, 1986)	0.27
" Airway dose-response curves to timolol (0-2%), L-714,465 (0-4%), and placebo (methyl cellulose) eye drops were performed in a double-blind randomised study in which airway response was measured as change in FEV1 and specific airway conductance (sGaw)."	( Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects. Richards, R; Tattersfield, AE, 1987)	0.27
" The mean times to AR and D were not significantly increased by either dosing regimen of timolol, although the trend was for an increase in the time to D after 7 days of timolol and an increase in the time to AR and D after 14 days of timolol."	( The effect of acute and chronic administration of timolol on cardiac sympathetic neural discharge, arrhythmia, and beta adrenergic receptor density associated with coronary occlusion in the cat. Lathers, CM; Lerner, JP; Levin, RM; Spivey, WH; Suter, LE; Tumer, N, 1986)	0.27
" To investigate the role of adrenergic mechanisms in regulating flow, the dose-response effect of topical timolol (0."	( Aqueous humor flow measured with fluorophotometry in timolol-treated primates. Bartels, SP, 1988)	0.27
" Subjects in whom the sinus rhythm returned or the ventricular rate decreased to less than 100 bpm were transferred to a dosing regimen of timolol in 10-mg tablets twice a day by mouth, 1 hr after the last intravenous dose."	( Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias. Moncloa, F; Sweany, AE; Vickers, FF; Zupkis, RV, 1985)	0.27
" This evidence suggests that timolol is as effective in dosage of 20 mg taken once daily as half the dose taken twice daily in the symptom management of angina pectoris."	( Once daily timolol in the prophylaxis of angina pectoris. Given-Wilson, R; Joy, M, 1985)	0.27
" and strict adjustment of dosage is recommended."	( [Evaluation of the systemic effects of timolol maleate in eye drops]. Dufier, JL; Hugues, FC; Le Jeunne, C; Munera, Y, 1985)	0.27
" 2 They were treated with once-daily timolol and followed up at 2, 4, 8 and 12 weeks when dosage was titrated against BP control (indirect measurement) and degree of beta-adrenoceptor antagonism (submaximal bicycle ergometry and sub-lingual GTN)."	( Control of blood pressure and reduction of echocardiographically assessed left ventricular mass with one-daily timolol. Glover, DR; Littler, WA; Rowlands, DB; Stallard, TJ, 1982)	0.26
" 2 Maximal suppression of exercise-induced tachycardia (bicycle ergometry) was dose-dependent and greater at 2 than at 6 h after dosing; activity up to 12 h was evident on the last dosing day."	( Relationships among timolol doses, plasma concentrations and beta-adrenoceptor blocking activity. Abrams, WB; Demetriades, J; Ferguson, RK; Holmes, GI; Huber, P; Koplin, JR; Vlasses, PH, 1982)	0.26
" The dosage of timolol was 10 mg twice daily and the patients were followed for 12--33 months (mean 17 months)."	( Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group. Abrahamsen, AM; Gundersen, T; Kjekshus, J; Rønnevik, PK, 1982)	0.26
" These differences account for many of the observed variations in drug action and dosage scheduling as well as for some of the side effects."	( Beta-adrenergic blockers. Choosing among them. McGoon, MD; Vlietstra, RE, 1984)	0.27
" Furthermore, dose-response studies, using direct systemic administration of the two beta-adrenoceptor antagonists, revealed that ICI 118,551 is about 60 times less potent than timolol in blocking isoprenaline-induced cardio-acceleration."	( ICI 118,551: an effective ocular hypotensive agent with selectivity for the ciliary process beta 2-adrenoceptor and with minimal cardiac side effects. Nathanson, JA, 1984)	0.27
"Timolol, a non selective beta-blocker was used one daily at a dosage of 10 to 20 mg, in 60 hypertensive patients with a diastolic blood pressure ranging from 100 to 120 mmHg."	( [Monotherapy of hypertension with a beta-blocker in a single daily dose (author's transl)]. Gilgenkrantz, JM; Languillat, JM; Zannad, F, )	0.13
" Neither timolol (a nonselective beta-antagonist) nor atenolol (a beta 1-selective antagonist) had a significant effect on basal secretory rate, but both shifted the isoproterenol dose-response curve to the right without changing its slope, suggesting competitive antagonism."	( Evidence that beta 1-adrenoceptor activation mediates isoproterenol-stimulated renin secretion in the rat. Churchill, MC; Churchill, PC; McDonald, FD, 1983)	0.27
" A similar study was carried out with 12 patients taking propranolol for various cardiovascular problems; their dosage of this agent was not varied, however."	( Effect of timolol eye drops in subjects receiving systemic propranolol therapy. Blondeau, P; Côté, M; Tétrault, L, 1983)	0.27
" The dosage of timolol was 10 mg twice daily and the follow-up period was 12-33 mo (mean: 17 mo)."	( Timolol treatment after myocardial infarction in diabetic patients. Gundersen, T; Kjekshus, J, )	0.13
"An open, multi-centre study was carried out in general practice to compare the efficacy and tolerance of antihypertensive therapy with once-daily and twice-daily dosage of a fixed ratio combination of hydrochlorothiazide (25 mg), amiloride (2."	( Comparison of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol ('Moducren') given once versus twice daily in mild to moderate hypertension. Currie, WJ; Isitt, VL; VandenBurg, MJ; Young, JH, 1984)	0.27
" At the concentration and dosage employed here there was no significant difference between the hypotensive effects of timolol and TFM."	( The effects of separate and combined topical treatment with timolol maleate and trifluormethazolamide on the intraocular pressure in normal rabbits. Bar-Ilan, A, 1984)	0.27
" Both NLO and eyelid closure seem to be safe, simple, and effective procedures that could minimize dosage requirements, as well as side effects."	( Improving the therapeutic index of topically applied ocular drugs. Kandarakis, AS; Kooner, KS; Ziegler, LP; Zimmerman, TJ, 1984)	0.27
" If patients failed to respond adequately at this dosage level, prazosin (0."	( Timolol/bendrofluazide combination ('Prestim') in the treatment of poorly controlled hypertensive patients in general practice. Douglas-Jones, AP, 1984)	0.27
" The results showed that the change in treatment led to a significant reduction in blood pressure in both groups, at a dosage of 1 tablet daily in over half the patients, and the majority (88%) preferred the new form of treatment."	( A general practice study of timolol/hydrochlorothiazide/amiloride ('Moducren'), a new therapy for hypertension, and the doctor's influence on management. Arr, S; Parry, EE; Tait, D, 1983)	0.27
" We can look forward to newer agents that are efficacious as monotherapy and on a daily or twice daily dosage regimen for the treatment of the vast majority of hypertensive patients."	( Newer antihypertensive agents. Thind, GS, 1980)	0.26
" In the remaining 19 patients, intraocular pressure was controlled well over the entire two-year period, but in some cases it was necessary after a while to increase the dosage to a higher concentration."	( [Results of long-term treatment of glaucoma with timolol ophthalmic solution (author's transl)]. Merkle, W; Merté, HJ, 1980)	0.26
" Side effects reported were correlated with dosage levels and estimated plasma levels."	( Potential side effects of timolol therapy in the treatment of glaucoma. Golob, DS; Leader, BJ; Zimmerman, TJ, 1981)	0.26
" Recording of intraocular pressure during the trial suggested the presence of a dose-response relationship between the dose of timolol and the decrease of intraocular pressure."	( Dose response of oral timolol combined with adrenaline. Ohrström, A, 1982)	0.26
" The patient groups were then crossed over to the other dosage interval."	( Additive effect of epinephrine to timolol therapy in primary open angle glaucoma. Cyrlin, MN; Epstein, DL; Thomas, JV, 1982)	0.26
"6%) patients who required a dosage reduction and 2 (0."	( A multi-centre general practice study on the use of a timolol/bendrofluazide combination ('Prestim') in the management of hypertension: preliminary report. Head, AC; Langrick, AF, 1981)	0.26
" In patients as well as in normal subjects, the data indicated considerable beta-blocking effects for both drugs at the end of a 12-hourly dosing schedule, suggesting that twice-daily timolol and propranolol may be clinically practical."	( Plasma timolol levels and systolic time intervals. Chew, C; Collett, J; Singh, BN; Whitlock, RM; Williams, FM, 1980)	0.26
" In a complementary investigation, 14 patients who completed the 16-weeks' treatment were changed onto a regimen in which the drug dosage remained unchanged but was taken on a once-daily basis for a further 16 weeks to assess the efficacy of once-daily dosing and to monitor any further long-term changes in biochemistry."	( A hospital out-patient study of timolol/bendrofluazide combination ('Prestim') in essential hypertension. Kubik, MM, 1980)	0.26
"5% timolol maleate twice daily for at least 4 weeks and who had 8 AM IOPs of at least 22 mm Hg and no greater than 30 mm Hg 12 hours after dosing were eligible for the study."	( The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group. Lehmann, RP; Ritch, R; Shin, DH; Shrader, CE; Stewart, WC; van Buskirk, EM, 1995)	0.29
"05% dipivefrin every 12 hours might be an adequate dosage for maximal effect."	( Nasolacrimal occlusion improves the therapeutic index of antiglaucoma medications. Sharir, M; Zimmerman, TJ, 1994)	0.29
" A better understanding of the mechanisms involved in transcorneal permeation could lead to improvements in drug dosage forms or the development of drug delivery devices which enhance the ocular bioavailability of drugs."	( Theoretical corneal permeation model for ionizable drugs. Cheng, YL; Friedrich, SW; Saville, BA, 1993)	0.29
" Interaction between topical isoprenaline and timolol on intraocular pressure was studied in conscious rabbits through changes of the dose-response curves."	( Evidence for a synergistic interaction between isoprenaline and timolol on intraocular pressure in conscious rabbits. Garrido, M; Martinez de Ibarreta, MJ; Pablo, V; Santafe, J; Segarra, J, 1993)	0.29
"To develop methods for constructing a pharmacokinetic model to predict the time course of aqueous humor and plasma drug concentrations after topical dosage in rabbits using the simulation program iThink (formerly STELLA; High Performance Systems, Lyme, NH)."	( A model to predict aqueous humor and plasma pharmacokinetics of ocularly applied drugs. Grass, GM; Lee, VH, 1993)	0.29
" Dosing was twice daily."	( Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma. Bahr, RL; DuBiner, HB; Gunn, R; Hill, R; Hurvitz, LM; Kaufman, H; Keates, EU; Mandell, AI; Mundorf, TK; Ropo, A; Sassani, JW; Schwartz, LW; Starita, RJ; Stewart, WC; Towey, AW; Zimmerman, TJ, 1996)	0.29
"To investigate the efficacy and dose-response relationship of three concentrations (0."	( A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group. Strahlman, E; Tipping, R; Vogel, R, 1996)	0.29
"5% timolol 8 hours after dosing on days 1, 30, and 90; and a significant difference (P < ."	( A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Horwitz, B; Kottler, M; Laibovitz, R; Ritch, R; Stewart, RH; Stewart, WC, 1996)	0.29
"The objective of the present study was to determine the basis for dosing time-dependent changes in the ocular and systemic absorption of topically applied timolol in pigmented rabbits."	( Basis for dosing time-dependent changes in the ocular and systemic absorption of topically applied timolol. Balant, L; Gex-Fabry, M; Gurny, R; Lee, VH; Martenet, M; Ohdo, S; Podder, SK; Sintzel, MB; Yamahara, H, 1996)	0.29
" Dose-response curves were fitted with a nonlinear regression microcomputer programme."	( A complex interaction between topical verapamil and timolol on intraocular pressure in conscious rabbits. Garrido, M; Martínez de Ibarreta, MJ; Melena, J; Santafé, J; Segarra, J, 1996)	0.29
"005%, once-a-day dosing of latanoprost is highly effective in significantly reducing intraocular pressure, causing only minimal, clinically acceptable short-term ocular side effects."	( Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Diestelhorst, M; Krieglstein, GK; Lusky, M; Nagasubramanian, S, 1997)	0.3
"055 nmol from the dose-response curve."	( Central regulation of urine production by a selective mu-opioid agonist, [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin, in rats. Matsuda, T; Mori, M; Tsushima, H, 1997)	0.3
"5% are highly effective in lowering intraocular pressure when measured at the end of the dosing interval."	( Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, H, 1997)	0.3
" The only variation in method between the two studies was the dosage of 2% dorzolamide."	( The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group. Adamsons, I; Clineschmidt, C; Laibovitz, R; Polis, A; Shedden, A; Taylor, J, 1998)	0.3
" Ninety-two percent of patients preferring timolol gel strongly agreed or agreed that once-daily dosing was a reason for their preference."	( Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Gormley, G; Hartenbaum, D; Liss, C; Maloney, S; Schenker, H, 1999)	0.3
"), when both are dosed once daily on the exercise performance."	( Systemic beta-blockade with once daily Betimol or Timoptic-XE. Cate, EA; Stewart, JA; Stewart, WC, 1999)	0.3
" In patients under long-term therapy, the periocular tissue can accumulate a greater quantity of beta-antagonist than is present in a daily dosage of applied eyedrops, manyfold higher than the maximal intraocular concentration."	( Periocular accumulation of timolol and betaxolol in glaucoma patients under long-term therapy. Frenzel, H; Khuu, HD; Lam, KW; Sponsel, WE; Terry, S, 1999)	0.3
"Phenylephrine dose-dependently contracted ciliary artery smooth muscle, and bunazosin (1 microM) shifted this dose-response curve to the right."	( Effects of beta antagonists on mechanical properties in rabbit ciliary artery. Hayashi, E; Hayashi-Morimoto, R; Ishikawa, H; Sato, Y; Yoshitomi, T, 1999)	0.3
"To compare the 24-hour diurnal ocular hypotensive efficacy of two dosing regimens of latanoprost, once daily (8 AM or 10 PM), vs timolol maleate, twice daily."	( Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Gandi, S; Hudgins, AC; Konstas, AG; Maltezos, AC; Stewart, WC, 1999)	0.3
"005% given at 8 AM or 10 PM for 1 month and then changed to the other dosing regimen for 1 month."	( Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Gandi, S; Hudgins, AC; Konstas, AG; Maltezos, AC; Stewart, WC, 1999)	0.3
" When dosed according to labeling, latanoprost had the lowest cost of therapy at $0."	( Daily cost of newer glaucoma agents. Hudgins, AC; Pruitt, CA; Sine, C; Stewart, WC, 1999)	0.3
" The peak level 2 hours after dosing for timolol hemihydate was 16."	( Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Day, DG; Dubiner, HB; Holmes, KT; Sharpe, ED; Stewart, JA; Stewart, WC, 1999)	0.3
"9 mm Hg with brinzolamide twice-daily dosing and -2."	( The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March, WF; Ochsner, KI, 2000)	0.31
"Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months."	( The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March, WF; Ochsner, KI, 2000)	0.31
" The efficacy of this formulation in short-term studies using once-daily dosing has been reported."	( Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Laurence, J; Shedden, A; Tipping, R, 2001)	0.31
" Twice-daily dosing of bimatoprost also provided significantly greater mean reductions in IOP than timolol at most time points but was not as effective as once-daily dosing."	( Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Brandt, JD; Chen, K; VanDenburgh, AM; Whitcup, SM, 2001)	0.31
" Each treatment period consisted of 6 weeks of chronic dosing followed by a diurnal curve for the intraocular pressure measured at 08:00, 10:00, 16:00, 18:00, 20:00, 22:00, and 24:00 hours."	( Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Holmes, KT; Konstas, AG; Stangos, NT; Stewart, WC; Tersis, I; Topouzis, F, 2001)	0.31
" BID dosing of bimatoprost also provided significantly greater mean IOP reductions than timolol at most timepoints, but was not as effective as QD dosing."	( Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Brandt, J; Sherwood, M, 2001)	0.31
"The objective of this study was to compare plasma concentrations of timolol following multiple dosing of the therapeutic regimens of timolol maleate ophthalmic gel-forming solution (Timolol GS; TIMOPTIC-XE) and timolol maleate ophthalmic solution."	( Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Barrish, A; Laurence, J; Olah, TV; Shedden, AH, 2001)	0.31
"Subjects who qualified at screening began a run-in period dosing timolol twice daily for 3 weeks."	( Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Davis, AA; Landry, T; Orengo-Nania, S; Silver, LH; Von Tress, M; Weiner, A, 2001)	0.31
" A clear dose-response relationship exists in all ocular tissues studied after an intraperitoneal dose of timolol."	( Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing. Archibald, ML; Chauhan, BC; Kelly, ME; LeVatte, TL; Tan, AY; Tremblay, F, 2002)	0.31
" Good linearity, precision and selectivity were found, and the proposed methods were applied successfully to the pharmaceutical dosage from containing the above-mentioned drug combination without any interference by the excipients."	( Simultaneous determination of dorzolamide HCL and timolol maleate in eye drops by two different spectroscopic methods. Erk, N, 2002)	0.31
" The reduction in IOP was maintained throughout the 24-hour dosage interval."	( Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Easthope, SE; Perry, CM, 2002)	0.31
"1 mm Hg) dosed latanoprost/timolol maleate compared with timolol maleate given twice daily (21."	( A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Konstas, AG; Lallos, NA; Leech, JN; Nakos, E; Stewart, WC; Tersis, I, 2002)	0.31
"The subjects in this prospective, double-masked, crossover comparison were dosed 15 min prior to treadmill testing."	( Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Jackson, AL; Stewart, JA; Stewart, WC, 2002)	0.31
"Rates of medication discontinuation reflect factors including effectiveness, tolerability, cost, and dosing frequency."	( Discontinuation rates of topical glaucoma medications in a managed care population. Cho, J; Mullins, CD; Shaya, FT; Wong, W, 2002)	0.31
" The diurnal intraocular pressure as well as the 08:00 trough and +2 hour post dosing pressures were statistically equal between groups, although a trend to a lower mean pressure was observed in the TXE (17."	( The safety and efficacy of timolol 0.5% in xanthan gum versus timolol gel forming solution 0.5%. Hott, CE; Sharpe, ED; Stewart, JA; Stewart, WC, 2002)	0.31
"TXE demonstrates a lower intraocular pressure eight hours after dosing than does TXG, but safety appears similar between products."	( The safety and efficacy of timolol 0.5% in xanthan gum versus timolol gel forming solution 0.5%. Hott, CE; Sharpe, ED; Stewart, JA; Stewart, WC, 2002)	0.31
"25% drops in twice daily dosage and does not result in any significant ocular and systemic adverse effects."	( A prospective, long-term, randomized study of the efficacy and safety of the drug combination pilocarpine 1% with clonidine 0.06% or clonidine 0.125% versus timolol 0.25%. Agarwal, H; Rajashekhar, YL; Sihota, R; Venkatesh, P, 2002)	0.31
"3%) mainly because of its once daily dosing (P < 0001)."	( The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Konstas, AG; Kozobolis, VP; Leech, J; Stewart, WC; Tersis, I, 2003)	0.32
"005% lasts for up to 24 hours after a single topical dose, which allows for a once-daily dosage regimen."	( Latanoprost : an update of its use in glaucoma and ocular hypertension. Culy, CR; Ibbotson, T; McGavin, JK; Perry, CM, 2003)	0.32
"Intravenous dosing was initially done via jugular cannula."	( Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation. Banga, AK; Betageri, GV; Chaturvedula, A; Conjeevaram, R; Sunkara, G, 2003)	0.32
" Once-a-day dosing with timolol + latanoprost has not been compared with a betablocker + pilocarpine combination."	( Timolol + latanoprost: new preparation. Last-resort eye drops. , 2003)	0.32
" Due to the unique mechanism of action of latanoprost, once-daily dosing of one drop of FC latanoprost/timolol results in additional IOP reduction compared with either drug administered separately."	( An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Feldman, RM, 2004)	0.32
"Fixed combination latanoprost/timolol administered once daily is both more effective and better tolerated than twice daily dosing with UFC brimonidine/timolol."	( A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. Cunliffe, I; García-Sánchez, J; Landry, J; Pajic, B; Rouland, JF; Spiegel, D; Traverso, C, 2004)	0.32
"005% dosed once in the evening."	( A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Harris, A; Janulevicienë, I; Kagemann, L; McCranor, L; Siesky, B, 2004)	0.32
"In previous analyses of primary efficacy data from two randomized clinical trials, standard dosing regimens of the dorzolamide/timolol fixed combination (COSOPT) and latanoprost (XALATAN) were shown to have equivalent efficacy with regard to reduction in mean daytime diurnal intraocular pressure (IOP)."	( Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. Adamsons, IA; Fechtner, RD; Lines, CR; McCarroll, KA, 2005)	0.33
"A prospective, observer-masked, crossover, active-controlled, randomized comparison in which after a 6-week medicine-free period, patients were randomized to either latanoprost-timolol-fixed combination therapy or latanoprost therapy, both dosed once each evening, alone for 8 weeks."	( Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Boboridis, K; Jenkins, JN; Kallinderis, K; Konstas, AG; Stewart, WC; Tzetzi, D, 2005)	0.33
" This study demonstrates that the fixed combination of travoprost/timolol produces significant and clinically relevant reductions of IOP in a once-daily dosing regimen."	( Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Bergamini, MV; Henry, JC; Katz, GJ; Landry, TA; Lewis, RA; Mallick, S; Robertson, SM; Schuman, JS; Sullivan, EK; Wells, DT, 2005)	0.33
" IOP was assessed pre-dose and 2 hours after morning dosing at weeks 2, 6, and 12."	( 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Goñi, FJ, )	0.13
" Its simplified dosing regimen has the potential to improve compliance."	( 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Goñi, FJ, )	0.13
"A retrospective, comparative, parallel group study was conducted on 78 eligible patients diagnosed with open-angle glaucoma who received topical timolol gel-forming solution either on morning (AM dosing group; 39 patients) or evening (PM dosing group; 39 patients) as monotherapy treatment."	( The efficacy of timolol in gel-forming solution after morning or evening dosing in Asian glaucomatous patients. Balaravi, P; Cheong, MT; Chieng, LL; Liza-Sharmini, AT; Ong, LB; Shin, HC; Vengadasalam, SR, 2005)	0.33
" Morning dosing was more effective in lowering the IOP compared to evening dosing."	( The efficacy of timolol in gel-forming solution after morning or evening dosing in Asian glaucomatous patients. Balaravi, P; Cheong, MT; Chieng, LL; Liza-Sharmini, AT; Ong, LB; Shin, HC; Vengadasalam, SR, 2005)	0.33
"5% ophthalmic solution dosed in the morning and evening."	( A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Andrew, R; Denis, P; Friren, B; Wells, D, )	0.13
"5% ophthalmic solution, dosed in the morning or evening, controlled IOP consistently throughout the day."	( A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Andrew, R; Denis, P; Friren, B; Wells, D, )	0.13
" The TRAV group (n = 29) dosed once daily at 9:00 PM while the DTFC group (n = 27) dosed twice daily at 9:00 AM and 9:00 PM."	( Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Batista, WD; da Silva, LJ; Figueiredo, CR; Franklin, LM; Netto, JA; Suzuki, ER, 2006)	0.33
" The steady-flow J of high, middle and low dosage groups of puerarin eye drops with borneol were increased by 49%, 32%, 5% respectively, and permeability parameter Kp increased by 49%, 32%, 5% respectively, as compared to that of the control group."	( Promoting effect of borneol on the permeability of puerarin eye drops and timolol maleate eye drops through the cornea in vitro. Guo, P; Hou, SX; Huang, QW; Qi, HY; Wu, CJ, 2006)	0.33
"After a medicine-free period, qualified patients were randomized to either placebo dosed in the morning with a latanoprost-timolol fixed combination dosed in the evening or timolol alone dosed twice daily for 8 weeks."	( 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Economou, AI; Jenkins, JN; Kaltsos, K; Konstas, AG; Lake, S; Stewart, WC, 2006)	0.33
"Qualified patients at Visit 1 were placed on travoprost dosed every evening for 4 weeks and then were randomized at baseline (Visit 2) to the addition of timolol maleate or brinzolamide each given twice daily."	( The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Berta, A; Chiselita, D; Cvenkel, B; Holló, G; Izgi, B; Liehneova, I; Petkova, N; Stewart, WC; Szaflik, J; Turacli, E, )	0.13
"5% ophthalmic solution (Lat/Tim), dosed once daily in the morning, in patients with open-angle glaucoma (OAG) or ocular hypertension (OH)."	( A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Andrew, R; Danesh-Meyer, H; Kozobolis, V; Melamed, S; Topouzis, F; Wells, AP; Wells, D; Wieland, H, )	0.13
"To evaluate the 24-h intraocular pressure (IOP) control of brimonidine/timolol fixed combination (BTFC) versusthe unfixed combination of its individual components, each dosed twice daily, in patients with primary open-angle glaucoma or ocular hypertension."	( Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Georgiadou, I; Kaltsos, K; Katsimpris, IE; Konstas, AG; Kordelou, A; Nelson, LA; Stewart, WC, 2008)	0.35
" Patients then began DTFC dosed at 08."	( Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy. Henry, JC; Nelson, LA; Sharpe, ED; Sonty, S; Stewart, JA; Stewart, WC; Weiss, MJ, 2008)	0.35
" Treatment with a fixed combination may, therefore, increase compliance as a result of simplifying the dosage regimen."	( Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension. Martinez, A; Sanchez, M, 2008)	0.35
"Both morning and evening dosing of LTFC were effective in lowering diurnal IOP in patients with POAG."	( Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Aşik, S; Can, I; Gurdal, C; Kürkçüoğlu, P; Takmaz, T, )	0.13
"5%, dosed twice daily and were followed up while receiving therapy for 6 months."	( Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Arzeno, G; Bergamini, MV; Dickerson, JE; Hua, SY; James, JE; Kaback, M; Landry, TA; Salem, C; Scoper, SV, 2008)	0.35
"To compare the 12-hour efficacy and safety of dorzolamide/timolol fixed combination (DTFC) dosed twice daily versus latanoprost dosed every evening following a timolol run-in in primary open-angle glaucoma patients."	( Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. Ahmad, A; Mulaney, J; Sonty, S; Stewart, JA; Stewart, WC, )	0.13
" Patients randomised to bimatoprost twice daily had been switched to bimatoprost once daily dosing at month 24 (bimatoprost twice daily/once daily treatment group), and continued with once daily dosing through month 48 (n = 39)."	( Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Batoosingh, AL; Cohen, JS; Gross, RL; Liu, CC; Safyan, E; Williams, RD, 2008)	0.35
" Patients with an IOP of 22-29 mmHg inclusive at 8 AMwere randomized to either bimatoprost dosed each evening or DTFC twice-daily."	( A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. Nelson, LA; Sharpe, ED; Stewart, JA; Stewart, WC; Williams, RD, 2008)	0.35
"To evaluate the 24 h efficacy and safety of the travoprost/timolol maleate fixed combination (TTFC) versus travoprost when both are dosed in the evening in primary open-angle glaucoma patients."	( Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Haidich, AB; Konstas, AG; Mikropoulos, D; Ntampos, KS; Stewart, WC, 2009)	0.35
"This study suggests that when both drugs are dosed in the evening the TTFC provides improved intraocular pressure reduction, compared with travoprost, over the 24 h curve and for each individual time point in primary open-angle glaucoma patients."	( Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Haidich, AB; Konstas, AG; Mikropoulos, D; Ntampos, KS; Stewart, WC, 2009)	0.35
" Patients were then treated with the opposite dosing regimen for 8 weeks and IOP measurements were repeated."	( Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Konstas, AG; Nasr, MB; Nelson, LA; Stewart, JA; Stewart, WC; Tsironi, S; Vakalis, AN, 2009)	0.35
"Both morning and evening administration of TTFC provide effective 24-hour IOP reduction, but evening dosing demonstrates better 24-hour pressure control."	( Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Konstas, AG; Nasr, MB; Nelson, LA; Stewart, JA; Stewart, WC; Tsironi, S; Vakalis, AN, 2009)	0.35
"Of the 437 patients enrolled, 220 dosed Brinz/Tim whereas 217 dosed Dorz/Tim twice daily."	( The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Aung, T; Chew, P; Coote, MA; Denis, P; Filatori, I; James, J; Laganovska, G; Manni, G; Orengo-Nania, S; Sharpe, ED; Volksone, L; Zeyen, T, )	0.13
"Patients with primary open-angle glaucoma or ocular hypertension with normal blood pressure were randomized to LTFC, dosed each evening, or timolol dosed twice daily in a cross-over design for 8 weeks and the opposite medicine for 8 weeks."	( 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Konstas, AG; Kozobolis, VP; Lasaridis, AN; Mikropoulos, D; Nelson, LA; Pikilidou, MI; Sarafidis, PA; Stewart, WC; Tsironi, S, 2009)	0.35
"Functional synergy between excipients in gellan gum formulations buffered with l-carnosine has potential for topical ocular dosage forms with sustained precorneal residence."	( L-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations. Carreiro, ST; Chu, J; Collette Iii, WW; Gukasyan, HJ; Niesman, MR; Prasanna, G; Sartnurak, S; Singh, SR; Younis, HS, 2009)	0.35
" For prostaglandins, dosing time was suggested in the morning by 18 (36%) ophthalmologists and in the evening by 24 (48%) (p=0."	( Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union. Kruft, B; Nelson, LA; Stewart, JA; Stewart, WC, )	0.13
"Both BTFC dosing regimens significantly reduce 24 h IOP in XFG compared with bimatoprost monotherapy."	( Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Embeslidis, T; Georgiadou, I; Haidich, AB; Holló, G; Irkec, M; Konstas, AG; Melamed, S; Mikropoulos, D; Tsironi, S, 2010)	0.36
" After topical dosing to the eye in a steroid induced mouse model of ocular hypertension, the compounds reduce intraocular pressure to baseline levels."	( Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. Allen, J; Almstead, ZY; Courtney, LF; Crist, M; Crosson, CE; Gardyan, M; Gopinathan, S; Gu, KJ; Hamman, BD; Harrison, BA; Key, B; Kimball, SD; Liu, Q; Liu, Y; Mabon, R; McKnight, B; Patel, N; Rawlins, DB; Rice, DS; Voronkov, MV; Whitlock, NA; Wilson, AG; Yates, PW; Zhang, Y; Zhou, J, 2009)	0.35
"To assess adherence in glaucoma patients using the Travatan Dosing Aid (TDA); to record differences in adherence by age, sex, therapy, systemic therapies, years from diagnosis, type of therapy and intraocular pressure (IOP)."	( Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Bianchi, PE; Milano, G; Pasinetti, GM; Rossi, GC; Scudeller, L; Tinelli, C, 2010)	0.36
" However, the fixed dosing may be a disadvantage in some cases."	( Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Katz, LJ; Razeghinejad, MR; Sawchyn, AK, 2010)	0.36
"Application of timolol maleate (TM) in a conventional dosage form (solution) into the eye results in almost 80% of the instilled dose being lost either through spillage or due to drainage into the nasolacrimal duct."	( Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. Aggarwal, D; Kakkar, S; Kaur, IP; Singh, H, 2010)	0.36
"After up to a 6-week medicine-free period, XFG patients were randomized to either TTFC or LTFC for 3 months, dosed each evening, and then changed to the opposite treatment for another 3 months."	( 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Dimopoulos, AT; Embeslidis, TA; Haidich, AB; Konstas, AG; Mikropoulos, DG; Papanastasiou, A; Stewart, WC, 2010)	0.36
"2%) and desire to simplify treatment with once-daily dosing (29."	( Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. Guzy, C; Heckmann, B; Miller, PJ; Schwenn, O, 2010)	0.36
"5%), in order to evaluate both efficacy (intraocular pressure lowering) and tolerability (patient and investigator satisfaction) of two dosing regimens--evening (PM) and morning (AM)."	( Comparison of evening and morning dosing of travoprost 0.004%/timolol 0.5% fixed combination in 6 month period. Bojić, L; Dosen, VM; Ekert, M; Laus, KN; Mandić, Z; Suić, SP, 2010)	0.36
"To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid® (TDA)."	( Do adherence rates and glaucomatous visual field progression correlate? Bianchi, PE; Pasinetti, GM; Radaelli, R; Rossi, GC; Scudeller, L, )	0.13
"Both topical β blockers with a once-daily dosing regimen temporarily deteriorate optical quality of the eye by increasing higher-order aberrations, and the increases are much larger after instillation of timolol gel than long-acting carteolol."	( Time course of changes in ocular aberrations after instillation of carteolol long-acting solution and timolol gel-forming solution. Daito, M; Hiraoka, T; Kiuchi, T; Okamoto, F; Oshika, T, 2011)	0.37
" The potential benefit to the human ocular surface with oncedaily dosing needs to be evaluated clinically."	( Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Baudouin, C; Brignole-Baudouin, F; Liang, H; Pauly, A; Riancho, L, 2011)	0.37
"In this prospective randomized controlled trial, subjects with IOP of at least 22 mm Hg in one or both eyes at 0900 h, and IOP of at least 21 mm Hg in one or both eyes at 1100 h and 1600 h at two eligibility visits were randomly assigned to receive either TRA/TIM BAK-free (n=195) or TRA/TIM (n=193), dosed once daily in the morning (0900 h) for 6 weeks."	( Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Bae, K; Iwamoto, Y; Kitazawa, Y; Kotake, S; Sasaki, N; Smith, P, 2011)	0.37
" Measurement of intraocular pressure (IOP) of the right eye (by a blinded observer) was performed on day 1 of each study period pre-dose and 2 h post dosing by means of Goldmann applanation tonometry."	( Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers. Demircheva, I; Gatchev, E; Hristova, R; Kolev, E; Koytchev, R; Petrov, A; Richter, W; Tegel, F; Thyroff-Friesinger, U, 2011)	0.37
" A change was done from prior monotherapy at day 0 to TTFC dosed once a day, regardless in the evening or in the morning, without washout period."	( Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%/timolol 0.5%) in 6 months follow up period. Barisić, F; Biuk, D; Bojić, L; Clementi, D; Dobutović, D; Dogan, KK; Dosen, VM; Ekert, M; Geser, MZ; Iveković, R; Jurić-Miletić, A; Kovacević, S; Kovacić, Z; Krolo, I; Mandić, Z; Novak-Laus, K; Pavan, J; Pelcić, G; Popović-Suić, S; Susić, N; Tomić, M, 2010)	0.36
"This 8-week, randomized, open-label, parallel-group, noninferiority study compared once-daily evening dosing of LTFC with the unfixed combination of latanoprost, one drop in the evening, and timolol, one drop in the morning (LTuFC)."	( Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. Ge, J; Li, XX; Li, YM; Sheng, YH; Sun, NX; Sun, XH; Yao, K; Zhao, JL; Zhong, Z, 2011)	0.37
" All subjects were given a Travalert(®) dosing aid and were reviewed after one and four months."	( [The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients]. Escalada, A; García Sánchez, J; García-Feijoó, J; Martínez-de-la-Casa, JM; Sáenz-Francés, F; Sánchez-Pulgarín, M, 2011)	0.37
"Compliance is very important in the treatment of glaucoma, and our study provides objective data through the use of Travalert dosing aid with relative compliances of 70%."	( [The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients]. Escalada, A; García Sánchez, J; García-Feijoó, J; Martínez-de-la-Casa, JM; Sáenz-Francés, F; Sánchez-Pulgarín, M, 2011)	0.37
" This study utilises the methods of cassette dosing and the perfused ovine eye model - to reduce animal usage and therefore animal time - to show that for a series of beta adrenoreceptor antagonists, lipophilicity is a key physicochemical property that governs drug distribution within the eye."	( A pharmacokinetic study of a combination of beta adrenoreceptor antagonists - in the isolated perfused ovine eye. Mains, J; Tan, LE; Urquhart, A; Wilson, C, 2012)	0.38
" Each participant underwent aqueous humor dynamics measurements at baseline and at 2 weeks of dosing in random order with latanoprost in the evening and placebo in the morning, timolol maleate twice daily, and dorzolamide hydrochloride twice daily."	( Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Fan, S; Gangahar, C; Gulati, V; Maslonka, MA; Toris, CB; Zhao, M, 2012)	0.38
"83 mmHg) was comparable with that by eye drops with similar drug dosing (4."	( Drug delivery by contact lens in spontaneously glaucomatous dogs. Ben-Shlomo, A; Chauhan, A; Mackay, EO; Peng, CC; Plummer, CE, 2012)	0.38
"005% (n = 75, dosed in the evening, with vehicle control in the morning to maintain masking) for 12 weeks."	( Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Cottingham, AJ; Hollander, DA; Katz, LJ; Rauchman, SH; Schiffman, RM; Simmons, ST; Williams, JM, 2012)	0.38
"To study the effect of patient education and the TravAlert(®) -Eyot(®) drop guider on intraocular pressure (IOP) and adherence in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) monitored with the TravAlert(®) dosing aid."	( Adherence improvement in Dutch glaucoma patients: a randomized controlled trial. Beckers, HJ; Brink, HM; Busch, MJ; Colen, TP; Schouten, JS; Webers, CA, 2013)	0.39
" Patients were randomized to one of the four study arms: (1) use of the dosing aid, (2) use of the dosing aid with the drop guider, (3) use of the dosing aid together with patient education or (4) use of the dosing aid and drop guider together with patient education."	( Adherence improvement in Dutch glaucoma patients: a randomized controlled trial. Beckers, HJ; Brink, HM; Busch, MJ; Colen, TP; Schouten, JS; Webers, CA, 2013)	0.39
" However, the effect and mechanism of dosage form pH upon skin permeation of these weak bases is not well understood."	( Evaluation of skin permeation of β-blockers for topical drug delivery. Chantasart, D; Hao, J; Li, SK, 2013)	0.39
" Based on the optimized formulation, triple-layered ocular inserts (reservoir type) of dual drug were prepared by solvent casting technique with an objective of reducing the frequency of administration, obtaining controlled release and greater therapeutic efficacy, preservative free dosage form for the treatment of glaucoma."	( Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate-brimonidine tartrate ocular inserts. Appapurapu, AK; Ravindran, VK; Repala, S; Subadhra, S, 2014)	0.4
"Bimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components."	( Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chen, X; Dong, Y; Fang, A; Hu, Y; Ling, Z; Liu, D; Sun, W; Sun, X; Wang, Y; Xing, Y; Ye, J; Yin, Z; Zhang, M, 2014)	0.4
" The method is successfully applied for the determination of TM in bulk powder and pharmaceutical dosage form."	( Development and validation of a stability-indicating micellar liquid chromatographic method for the determination of timolol maleate in the presence of its degradation products. Merey, HA; Rizk, MS; Sweilam, MN; Tawakkol, SM, 2015)	0.42
" The aqueous humor concentration of the second administered drug (tafluprost) was not affected by the dosing conditions, whereas the concentration of the first instilled drug (timolol) without the interval was lower than that with a 5-min interval (1,200 ng · h/mL vs."	( Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models. Akaishi, T; Kawazu, K; Miyawaki, N; Shimazaki, A; Tonouchi, A; Ueda, K, 2015)	0.42
" A wash-out interval of at least 4 weeks separated each three 8-day dosing period."	( Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Ikäheimo, K; Kaarniranta, K; Mannermaa, E; Ropo, A, 2016)	0.43
"Plasma concentrations of tafluprost acid were low, with similar levels measured subsequent to either single or repeated dosing of PF FDC and PF tafluprost."	( Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Ikäheimo, K; Kaarniranta, K; Mannermaa, E; Ropo, A, 2016)	0.43
" Globally, eye drops are among the most common and popular conventional formulations, but they are also associated with some limitations in terms of therapeutic response, bioavailability, dosing frequency and poor patient compliance."	( Medical management of glaucoma: focus on ophthalmologic drug delivery systems of timolol maleate. Sah, AK; Suresh, PK, 2017)	0.46
"5% (TRAV+TIM; unfixed) using electronic dosing aids."	( Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. Barnebey, HS; Robin, AL, 2017)	0.46
"TTFC was administered once daily in the morning or evening with a single dosing aid."	( Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. Barnebey, HS; Robin, AL, 2017)	0.46
"Adherence with administered medication, as recorded by the dosing aids."	( Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. Barnebey, HS; Robin, AL, 2017)	0.46
" However, the appropriate indications, drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects still remains controversial."	( [Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas]. Fan, XD; Huo, R; Jiang, CH; Lei, SR; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016)	0.43
" This includes liquid phase formulation localisation on the ocular surface once administered as formulated eye-drops; with the vast majority of dosage (>90%) escaping from the administered site due to tear production and various drainage mechanisms."	( Electrically atomised formulations of timolol maleate for direct and on-demand ocular lens coatings. Ahmad, Z; Al-Kinani, AA; Alany, RG; Arshad, MS; Chang, MW; Haj-Ahmad, R; Mehta, P, 2017)	0.46
" Gel dosage form allows easy and precise application and maximizes timolol's therapeutic efficacy at the sites of application."	( Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas. Choo, W, )	0.13
"This study also indicates that in vitro hepatic metabolism is over-predictive of ocular metabolism following topically ocular dosed timolol."	( Investigation of Ocular Bioactivation Potential and the Role of Cytochrome P450 2D Enzymes in Rat. Argikar, UA; Brown, A; Cirello, AL; Dumouchel, JL; Dunne, CE; Gunduz, M; Kramlinger, VM; Spear, J, )	0.13
" Transdermal drug delivery system is the main route with discrete, self-contained dosage forms when placed on the skin, transporting the medicament through the skin into the systemic circulation in a wellcontrolled manner."	( Design and Evaluation of Transdermal Patches of Timolol Maleate. Jamakandi, VG; Panchayya Hiremath, SS; Reddy, JJ, 2018)	0.48
" This report offers a simplified calculation of the maximum daily safe dosage as 1 drop of medication per kilogram of body weight."	( Doing the math: A simple approach to topical timolol dosing for infantile hemangiomas. Dalla Costa, R; Prindaville, B; Wiss, K, 2018)	0.48
" Fixed dose combinations (FDCs) are a pharmacological form of eye drops that combines two or more active drugs in a single dosage form."	( [The role of fixed dose combinations in the treatment of primary open-angle glaucoma]. Petrov, SY; Volzhanin, AV; Zinina, VS, )	0.13
" This is likely to offer an alternative dosage form for management of glaucoma with particular emphasis on improving poor patient compliance."	( Engineering and Development of Chitosan-Based Nanocoatings for Ocular Contact Lenses. Ahmad, Z; Al-Kinani, AA; Alany, RG; Arshad, MS; Chang, MW; Mehta, P; Singh, N; van der Merwe, SM, 2019)	0.51
"Timolol is a non-cardioselective beta blocker and has different combined ophthalmic dosage forms for treatment of glaucoma."	( A versatile HPLC method with an isocratic single mobile phase system for simultaneous determination of anti-glaucoma formulations containing timolol. El Abass, SA; Elmansi, HM; Ibrahim, FA, 2019)	0.51
" The utilization of simulated biological fluids can give a superior understanding of the release mechanisms and practicable in vivo nature of a dosage form that can improve the predictive potential of in vitro drug release testing."	( Simultaneous determination of dorzolamide and timolol by first-order derivative UV spectroscopy in simulated biological fluid for in vitro drug release testing. Amin, P; Jain, D; Tambe, S, 2021)	0.62
" Propranolol can commence for most infants in the outpatient setting and the most frequently employed dosing regimen is 1 mg/kg twice daily."	( Infantile hemangioma. Part 2: Management. Rodríguez Bandera, AL; Sebaratnam, DF; Wargon, O; Wong, LF, 2021)	0.62
" Both the PD(+) group and the PD(-) group were evaluated using clinical data such as age, sex, dosing duration, presence of benzalkonium chloride (BAK) in the formulation, ocular surgery history (e."	( Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops. Jang, H; Kim, M; Rho, S, 2021)	0.62
" However, they were not necessarily considered unreasonable because the dosage forms were administered at different times."	( The use of fixed dose drug combinations for glaucoma in clinical settings: a retrospective, observational, single-centre study. Huang, T; Shen, J; Xiong, X; Yan, J, 2022)	0.72
"Most common intraocular pressure (IOP) reduction regimens for the management of glaucoma include the topical use of eye drops, a dosage form that is associated with short residence time at the site of action, increased dosing frequency, and reduced patient compliance."	( In Situ Gelling Electrospun Ocular Films Sustain the Intraocular Pressure-Lowering Effect of Timolol Maleate: In Vitro, Ex Vivo, and Pharmacodynamic Assessment. Andreadis, D; Andreadis, II; Bouropoulos, N; Fatouros, DG; Karavasili, C; Komnenou, A; Thomas, A; Tzetzis, D; Tzimtzimis, M, 2022)	0.72
" All subjects were randomized in a 1:1 ratio to LBN dosed once daily or timolol dosed twice daily in both eyes (OU) for a duration of 4 weeks each, separated by a 2-week washout period."	( Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial. Brye, N; Camp, A; Do, JL; El-Nimri, NW; Ghahari, E; Moghimi, S; Penteado, RC; Proudfoot, J; Rubio, V; Salcedo, M; Weinreb, RN; Yang, D, 2022)	0.72
" Country-level subanalysis examined outcomes by prior monotherapy, diagnosis and timing of dosing for those countries recruiting ≥20 patients (Country-level Subanalysis Population)."	( A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy. Fassari, C; Holló, G; Kirwan, J; Lopez-Lopez, F; Oddone, F; Zimina, M, 2022)	0.72
" Within country, outcomes were consistent regardless of diagnosis, dosing or prior monotherapy."	( A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy. Fassari, C; Holló, G; Kirwan, J; Lopez-Lopez, F; Oddone, F; Zimina, M, 2022)	0.72

Role	Description
antiglaucoma drug	Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
anti-arrhythmia drug	A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
beta-adrenergic antagonist	An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
timolol	1,2,5-Thiadiazole substituted at the 3 position by a 3-(tert-butylamino)-2-hydroxypropoxy group and at the 4 position by a morpholin-4-yl group. The (S)-(-) enantiomer, also known as timolol, is a beta-adrenergic antagonist and is used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	22.3872	0.0040	23.8416	100.0000	AID485290
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	1.4125	0.1000	20.8793	79.4328	AID588453
NFKB1 protein, partial	Homo sapiens (human)	Potency	10.0000	0.0282	7.0559	15.8489	AID895; AID928
TDP1 protein	Homo sapiens (human)	Potency	33.4983	0.0008	11.3822	44.6684	AID686978
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	6.7016	0.5318	15.4358	37.6858	AID504845
cytochrome P450 2D6	Homo sapiens (human)	Potency	7.7619	0.0010	8.3798	61.1304	AID1645840
arylsulfatase A	Homo sapiens (human)	Potency	0.2685	1.0691	13.9551	37.9330	AID720538
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	6.0070	19.7391	45.9784	64.9432	AID1159509
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	17.3851	0.0020	7.5337	39.8107	AID891
chromobox protein homolog 1	Homo sapiens (human)	Potency	31.6228	0.0060	26.1688	89.1251	AID488953
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	19.9526	0.0316	10.2792	39.8107	AID884; AID885
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	5.0119	0.0010	6.0009	35.4813	AID943
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0008	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	19.9526	1.0000	12.2248	31.6228	AID885
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	42.5615	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	134.0000	0.1100	7.1903	10.0000	AID1443980; AID1473738
Beta-2 adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0003	0.0002	0.9326	7.2000	AID625205
Beta-2 adrenergic receptor	Homo sapiens (human)	Ki	0.0002	0.0000	0.6635	9.5499	AID1350481; AID625205
Beta-1 adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0026	0.0002	1.4681	9.0000	AID625204
Beta-1 adrenergic receptor	Homo sapiens (human)	Ki	0.0034	0.0001	1.3391	9.9840	AID1350482; AID625204
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	11.0000	0.0000	2.0151	10.0000	AID241889
Beta-3 adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.4520	0.0023	3.2415	8.0600	AID625206
Beta-3 adrenergic receptor	Homo sapiens (human)	Ki	0.3390	0.0030	2.3098	6.0450	AID625206
Beta-1 adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.1379	0.0000	0.6673	10.0000	AID266006; AID266007; AID266008; AID266009; AID266010
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.7120	0.0003	1.3833	8.4000	AID625190
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	1.0833	0.0001	0.7396	10.0000	AID4411; AID625190
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.7120	0.0005	1.4835	7.8000	AID625190
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	Ki	1.5500	0.0003	1.2967	9.2440	AID625190
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-1 adrenergic receptor	Cavia porcellus (domestic guinea pig)	Kd	0.0004	0.0000	0.5358	8.3176	AID39943; AID42215
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0001	2.2933	8.5114	AID40869
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Beta-2 adrenergic receptor	Cavia porcellus (domestic guinea pig)	Kd	0.0002	0.0002	0.5477	4.4668	AID40868; AID40869
GABA theta subunit	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Kd	0.0002	0.0002	0.5629	4.4668	AID40869
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
diet induced thermogenesis	Beta-2 adrenergic receptor	Homo sapiens (human)
regulation of sodium ion transport	Beta-2 adrenergic receptor	Homo sapiens (human)
transcription by RNA polymerase II	Beta-2 adrenergic receptor	Homo sapiens (human)
receptor-mediated endocytosis	Beta-2 adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Beta-2 adrenergic receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome to lysosome transport	Beta-2 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase A signaling	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of bone mineralization	Beta-2 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-2 adrenergic receptor	Homo sapiens (human)
bone resorption	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of smooth muscle contraction	Beta-2 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of mini excitatory postsynaptic potential	Beta-2 adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of autophagosome maturation	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of lipophagy	Beta-2 adrenergic receptor	Homo sapiens (human)
cellular response to amyloid-beta	Beta-2 adrenergic receptor	Homo sapiens (human)
response to psychosocial stress	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of AMPA receptor activity	Beta-2 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Beta-1 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-1 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-1 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-1 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-1 adrenergic receptor	Homo sapiens (human)
fear response	Beta-1 adrenergic receptor	Homo sapiens (human)
regulation of circadian sleep/wake cycle, sleep	Beta-1 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-1 adrenergic receptor	Homo sapiens (human)
regulation of postsynaptic membrane potential	Beta-1 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-1 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-1 adrenergic receptor	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
receptor-mediated endocytosis	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
carbohydrate metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
generation of precursor metabolites and energy	Beta-3 adrenergic receptor	Homo sapiens (human)
energy reserve metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-3 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-3 adrenergic receptor	Homo sapiens (human)
eating behavior	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-3 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-3 adrenergic receptor	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
amyloid-beta binding	Beta-2 adrenergic receptor	Homo sapiens (human)
beta2-adrenergic receptor activity	Beta-2 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase binding	Beta-2 adrenergic receptor	Homo sapiens (human)
potassium channel regulator activity	Beta-2 adrenergic receptor	Homo sapiens (human)
identical protein binding	Beta-2 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-2 adrenergic receptor	Homo sapiens (human)
protein-containing complex binding	Beta-2 adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Beta-2 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-1 adrenergic receptor	Homo sapiens (human)
beta1-adrenergic receptor activity	Beta-1 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-1 adrenergic receptor	Homo sapiens (human)
PDZ domain binding	Beta-1 adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Beta-1 adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Beta-1 adrenergic receptor	Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential	Beta-1 adrenergic receptor	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
norepinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta3-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-3 adrenergic receptor binding	Beta-3 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-3 adrenergic receptor	Homo sapiens (human)
epinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nucleus	Beta-2 adrenergic receptor	Homo sapiens (human)
lysosome	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome	Beta-2 adrenergic receptor	Homo sapiens (human)
early endosome	Beta-2 adrenergic receptor	Homo sapiens (human)
Golgi apparatus	Beta-2 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
apical plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
neuronal dense core vesicle	Beta-2 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-2 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
early endosome	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-1 adrenergic receptor	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Beta-1 adrenergic receptor	Homo sapiens (human)
neuronal dense core vesicle	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-1 adrenergic receptor	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-3 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1211792	Hepatic clearance in human	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID165803	Percentage change of IOP in rabbits after 2 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID1350482	Displacement of [3H]-CGP12177 from human beta1 ADR expressed in HEK293T cell membranes after 90 mins by scintillation counting	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID266009	Antagonist activity at rat beta-1 adrenergic receptor W134A mutant expressed in CHO cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.
AID1487626	Reduction in intraocular pressure in Chinchilla rabbit assessed as maximal change in intraocular pressure at 0.1% after application of one drop (0.06 ml) of solution containing active compound/vehicle every hour (during 6 hours and after 24 hours) by auto	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Oxindole-based intraocular pressure reducing agents.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID42218	In vitro beta-1 adrenergic receptor activity was determined via inhibition of the positive chronotropic actions of isoproterenol in isolated guinea pig atrial preparations	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID7779	Oral bioavailability in human	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates.
AID781326	pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID42215	Compound was tested for its Beta-1 adrenergic receptor antagonistic activity on guinea pig atria	1982	Journal of medicinal chemistry, Aug, Volume: 25, Issue:8	Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene.
AID165798	Percentage change of IOP in rabbits after 0 min administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID409952	Inhibition of human brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID165807	Percentage change of IOP in rabbits after 3h administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID1211794	Fraction unbound in blood (not specified)	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID227718	Binding energy by using the equation deltaG obsd = -RT ln KD	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Functional group contributions to drug-receptor interactions.
AID40869	In vitro beta-2 adrenergic receptor activity was determined by measuring inhibition of the isoproterenol induced relaxation in isolated guinea pig tracheal chains contracted with PGF2-alpha	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID1487633	Reduction in intraocular pressure in Chinchilla rabbit assessed as maximum effective time required for reduction of intraaocular pressure at 0.1% after application of one drop (0.06 ml) of solution containing active compound/vehicle every hour (during 6 h	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Oxindole-based intraocular pressure reducing agents.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID165812	Percentage change of IOP in rabbits after 4 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID165814	Percentage change of IOP in rabbits after 5 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID1350490	Anti-glaucoma activity in hypertonic saline-induced hypertensive New Zealand albino rabbit model assessed as decrease in intraocular pressure at 0.25% instilled into eye vitreous along with 1% DRZ measured at 4 hrs post administration by pneumatonometric	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID166292	Effect on IOP of rabbits 1 hr after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID1434532	Antiglaucoma activity in hypertonic saline-induced New Zealand white rabbit transient ocular hypertensive model assessed as IOP lowering efficacy at 0.5% administered topically immediately after hypertonic saline injection measured at 120 mins post dose	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	New furoxan derivatives for the treatment of ocular hypertension.
AID350217	Octanol-water partition coefficient, log P of the cationic form of the compound	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID166309	Effect on IOP of rabbits 8 hr after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID165813	Percentage change of IOP in rabbits after 5 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID166306	Effect on IOP of rabbits 6 hr after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID230146	The cardioselectivity ratio was obtained by taking the antilog (pA2 beta1-pA2 beta2)	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.
AID1487625	Reduction in intraocular pressure in Chinchilla rabbit assessed as maximum effective time required for reduction of intraaocular pressure at 0.1% after application of one drop (0.06 ml) of solution containing active compound/vehicle every hour (during 6 h	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Oxindole-based intraocular pressure reducing agents.
AID350220	Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID266006	Antagonist activity at rat wild type beta-1 adrenergic receptor expressed in CHO cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID373867	Hepatic clearance in human hepatocytes in absence of fetal calf serum	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID40537	Selectivity for beta-1 adrenergic receptor	1988	Journal of medicinal chemistry, Nov, Volume: 31, Issue:11	Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID166300	Effect on IOP of rabbits 4 hr after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID165817	Percentage change of IOP in rabbits after 6 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID166298	Effect on IOP of rabbits 3h after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1487627	Reduction in intraocular pressure in Chinchilla rabbit assessed as maximum effective time required for reduction of intraaocular pressure at 0.1% after application of one drop (0.06 ml) of solution containing active compound/vehicle every hour (during 6 h	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Oxindole-based intraocular pressure reducing agents.
AID104489	Effect on intraocular pressure in right eye was tested by using transition ocular hypertension model at 10 min.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID241889	Inhibitory activity against recombinant human Cytochrome P450 2D6 (CYP2D6) after incubated for 45 minutes	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID21278	Permeability through isolated albino rabbit denuded (epithelium-free) cornea	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID1350487	Anti-glaucoma activity in hypertonic saline-induced hypertensive New Zealand albino rabbit model assessed as decrease in intraocular pressure at 0.25% instilled into eye vitreous measured at 2 hrs post administration by pneumatonometric analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID166289	Effect on IOP of rabbits 0 min after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID266010	Antagonist activity at rat beta-1 adrenergic receptor S190A mutant expressed in CHO cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.
AID165809	Percentage change of IOP in rabbits after 3h administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID350219	Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID165819	Percentage change of IOP in rabbits after 6 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID165822	Percentage change of IOP in rabbits after 8 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID467611	Dissociation constant, pKa of the compound	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID165800	Percentage change of IOP in rabbits after 1 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID1137403	In vivo beta-adrenergic receptor blockade in iv dosed anesthetized dog assessed as inhibition of isoproterenol-induced tachycardia	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID166302	Effect on IOP of rabbits 5 hr after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID186705	Comparative effect on Maximum fall in mean arterial pressure of spontaneously hypertensive rat at the dose 0.312 mg/kg per os	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID104346	Effect on intraocular pressure in left eye was tested by using transition ocular hypertension model at 20 min.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID28926	Effective permeability corrected for ionization	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID29813	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID91481	Binding constant against human serum albumin (HSA)	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Cheminformatic models to predict binding affinities to human serum albumin.
AID350218	Octanol-water partition coefficient, log PC of the compound	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID1137402	In vivo beta-adrenergic receptor blockade in iv dosed anesthetized dog assessed as inhibition of isoproterenol-induced hypotension	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID165806	Percentage change of IOP in rabbits after 30 min administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID39943	In vitro inhibitory activity against beta-1 adrenergic receptor measured by inhibition of positive chronotropic effect of isoproterenolin in isolated guinea pig atria	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.
AID1350488	Anti-glaucoma activity in hypertonic saline-induced hypertensive New Zealand albino rabbit model assessed as decrease in intraocular pressure at 0.25% instilled into eye vitreous along with 1% DRZ measured at 2 hrs post administration by pneumatonometric	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID165801	Percentage change of IOP in rabbits after 2 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID186706	Comparative effect on Maximum fall in mean arterial pressure of spontaneously hypertensive rat at the dose 0.625 mg/kg per os	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID104488	Effect on intraocular pressure in right eye was tested by using transition ocular hypertension model at 0 min.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID404304	Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1668042	Antiproliferative activity against human A375 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID4411	Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
AID165799	Percentage change of IOP in rabbits after 1 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID166296	Effect on IOP of rabbits 30 mins after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID166293	Effect on IOP of rabbits 2 hr after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID1137376	Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 0.625 mg/kg, po	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID104492	Effect on intraocular pressure in right eye was tested by using transition ocular hypertension model at 20 min.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID1350486	Anti-glaucoma activity in hypertonic saline-induced hypertensive New Zealand albino rabbit model assessed as decrease in intraocular pressure at 0.25% instilled into eye vitreous measured at 60 mins post administration by pneumatonometric analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID59473	Beta adrenergic blockade activity was measured in anesthetized dogs by blockade of isoproterenol induced tachycardia after iv administration	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID1137372	Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 1.25 mg/kg, po	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1137375	Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 0.312 mg/kg, po	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID186707	Comparative effect on Maximum fall in mean arterial pressure of spontaneously hypertensive rat at the dose 1.25 mg/kg per os	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID205268	Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM	1985	Journal of medicinal chemistry, Mar, Volume: 28, Issue:3	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1668041	Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition at 100 uM measured after 48 hrs by MTT assay relative to control	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID28928	Intrinsic permeability of the compound	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID165820	Percentage change of IOP in rabbits after 8 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID19006	Calculated membrane partition coefficient (Kmemb)	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID104343	Effect on intraocular pressure in left eye was tested by using transition ocular hypertension model at 10 min.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID28925	Highest effective permeability across hexadecane membrane (pH 4-8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID679124	TP_TRANSPORTER: uptake in K562 and K562/ADR cell	1996	The Journal of pharmacy and pharmacology, Oct, Volume: 48, Issue:10	Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier.
AID424015	Vasodilation activity in rabbit aortic rings assessed as relaxation of 3 uM methoxamine-induced contraction in absence of guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one	2009	Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10	Synthesis of novel nitric oxide (NO)-releasing esters of timolol.
AID1350481	Displacement of [3H]-CGP12177 from human beta2 ADR expressed in HEK293T cell membrane after 90 mins by scintillation counting	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID104495	Effect on intraocular pressure in right eye was tested by using transition ocular hypertension model at 40 min.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID59472	Beta adrenergic blockade activity was measured in anesthetized dogs by blockade of isoproterenol induced hypotension after iv administration	1980	Journal of medicinal chemistry, Jan, Volume: 23, Issue:1	Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID7812	In vitro rate of absorption observed as Caco-2 permeability in humans	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates.
AID104340	Effect on intraocular pressure in left eye was tested by using transition ocular hypertension model at 0 min.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID28679	Partition coefficient (logD6.8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1350474	Anti-glaucoma activity in hypertonic saline-induced hypertensive New Zealand albino rabbit model assessed as decrease in intraocular pressure at 0.25% instilled into eye vitreous measured at 4 hrs post administration by pneumatonometric analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
AID165810	Percentage change of IOP in rabbits after 4 hr administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID21271	Mean apparent permeability through fuzzy rat skin	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID603953	In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID40868	Beta-2 adrenergic receptor antagonistic activity on guinea pig tracheal chains	1982	Journal of medicinal chemistry, Aug, Volume: 25, Issue:8	Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1668034	Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID237685	Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28234	% absorbed in human GI-tract	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID266007	Antagonist activity at rat beta-1 adrenergic receptor Y356F mutant expressed in CHO cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.
AID186074	Compound was tested for effect on arterial pressure in spontaneously hypertensive rats (SHR) at 1.25 mg/kg, po	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	Approaches to vasodilating/beta-adrenergic blocking agents: examples of the dihydrolutidine type.
AID21277	Permeability through isolated albino rabbit cornea	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID1211798	Intrinsic clearance in human using well stirred liver model by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1434531	Antiglaucoma activity in hypertonic saline-induced New Zealand white rabbit transient ocular hypertensive model assessed as IOP lowering efficacy at 0.5% administered topically immediately after hypertonic saline injection measured at 60 mins post dose	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	New furoxan derivatives for the treatment of ocular hypertension.
AID41890	Tested for intrinsic sympathomimetic activity (ISA); Pure antagonist	1988	Journal of medicinal chemistry, Nov, Volume: 31, Issue:11	Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID424016	Vasodilation activity in rabbit aortic rings assessed as relaxation of 3 uM methoxamine-induced contraction in presence of 10 uM guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one	2009	Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10	Synthesis of novel nitric oxide (NO)-releasing esters of timolol.
AID1668032	Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition at 100 uM incubated for 48 hrs by MTT assay relative to control	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID167755	Compound was evaluated for ocular hypotensive effects (intraocular pressure, IOP) by administering 0.5% of the drug twice daily	1997	Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18	New approaches to antiglaucoma therapy.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID441223	Inhibition of dexamethasone-induced ocular hypertension in C57BL/6J Tyr c-Brd x 129S5/SvEvBrD hybrid mouse assessed as reduction of intraocular pressure at 3 ug after 2 hrs administered as cosolvent/HPMC based formulation	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.
AID165804	Percentage change of IOP in rabbits after 30 min administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID1668033	Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID1211795	Dissociation constant, pKa of the compound	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID59479	Beta-adrenergic blocking activity in anesthetized dog, by the inhibition of isoproterenol -induced tachycardia after iv administration	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Urinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activities.
AID1487624	Reduction in intraocular pressure in Chinchilla rabbit assessed as maximal change in intraocular pressure at 0.1% after application of one drop (0.06 ml) of solution containing active compound/vehicle every hour (during 6 hours and after 24 hours) by appl	2017	Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16	Oxindole-based intraocular pressure reducing agents.
AID40872	In vitro inhibitory activity against beta-2 adrenoceptor was measured by the inhibition of isoproterenol-induced relaxation of PGF2-alpha contracted guinea pig trachea	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID104353	Effect on intraocular pressure in left eye was tested by using transition ocular hypertension model at basal condition	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID1211797	Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID7974	Metabolic stability observed at 30 min after administration in human liver microsomes	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates.
AID1668035	Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9	Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1211791	Fraction unbound in human hepatocytes	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID28921	Partition coefficient (logP) (hexadecane)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID104349	Effect on intraocular pressure in left eye was tested by using transition ocular hypertension model at 40 min.	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID21234	Partition coefficient of compound in to octanol/buffer	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID59477	Beta-adrenergic blocking activity in anesthetized dog, by the inhibition of isoproterenol -induced hypotension after iv administration	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Urinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activities.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28924	Effective permeability (Pe) across a hexadecane membrane (pH 6.8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409950	Inhibition of human brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID350216	Dissociation constant, pKa of the compound	2009	Journal of medicinal chemistry, May-28, Volume: 52, Issue:10	Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID455986	Permeability across human Caco-2 cells	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID41487	Selectivity towards beta-2 adrenergic receptor; Nonselective towards beta-2 adrenergic receptor	1988	Journal of medicinal chemistry, Nov, Volume: 31, Issue:11	Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID104498	Effect on intraocular pressure in right eye was tested by using transition ocular hypertension model at basal condition	1992	Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14	Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
AID218848	Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID165796	Percentage change of IOP in rabbits after 0 min administration (1%) of compound	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID266008	Antagonist activity at rat beta-1 adrenergic receptor Y356A mutant expressed in CHO cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.
AID21233	Partition coefficient of compound in to biological membranes	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID59474	Beta-adrenergic blocking activity in anesthetized dog, by the inhibition of isoproterenol -induced bronchodilatation after iv administration	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Urinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activities.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1137386	Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 0.312 mg/kg, po	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
AID230147	The cardioselectivity ratio was obtained by taking the antilog of (pA2(beta-1)-pA2(beta2))	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID166291	Effect on IOP of rabbits 0 min after administration (1%)	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
AID16351	Percent diffusion through fuzzy rat skin after 48 h of incubation	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346250	Human beta2-adrenoceptor (Adrenoceptors)	2005	British journal of pharmacology, Feb, Volume: 144, Issue:3	The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1297 (35.91)	18.7374
1990's	679 (18.80)	18.2507
2000's	750 (20.76)	29.6817
2010's	672 (18.60)	24.3611
2020's	214 (5.92)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,198 (30.47%)	5.53%
Reviews	249 (6.33%)	6.00%
Case Studies	396 (10.07%)	4.05%
Observational	14 (0.36%)	0.25%
Other	2,075 (52.77%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (266)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (Azarga®) to Prostaglandin Monotherapy [NCT00966576]	Phase 4	47 participants (Actual)	Interventional	2009-07-31	Completed
Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study [NCT03323164]	Phase 4	35 participants (Actual)	Interventional	2017-07-10	Completed
Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects With Open-angle Glaucoma or Ocular Hypertension [NCT06152861]	Phase 2	250 participants (Anticipated)	Interventional	2023-11-15	Recruiting
A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma [NCT03193333]	Phase 3	51 participants (Anticipated)	Interventional	2017-11-06	Recruiting
[NCT01111890]	Phase 4	70 participants (Actual)	Interventional	2010-04-30	Completed
The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitor-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study [NCT05165082]		8 participants (Actual)	Interventional	2021-12-21	Completed
A Randomized Active-controlled Study to Evaluate Safety and Tolerability of QLS-101 Versus Timolol Preservative Free (PF) Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG) [NCT04857827]	Phase 2	30 participants (Actual)	Interventional	2021-09-15	Completed
A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those Given Individually in Patients With Open Angle Glaucoma or Ocular Hyperten [NCT01292460]	Phase 3	600 participants (Anticipated)	Interventional	2011-02-28	Completed
Efficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled Trial [NCT04139018]	Phase 2	27 participants (Actual)	Interventional	2019-10-20	Completed
Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes: A Randomized, Controlled Trial [NCT03579160]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2019-01-02	Terminated(stopped due to Due to the insufficient accrual rate and strategic reasons to focus our efforts on higher impact research projects.)
A Randomized, Single Center, Masked, Crossover Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity in Patients With Ocular Hypertension or Primary Open Angle Glaucoma [NCT03931317]		70 participants (Actual)	Interventional	2018-12-03	Completed
Topical Timolol for the Treatment of Benign Vascular Periocular Lesions [NCT01250457]	Phase 4	0 participants (Actual)	Interventional	2010-06-30	Withdrawn(stopped due to Unknown, PI has left the institution. There was no enrollment.)
Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination: a Single Center, Open Cohort Study. [NCT03842631]		150 participants (Anticipated)	Observational	2019-02-16	Recruiting
A Randomized Controlled Trial Comparing the Effect of Topical Dorzolamide-Timolol Versus Placebo Combined With Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Injections in Patients With Neovascular Age-Related Macular Degeneration Who Are Inc [NCT03034772]	Phase 2/Phase 3	52 participants (Actual)	Interventional	2017-02-08	Completed
Clinical Study to Evaluate the Non-inferiority of PRO-122 an Ophthlamic Solution Manufactured by Laboratorios Sophia, Previous Treatment With Krytantek Ofteno ®, in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension. [NCT03257813]	Phase 3	60 participants (Actual)	Interventional	2016-04-01	Completed
A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those of Tafluprost and Timolol Eye Drops Given Concomitantly in Patients With O [NCT01306461]	Phase 3	401 participants (Actual)	Interventional	2011-03-31	Completed
Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents [NCT02140450]		70 participants (Actual)	Interventional	2012-02-29	Completed
Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients [NCT02053298]	Phase 4	30 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Topical Timolol Gel for the Treatment of Infantile Hemangiomas [NCT02145884]	Phase 2	26 participants (Actual)	Interventional	2014-05-31	Completed
[NCT01284166]	Phase 3	0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to Study was never initiated due to company decision. No study subjects were ever enrolled or treated.)
Evaluation of a New Method for Instilling Eye Drops [NCT02697318]	Early Phase 1	30 participants (Actual)	Interventional	2016-05-31	Completed
[NCT00872651]	Phase 3	242 participants (Actual)	Interventional	2010-01-31	Completed
Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) [NCT01327599]	Phase 4	60 participants (Actual)	Interventional	2011-08-31	Completed
A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma [NCT00913029]	Phase 4	192 participants (Actual)	Interventional	2009-05-31	Completed
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma [NCT03966560]	Phase 4	96 participants (Actual)	Interventional	2014-01-31	Completed
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost [NCT01302249]	Phase 2	66 participants (Actual)	Interventional	2011-02-28	Completed
A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004%/Timolol 0.5% BAC-free Compared to Travoprost 0.004%/Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00760539]	Phase 3	87 participants (Actual)	Interventional	2008-06-30	Completed
Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops [NCT03220490]		65 participants (Anticipated)	Interventional	2017-11-01	Recruiting
African Glaucoma Laser Trial [NCT03648229]	Phase 4	0 participants (Actual)	Interventional	2019-09-01	Withdrawn(stopped due to Funding unavailable)
Comparative Clinical Study of The Safety And Efficacy of A New Fixed-Combination of Timolol-Brimonidine-Dorzolamide In Patients With Open Angle Glaucoma Or Ocular Hypertension [NCT01062971]	Phase 2	124 participants (Actual)	Interventional	2006-02-28	Completed
A 3-month Study Investigating the 24-hour Efficacy With the Preservative-free Tafluprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy [NCT03612817]	Phase 4	42 participants (Actual)	Interventional	2017-01-31	Completed
A Randomized, Parallel-Group, Multi-Center, Investigator-Masked, Active-and Placebo-Controlled, Phase 1-2 Evaluation of the Safety and Efficacy of OT-730 Ophthalmic Solution in Reducing the Intraocular Pressure in Subjects With Ocular Hypertension or Open [NCT00753168]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2008-09-30	Completed
Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus Placebo [NCT02484716]	Phase 2	58 participants (Actual)	Interventional	2015-06-30	Completed
Timolol for the Treatment of Acne and Rosacea [NCT02774590]	Phase 1	8 participants (Actual)	Interventional	2016-03-31	Completed
Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan) [NCT01191008]		661 participants (Actual)	Observational	2010-10-31	Completed
Safety and Efficacy of Using the Travoprost/Timolol Fixed Combination (DuoTrav®) in Patients With Open-Angle Glaucoma or Uncontrolled Ocular Hypertension by Beta-blocker Monotherapy (Timolol 0.5%) [NCT01336569]	Phase 4	50 participants (Actual)	Interventional	2011-02-28	Completed
Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients. [NCT04898387]	Phase 3	554 participants (Actual)	Interventional	2021-03-26	Completed
Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds [NCT04903366]		40 participants (Actual)	Observational	2017-11-21	Completed
Evaluation of Glaucoma or Ocular Hypertension Patients With Pre-existing Ocular Surface Disease Switched From a Preserved Prostaglandin Analog - Timolol Fixed Combination to a Preservative - Free Latanoprost - Timolol Fixed Combination [NCT04891588]		50 participants (Anticipated)	Interventional	2021-03-08	Recruiting
A Twelve-Month Open-Label Safety Study of Polyquaternium-Preserved DuoTrav APS Dosed Once Daily in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00928590]	Phase 3	155 participants (Actual)	Interventional	2009-07-31	Completed
Comparison of Safety and Efficacy of Al-37807 Ophthalmic Suspension vs. Timolol Gel Forming Solution and Vehicle, All Dosed Concomitantly With Xalatan in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00620256]	Phase 2	129 participants (Actual)	Interventional	2007-11-30	Completed
A Single Dose Patient Preference Study Comparison in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00576342]	Phase 3	129 participants (Actual)	Interventional	2007-12-31	Completed
A Prospective, Multicenter, Randomized, Double-Masked, Parallel-Arm Phase 2b Study Evaluating the Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension [NCT02312544]	Phase 2	72 participants (Actual)	Interventional	2014-11-30	Completed
Assessing the Safety and Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients Uncontrolled on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) [NCT01230736]	Phase 4	105 participants (Actual)	Interventional	2010-10-31	Completed
Circadian Rhythms of Aqueous Humor Dynamics in Humans [NCT00572936]	Phase 2	30 participants (Actual)	Interventional	2006-03-13	Completed
Stop Retinal Ganglion Cell Dysfunction Study [NCT02390284]	Phase 3	500 participants (Anticipated)	Interventional	2015-09-30	Active, not recruiting
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds: A Randomized Controlled Trial [NCT03452072]	Phase 2/Phase 3	88 participants (Actual)	Interventional	2018-08-20	Completed
Efficacy, Safety, and Pharmacokinetics of Timolol in Infants With Infantile Hemangioma (IH) [NCT02913612]	Phase 2	105 participants (Actual)	Interventional	2017-05-05	Completed
Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AZARGA®) to Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy [NCT01263444]	Phase 4	47 participants (Actual)	Interventional	2011-03-31	Completed
Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP 0.5% [NCT02754596]	Phase 2	154 participants (Actual)	Interventional	2016-03-29	Completed
A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) [NCT02863705]	Phase 4	118 participants (Actual)	Interventional	2016-07-05	Completed
Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma [NCT04288700]	Phase 4	100 participants (Anticipated)	Interventional	2019-10-01	Recruiting
Phase IV, Multicenter, Double-blind, Randomized, Controlled, Parallel-group, Trial to Evaluate the Efficacy and Safety of Dozolamide 2%/Timolol 0,5% PF vs Dorzolamide 2%/Timolol 0,5% BAK-preserved in OAG or OH [NCT05857267]	Phase 4	84 participants (Anticipated)	Interventional	2023-03-07	Recruiting
The International Collaborative Exfoliation Syndrome Treatment Study [NCT00804115]		277 participants (Actual)	Interventional	2000-08-31	Active, not recruiting
[NCT00822055]	Phase 4	140 participants (Actual)	Interventional	2005-05-31	Completed
Prospective, Open-label, Single-arm Study to Evaluate Efficacy and Safety of Combination Therapy of Timolol and Dorzolamide (COSOPT) as Initial Treatment for Patients With Normal Tension Glaucoma [NCT00832377]	Phase 2	37 participants (Actual)	Interventional	2009-04-24	Completed
A Randomized, Multi-site, Double-masked Study Evaluating the Safety and Tolerability of QLS-111 vs Timolol Maleate Preservative Free 0.5% Ophthalmic Solution and Vehicle in Primary Open-angle Glaucoma or Ocular Hypertension Patients [NCT06016972]	Phase 2	120 participants (Anticipated)	Interventional	2024-01-29	Not yet recruiting
Phase IV Clinical Study to Compare the Efficacy of the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination to the Krytantek Ofteno PF® Plus Gaap Ofteno PF® Combination, in Primary Open Angle Glaucoma or Ocular Hypertension Patients. [NCT04702789]	Phase 4	28 participants (Actual)	Interventional	2021-10-19	Terminated(stopped due to For interests of sponsor.)
A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004%/Timolol 0.5% BAC-free Compared to Travoprost 0.004%/Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00672997]	Phase 3	301 participants (Actual)	Interventional	2008-05-31	Completed
A Phase 1B, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety of a Fixed Combination Bimatoprost/Timolol Ocular Insert Compared to Its Individual Components With Crossover to Timolol 0.5% in Subjects With Open-an [NCT02742649]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2016-04-30	Completed
A Double-masked Study of DE-111 Ophthalmic Solution Versus Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocu [NCT01342081]	Phase 3	489 participants (Actual)	Interventional	2011-05-31	Completed
A Randomized, Single Center, Masked, Crossover Study Comparing the Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity in Patients With Ocular Hypertension or Primary Open Angle Glaucoma [NCT04064918]		0 participants (Actual)	Interventional	2021-12-31	Withdrawn(stopped due to Due to COVID-19 related restrictions it was decided to close this study)
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy, and Dose-response of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5% [NCT06120842]	Phase 1/Phase 2	140 participants (Anticipated)	Interventional	2023-10-13	Recruiting
Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures [NCT02154217]	Phase 3	200 participants (Actual)	Interventional		Completed
Topical Timolol Benefit in Venous Ulcers [NCT02422017]	Phase 2	42 participants (Actual)	Interventional	2015-04-30	Completed
Beta Adrenergic Antagonist For The Healing of Chronic Diabetic Foot Ulcers [NCT03282981]	Phase 3	35 participants (Actual)	Interventional	2018-06-14	Active, not recruiting
Multicenter, Double-Blind, Active Comparator-controlled Study to Evaluate the Safety and Efficacy of MK0507A in Patients With Glaucoma and Ocular Hypertension Who Are Inadequately Controlled on Beta-Blockers [NCT00449956]	Phase 3	474 participants (Actual)	Interventional	2007-03-12	Completed
Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. [NCT00941096]	Phase 4	30 participants (Anticipated)	Interventional	2009-07-31	Completed
Phase III Multi-center, Randomized, Double-masked, Active- and Placebo-controlled Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma [NCT02565173]	Phase 3	303 participants (Actual)	Interventional	2015-09-30	Completed
A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients [NCT00972426]	Phase 4	32 participants (Anticipated)	Interventional	2009-10-31	Completed
A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s) [NCT00545064]	Phase 4	176 participants (Actual)	Interventional	2007-05-23	Completed
Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in Subjects With Open-angle Glaucoma [NCT00981786]	Phase 4	51 participants (Actual)	Interventional	2009-08-31	Completed
A 6-month, Randomized, Double-masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in the United Kingdom [NCT00751049]	Phase 3	294 participants (Actual)	Interventional	1992-12-31	Completed
A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in the United States. [NCT00751127]	Phase 3	268 participants (Actual)	Interventional	1993-01-31	Completed
24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma [NCT00757835]	Phase 4	40 participants (Actual)	Interventional	2008-05-31	Completed
[NCT00759239]	Phase 4	36 participants (Actual)	Interventional	2008-09-30	Completed
Comparison of Selective Laser Trabeculoplasty With Prostaglandin Analogues for Lowering Intraocular Pressure in Eyes With Primary Angle Closure Glaucoma [NCT01004900]	Phase 3	90 participants (Anticipated)	Interventional	2009-06-30	Recruiting
A 6-month, Randomized, Double-masked Comparison of Fixed Combination of Latanoprost and Timolol With the Individual Components, Continuing Into a 6-month Open Label Safety Study of Fixed Combination in Patients With Glaucoma or Ocular Hypertension. A Mult [NCT00800267]	Phase 3	418 participants (Actual)	Interventional	1997-07-31	Completed
Phase 3 Study of Brimonidine Tartrate Drops Efficacy in Reducing Post Operative Corneal Edema After Cataract Surgery [NCT00800423]	Phase 3	150 participants (Anticipated)	Interventional	2009-01-31	Not yet recruiting
12-Month Stability of Diurnal IOP Control on Cosopt [NCT00379834]	Phase 4	10 participants (Actual)	Interventional	2006-09-30	Completed
Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses [NCT02852057]	Phase 1	2 participants (Actual)	Interventional	2018-01-18	Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study) [NCT00887029]	Phase 4	54 participants (Actual)	Interventional	2009-01-31	Completed
Safety and Efficacy of Switching to the Travoprost/Timolol Maleate Fixed Combination (DUOTRAV®) From Prior Mono or Two-Drug Therapy in Germany [NCT00519753]	Phase 4	522 participants (Actual)	Interventional	2007-08-31	Completed
[NCT00651612]	Phase 3	604 participants (Actual)	Interventional	2005-11-30	Completed
A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study [NCT02822729]	Phase 3	125 participants (Actual)	Interventional	2016-07-01	Completed
24-hour Efficacy and Ocular Surface Health With PF Tafluprost and Combined Therapy With PF Tafluprost and Dorzolamide/Timolol Fixed Combination in Open-angle Glaucoma Subjects Insufficiently Controlled With Latanoprost [NCT02802137]	Phase 4	43 participants (Actual)	Interventional	2015-03-31	Completed
Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma: A Randomised Controlled Trial [NCT00980473]	Phase 3	80 participants (Anticipated)	Interventional	2007-09-30	Recruiting
Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®, Elaborated by Sophia Laboratories, S.A. of C.V. on the Ocular Surface of Ophthalmologically and Clinicall [NCT03966365]	Phase 1	24 participants (Actual)	Interventional	2019-05-02	Completed
Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolol Fixed Combination (DTFC) Compared With the Brimonidine/Timolol Fixed Combination (BTFC) in Subjects With Primary Open-angle Glaucoma [NCT00972257]	Phase 4	64 participants (Actual)	Interventional	2009-01-31	Completed
[NCT00332384]	Phase 3	573 participants (Actual)	Interventional	2000-01-31	Completed
Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension [NCT00348023]	Phase 4	0 participants	Interventional		Completed
Efficacy and Safety of Latanoprost/Timolol Fixed Combination Dosed Twice Daily Compared to Once Daily in Patients With Primary Open Angle Glaucoma [NCT04098861]	Phase 4	40 participants (Anticipated)	Interventional	2019-01-02	Recruiting
A Pilot Study of Adherence Assessment With the Travalert™ Dosing Aid in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Who Are Treated With the Travoprost/Timolol Maleate Fixed Combination Every Evening [NCT00676637]		55 participants (Actual)	Observational	2008-05-31	Completed
Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients With Open-Angle Glaucoma [NCT00800540]	Phase 4	35 participants (Actual)	Interventional	2009-02-28	Completed
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma. [NCT00716859]	Phase 3	139 participants (Actual)	Interventional	2008-07-31	Completed
Efficacy of Topical Latanoprost 0.005% Verses Timolol 0.5% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism [NCT04178863]	Phase 4	72 participants (Anticipated)	Interventional	2018-07-01	Recruiting
[NCT01217606]	Phase 3	185 participants (Actual)	Interventional	2011-01-31	Completed
A Comparative Analysis of the Effects of Cosopt® Versus Xalacom® on Ocular Hemodynamics and Intraocular Pressure in Patients With Primary Open-angle Glaucoma [NCT00815373]		0 participants (Actual)	Interventional	2008-12-31	Withdrawn(stopped due to no participants recruded.)
[NCT00822081]	Phase 4	140 participants (Actual)	Interventional	2005-01-31	Completed
A Pilot Study of Adherence Assessment With the Travalert™ Dosing Aid in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Who Are Treated With the Travoprost/Timolol Maleate Fixed Combination Every Evening [NCT00680329]		55 participants (Actual)	Observational	2008-05-31	Completed
Change in Optic Nerve Head Blood Flow,Optic Nerve Topography and Diurnal Fluctuation of Intraocular Pressure and Pulsatile Ocular Blood Flow in Glaucoma:Cosopt and Xalatan vs Xalatan Alone [NCT00957190]	Phase 4	25 participants (Actual)	Interventional	2009-05-04	Completed
A 6-month, Randomized, Double-masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in Scandinavia [NCT00751062]	Phase 3	267 participants (Actual)	Interventional	1992-11-30	Completed
A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma [NCT01917383]	Phase 2	101 participants (Actual)	Interventional	2013-08-31	Completed
The Effect of Paroxetine on the Plasma Levels of Timolol Using Ophthalmic 0.5% Timolol Eye Drops and 0.1% Timolol Eye Gel in Healthy Volunteers [NCT00879099]	Phase 1	12 participants (Anticipated)	Interventional	2009-04-30	Completed
The Efficacy of Timolol 0.5% Gel Forming Solution for the Treatment of Ulcerated Hemangiomas [NCT01408056]	Phase 2	0 participants (Actual)	Interventional	2011-02-28	Withdrawn(stopped due to Difficulty with recruitment)
[NCT00862472]	Phase 3	0 participants (Actual)	Interventional	2009-03-31	Withdrawn(stopped due to Management decision not to conduct an additional efficacy study.)
A Double-masked Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma [NCT00991822]	Phase 2/Phase 3	160 participants (Actual)	Interventional	1999-05-31	Completed
Comparison of the Effects of Latanoprost and Timolol on Aqueous Humor Dynamics in Ocular Hypertensive Patients [NCT00579969]	Phase 2	30 participants (Actual)	Interventional	2003-12-31	Terminated(stopped due to Study stopped and data not analyzed)
Efficacy and Safety of Topical Timolol Maleate 0.5% Solution for Superficial Infantile Hemangioma in Early Proliferative Phase. A Randomized Clinical Trial [NCT02731287]	Phase 2	70 participants (Actual)	Interventional	2014-03-31	Completed
A Randomized Active-controlled Multi-site Double-masked Study to Evaluate the Safety and Tolerability of 3 Concentrations of QLS-101 Versus Timolol Maleate Preservative Free (PF) 0.5% Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocu [NCT04830397]	Phase 2	84 participants (Actual)	Interventional	2021-03-31	Completed
Assessing the Efficacy of DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination), as a Replacement Therapy in Glaucoma Patients in Russia, Previously on Prior Prostaglandin Analogue or Beta-blocker Monotherapy [NCT01696383]	Phase 4	0 participants (Actual)	Interventional	2013-02-28	Withdrawn(stopped due to Management decision)
24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. [NCT05299593]	Phase 4	43 participants (Anticipated)	Interventional	2020-06-04	Recruiting
Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using Thalidomide [NCT00787436]	Phase 3	0 participants (Actual)	Interventional	2006-05-31	Withdrawn
Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT00804648]	Phase 4	30 participants (Actual)	Interventional	2008-11-30	Completed
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension [NCT00326092]	Phase 2	88 participants	Interventional	2006-05-31	Completed
Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months [NCT01699464]	Phase 2	211 participants (Actual)	Interventional	2012-10-31	Completed
A 12 Week, Open-Label, Study to Evaluate the Effectiveness of Dorzolamide-Timolol as First Line Therapy to Reduce Intraocular Pressure in Patients With Untreated Open Angle Glaucoma (OAG) or Ocular Hypertension (OH) [NCT00546286]	Phase 3	170 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine [NCT03836664]	Phase 2	25 participants (Actual)	Interventional	2017-02-27	Completed
Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Treatment in Encapsulated Blebs: a 12-month Prospective Study [NCT01887223]	Phase 2	40 participants (Actual)	Interventional	2010-05-31	Completed
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension [NCT00061542]	Phase 3	105 participants (Actual)	Interventional	2003-01-31	Completed
[NCT00273442]	Phase 4	60 participants	Interventional	2005-11-30	Completed
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Oc [NCT00230763]	Phase 3	396 participants (Actual)	Interventional	2005-09-30	Completed
An 8-Week, Randomized, Open-Label, Parallel Group Study Comparing The Efficacy And Safety Of Xalacom With The Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension [NCT00219596]	Phase 3	240 participants	Interventional	2005-06-30	Completed
Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma [NCT01978015]	Phase 4	69 participants (Actual)	Interventional	2011-10-31	Completed
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension [NCT02250612]	Phase 2	184 participants (Actual)	Interventional	2014-10-31	Completed
A Phase III, Randomized, Active Comparator-Controlled, Twelve-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma and [NCT01026831]	Phase 3	643 participants (Actual)	Interventional	2010-01-06	Completed
The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter [NCT02214680]	Phase 2	25 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients [NCT06078592]	Phase 4	60 participants (Actual)	Interventional	2021-10-08	Completed
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept [NCT01752049]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2013-05-31	Completed
Comparison of Efficacy and Safety of Brinzolamide/Timolol Fixed Combination (AZARGA™) vs Brinzolamide (AZOPT®) and Timolol in Chinese Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT01357616]	Phase 3	328 participants (Actual)	Interventional	2010-11-30	Completed
A Double-masked Study of DE-111 Ophthalmic Solution Versus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension - Phase 3, Confirmatory Study - [NCT01342094]	Phase 3	166 participants (Actual)	Interventional	2011-05-31	Completed
Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension [NCT02571712]	Phase 4	750 participants (Actual)	Interventional	2015-11-10	Completed
[NCT00652106]	Phase 3	432 participants (Actual)	Interventional	2003-06-30	Completed
The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema [NCT02718547]		25 participants (Anticipated)	Interventional	2017-03-26	Recruiting
Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data [NCT01145898]		56 participants (Actual)	Observational	2010-06-30	Completed
A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy [NCT01257698]		21 participants (Actual)	Interventional	2010-02-28	Completed
A Double-masked Randomized Cross-over Study Comparing of the Effect of Xalacom® (Latanoprost/Timolol)and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular [NCT00706927]		16 participants (Actual)	Interventional	2006-01-31	Completed
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG) [NCT00824824]		21 participants (Actual)	Interventional	2009-01-31	Completed
The Effect of Myocilin Genetic Variants on Intraocular Pressure and Blood Pressure Variation in Sitting and Supine Positions. [NCT00906087]	Phase 4	14 participants (Actual)	Interventional	2009-08-04	Completed
[NCT00332072]	Phase 3	541 participants (Actual)	Interventional	2001-08-31	Completed
[NCT00332345]	Phase 2	73 participants (Actual)	Interventional	1999-07-31	Completed
[NCT00332540]	Phase 3	520 participants (Actual)	Interventional	2001-08-31	Completed
Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After Laser in Situ Keratomileusis: A Randomized Clinical Trial [NCT01506635]		45 participants (Actual)	Interventional	2010-03-31	Completed
A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension. [NCT00856622]	Phase 3	436 participants (Actual)	Interventional	1997-08-31	Completed
[NCT01628601]		392 participants (Actual)	Observational	2010-05-31	Completed
A Phase 2b Randomized, Double-masked, Active-controlled, Dose-response Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension [NCT05913232]	Phase 2	200 participants (Anticipated)	Interventional	2023-08-28	Recruiting
Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients [NCT01446497]	Phase 4	22 participants (Anticipated)	Interventional	2010-10-31	Recruiting
A Phase III, Randomized, Active Comparator-Controlled, Four-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma or O [NCT01254604]	Phase 3	190 participants (Actual)	Interventional	2011-12-01	Completed
[NCT01151904]	Phase 4	17 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to Difficulty with patient recruitment)
A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multi-center Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypert [NCT03691649]	Phase 3	426 participants (Actual)	Interventional	2018-09-14	Completed
Assessing the Efficacy and Tolerability of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Prior Prostaglandin Fixed Combination [NCT01514721]	Phase 4	37 participants (Actual)	Interventional	2012-06-30	Terminated(stopped due to low enrollment)
A 3-month, 4-centre, Crossover, Double-masked Study Investigating the 24-hour Intraocular Pressure Control With the Bimatoprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Exfoliative Glaucoma [NCT00486486]	Phase 4	60 participants (Actual)	Interventional	2007-03-31	Completed
To Prove the Non-inferiority of Cosopt Compared to Xalatan in the Aspects of Intraocular Pressure and Ocular Perfusion Pressure in Subjects With Normal Tension Glaucoma [NCT01175902]		44 participants (Actual)	Interventional	2011-03-31	Completed
24-Hour Intraocular Pressure Control Obtained With the Bimatoprost/Timolol Fixed Combination Compared With Latanoprost as First Choice Therapy in Subjects With Exfoliation Syndrome, or Exfoliative Glaucoma [NCT01448837]	Phase 4	37 participants (Actual)	Interventional	2010-04-30	Completed
Randomized, Multicenter, Observer-Masked Study to Compare Safety/Efficacy of Nebivolol Suspension 0.5% or 1.0%, or Timolol Suspension 0.5% to Timolol Solution 0.5% in Participants With Primary Open Angle Glaucoma or Ocular Hypertension [NCT04910100]	Phase 2	225 participants (Actual)	Interventional	2021-04-15	Completed
[NCT00332059]	Phase 3	445 participants (Actual)	Interventional	2003-05-31	Completed
Treatment of Cutaneous Hemangioma of Infancy With Topical 0.5% Timolol Maleate Eye Drop Compared With Placebo in Pediatric Patients, Siriraj Hospital [NCT01685398]	Phase 3	48 participants (Actual)	Interventional	2012-09-30	Completed
Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Patients With Open-Angled Glaucoma or Ocular Hypertension [NCT01471158]	Phase 4	120 participants (Actual)	Interventional	2010-09-30	Completed
[NCT01170884]	Phase 4	121 participants (Actual)	Interventional	2009-12-31	Completed
A Randomized, Open-label, 2-period, Parallel Group, Multiple-dose Study to Evaluate the Drug-drugs Interaction Between Dorzolamide and Brimonidine in Healthy Korean Male Volunteers [NCT02967614]	Phase 1	32 participants (Actual)	Interventional	2016-12-31	Completed
[NCT00273481]	Phase 4	33 participants	Interventional	2005-09-30	Completed
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension In The United States. [NCT00277498]	Phase 3	528 participants	Interventional	2005-12-31	Completed
[NCT00287521]	Phase 2	87 participants (Actual)	Interventional	2005-11-30	Completed
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00311389]	Phase 3	408 participants (Actual)	Interventional	2003-01-31	Completed
[NCT00293800]	Phase 3	173 participants (Actual)	Interventional	2004-07-31	Completed
[NCT00314158]	Phase 3	523 participants (Actual)	Interventional	2005-11-30	Completed
24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients [NCT00330577]	Phase 4	30 participants	Interventional	2006-04-30	Completed
24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination [NCT00331240]	Phase 3	32 participants	Interventional	2006-03-31	Completed
Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial [NCT00435058]		54 participants	Interventional	2005-09-30	Completed
Randomized, Multicenter, Dbl-Masked, Parallel Study Evaluating the 24 Hr. Diurnal Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Maleate Combo. Ophthalmic Sol. in Patients w/ Open Angle Glaucoma or Ocular Hypertension [NCT00108017]	Phase 3	330 participants (Actual)	Interventional	2005-04-30	Completed
A Crossover, Double-Masked Comparison Investigating the 24-Hour Intraocular Pressure Control With the Travoprost/Timolol Fixed Combination Versus Travoprost, When Both Are Given in the Evening, in Subjects With Primary Open-Angle Glaucoma [NCT00444184]	Phase 4	32 participants (Actual)	Interventional	2007-03-31	Completed
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocul [NCT01915940]	Phase 2	169 participants (Actual)	Interventional	2013-10-23	Completed
[NCT01177098]	Phase 3	561 participants (Actual)	Interventional	2010-10-31	Completed
[NCT01215786]	Phase 1	50 participants (Actual)	Interventional	2010-10-31	Completed
Preventing Growth of Hemangioma Tumors in Newborn: A Prospective Randomized Clinical Study [NCT01873131]		126 participants (Anticipated)	Interventional	2011-02-28	Recruiting
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension. [NCT00159653]	Phase 3	500 participants (Actual)	Interventional	2005-07-31	Completed
Efficacy and Safety of add-on Topical Timolol in the Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-induced Paronychia: A Prospective Randomized Open-labelled Trial [NCT06140186]	Phase 3	40 participants (Anticipated)	Interventional	2023-04-01	Recruiting
[NCT00333125]	Phase 3	319 participants (Actual)	Interventional	2006-04-30	Completed
[NCT01241240]	Phase 3	192 participants (Actual)	Interventional	2011-03-31	Completed
A Phase 1/2a Randomized, Investigator-masked, Placebo- and Active-controlled, Dose-ranging Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension [NCT01520116]	Phase 1/Phase 2	180 participants (Anticipated)	Interventional	2012-01-31	Active, not recruiting
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol [NCT01533376]	Phase 1	3 participants (Actual)	Interventional	2012-02-29	Terminated
Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study [NCT01542710]		80 participants (Actual)	Interventional	2011-01-31	Completed
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma [NCT00869141]	Phase 4	52 participants (Actual)	Interventional	2009-03-31	Completed
Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis [NCT00006398]	Phase 3	213 participants (Actual)	Interventional	1993-08-31	Completed
Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans [NCT00275756]		0 participants (Actual)	Interventional	2008-09-30	Withdrawn
24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC and Latanoprost in Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy. [NCT00397241]	Phase 4	33 participants (Actual)	Interventional	2006-09-30	Completed
A 6-Week Safety and Efficacy Study of TRAVATAN Compared to XALCOM in Subjects With Open-Angle Glaucoma or Ocular Hypertension. [NCT00051155]	Phase 3	0 participants	Interventional	2001-01-31	Completed
[NCT01881126]	Phase 4	93 participants (Actual)	Interventional	2013-06-30	Completed
Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5% [NCT00508469]	Phase 4	102 participants (Actual)	Interventional	2007-10-31	Completed
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects [NCT00735449]	Phase 4	204 participants (Actual)	Interventional	2008-07-31	Completed
A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00763061]	Phase 4	111 participants (Actual)	Interventional	2006-05-31	Completed
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With Timolol Hemihydrate 0.5% Solution Once or Twice Daily Versus Timolol Maleate in Sorbate [NCT00823043]		103 participants (Actual)	Observational	2009-01-31	Completed
Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension [NCT00471068]	Phase 4	46 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to Question raised by Ethics Committee)
A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT01749930]	Phase 3	420 participants (Actual)	Interventional	2013-01-31	Completed
A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Scleral Buckling and Pneumatic Retinopexy. [NCT01843920]		21 participants (Actual)	Interventional	2011-06-30	Completed
[NCT01987752]		732 participants (Actual)	Observational	2009-01-31	Completed
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety of AR-13324 Ophthalmic Solution, 0.02% QD & BID Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pre [NCT02246764]	Phase 3	93 participants (Actual)	Interventional	2014-09-30	Completed
[NCT00273429]	Phase 4	0 participants	Interventional	2005-04-30	Completed
Can Urgent Reduction of Intraocular Pressure With Ophthalmic Timolol Improve Recovery From Non-arteritic Anterior Ischemic Optic Neuropathy (NAION): a Randomized Study. [NCT01607671]	Phase 1	0 participants (Actual)	Interventional	2012-06-30	Withdrawn(stopped due to Unable to recruit participants from recruiting sites.)
Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT01340014]	Phase 4	112 participants (Actual)	Interventional	2011-09-30	Completed
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension [NCT00293787]	Phase 3	156 participants (Actual)	Interventional	2004-06-30	Completed
Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel [NCT01272609]	Phase 3	44 participants (Anticipated)	Interventional	2011-01-31	Recruiting
[NCT00273455]	Phase 4	34 participants	Interventional	2006-01-31	Completed
[NCT00811564]	Phase 4	148 participants (Actual)	Interventional	2008-12-31	Completed
A Multicenter, Double-Masked, 2-Arm Parallel Group Study Comparing the Effect of Brimonidine 0.2% Versus Timolol 0.5% on Visual Field Stability in Patients With Low-Pressure Glaucoma [NCT00317577]	Phase 2	160 participants	Interventional	1998-12-31	Completed
[NCT00332436]	Phase 3	586 participants (Actual)	Interventional	1999-12-31	Completed
Effect of Topical Aqueous Suppressants on Response to Intravitreal Anti-vascular Endothelial Growth Factor Injections in Age-related Macular Degeneration (AMD), Retinal Vein Occlusions (RVO) or Diabetic Macular Edema (DME). [NCT02571972]	Phase 2	14 participants (Actual)	Interventional	2015-02-01	Completed
Topical Timolol: a Comparison of Surgical Outcomes [NCT05114239]	Phase 2	30 participants (Anticipated)	Interventional	2021-04-07	Recruiting
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension [NCT00314171]	Phase 3	437 participants (Actual)	Interventional	2005-10-31	Completed
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas [NCT05479123]	Phase 4	174 participants (Anticipated)	Interventional	2022-06-23	Recruiting
Post Marketing Surveillance Study to Evaluate the Safety Profile of Travacom (Travoprost/Timolol Fixed Combination) in Patients With Open-Angle Glaucoma or Ocular Hypertension Across India [NCT01510132]	Phase 4	0 participants (Actual)	Interventional	2012-01-31	Withdrawn
The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs. [NCT01655758]	Phase 4	61 participants (Actual)	Interventional	2002-01-31	Completed
A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension [NCT00471380]	Phase 4	46 participants (Actual)	Interventional	2007-03-31	Completed
Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects [NCT01746602]	Phase 3	38 participants (Actual)	Interventional	2011-07-31	Terminated
Effect of Topical Anti-glaucoma Medications on Late Pupillary Light Reflex, as Evaluated by Pupillometry [NCT02522039]		21 participants (Actual)	Interventional	2014-05-31	Completed
24-Hour Efficacy of Travoprost/Timolol Benzalkonium Chloride BAK Free Compared With Latanoprost/Timolol Fixed Combination Therapy in Subjects With Open-Angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy [NCT01779284]	Phase 4	42 participants (Actual)	Interventional	2012-01-31	Completed
Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid [NCT00465803]	Phase 3	81 participants (Actual)	Interventional	2007-03-31	Completed
Early Intra Ocular- Pressure Control Using Aqueous Suppressive Agents After Ahmed Glaucoma Valve Implantation [NCT01814514]	Phase 2	94 participants (Anticipated)	Interventional	2011-01-31	Recruiting
[NCT01068964]		235 participants (Actual)	Interventional	2010-02-01	Completed
A Prospective, Multicenter, Randomized, Double-Masked, Multi-Arm Feasibility Study Evaluating the Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension [NCT01845038]	Phase 1	41 participants (Actual)	Interventional	2013-04-30	Completed
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients [NCT01652664]	Phase 3	184 participants (Actual)	Interventional	2012-09-30	Completed
[NCT01229462]		238 participants (Actual)	Interventional	2010-10-31	Completed
[NCT01547598]	Phase 4	135 participants (Actual)	Interventional	2011-12-31	Completed
An Open-Label, Long-Term Phase III Study of STN1012600 Ophthalmic Solution Alone and in Combination With Timolol Ophthalmic Solution, in Subjects With Open Angle Glaucoma or Ocular Hypertension (Angel-J2 Study) [NCT05503901]	Phase 3	138 participants (Anticipated)	Interventional	2022-08-08	Recruiting
Efficacy and Safety Assessment of Fixed Combination Unpreserved Latanoprost Eye Drops and Timolol 0.5% (T2347) Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients. [NCT02278614]	Phase 3	242 participants (Actual)	Interventional	2014-12-31	Completed
Phase 1 Study of Topical Beta Blocker to Prevent the Proliferative Stage of Infantile Hemangioma [NCT01434849]	Phase 1	26 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Difficulty with enrolled patients to complete trial.)
A Phase I, Randomized, Double-masked, 3-period Cross-over Clinical Study to Compare the Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops to Those of Preservative-fre [NCT01434888]	Phase 1	15 participants (Actual)	Interventional	2011-09-30	Completed
Timolol Eye Drops in the Treatment of Acute Migraine Headache [NCT02630719]		10 participants (Actual)	Interventional	2016-01-31	Terminated(stopped due to Unable to enroll sufficient participants)
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. [NCT01927406]	Phase 4	0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to Funding source unavailable)
Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema [NCT05083689]	Phase 2/Phase 3	62 participants (Anticipated)	Interventional	2021-10-06	Active, not recruiting
[NCT01243567]	Phase 4	81 participants (Actual)	Interventional	2010-06-01	Completed
A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension [NCT01279083]	Phase 1/Phase 2	147 participants (Actual)	Interventional	2011-01-31	Completed
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% q.d. and b.i.d. Compared to Timolol Maleate Ophthalmic Solution, 0.5% b.i.d. [NCT02207621]	Phase 3	756 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, Double-masked, Controlled Parallel Group, Multi-center Study of DE-111A (Fixed Dose Combination of Tafluprost and Timolol Eye Drops) on the Treatment of Open Angle Glaucoma or Ocular Hypertension (With Tafluprost Eye Drops as a Comparator) [NCT03822559]	Phase 3	219 participants (Actual)	Interventional	2019-01-20	Completed
A Randomized, Single-Center, Open-Label, Crossover Study Comparing the Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension. [NCT01707381]	Phase 2	25 participants (Actual)	Interventional	2012-11-30	Completed
A Phase 1/2a Assessment of WB007 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension [NCT04149899]	Phase 1/Phase 2	77 participants (Actual)	Interventional	2019-11-14	Completed
Beta Adrenergic Receptor Modulation of Burn Wound Healing [NCT00368602]	Phase 2	40 participants (Actual)	Interventional	2005-06-30	Terminated(stopped due to Lack of funding.)
A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2 mg, 13 mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocul [NCT02358369]	Phase 2	156 participants (Actual)	Interventional	2015-01-19	Completed
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting [NCT04828057]		50 participants (Actual)	Observational	2021-09-01	Completed
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension [NCT02250651]	Phase 3	528 participants (Actual)	Interventional	2014-12-15	Completed
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension [NCT02247804]	Phase 3	594 participants (Actual)	Interventional	2014-12-15	Completed
Assessing the Safety and Efficacy of Switching to AZARGA® (Brinzolamide/Timolol Fixed Combination) as Replacement Therapy in Patients With Uncontrolled Intraocular Pressure in Taiwan [NCT01484951]	Phase 4	74 participants (Actual)	Interventional	2011-05-31	Completed
The Effects of Topical Beta Blocker and Prostaglandin on Interval Intraocular Pressure in Intravitreal Injection - a Randomised Controlled Prospective Study [NCT04868175]		64 participants (Actual)	Interventional	2019-10-01	Completed
A Phase IIb, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle [NCT04742283]	Phase 2	323 participants (Actual)	Interventional	2020-12-17	Completed
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Canada [NCT01415401]	Phase 4	57 participants (Actual)	Interventional	2011-09-30	Completed
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas: A Prospective Double Blinded Placebo Controlled Study [NCT01147601]	Early Phase 1	6 participants (Actual)	Interventional	2010-03-31	Terminated
A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hyperte [NCT03691662]	Phase 3	417 participants (Actual)	Interventional	2018-09-27	Completed
[NCT01426113]	Phase 3	6 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to Study terminated due to corporate decision.)
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance [NCT04412096]	Phase 4	100 participants (Anticipated)	Interventional	2020-11-23	Recruiting
[NCT01999348]		1,553 participants (Actual)	Observational	2013-11-25	Completed
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-daily 0.01% Bimatoprost/0.15% Brimonidine/0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, [NCT01216943]	Phase 3	126 participants (Actual)	Interventional	2010-11-30	Completed
[NCT00811850]	Phase 4	15 participants (Actual)	Interventional	2008-12-31	Completed
[NCT01976624]		756 participants (Actual)	Observational	2009-08-31	Completed
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Brazil [NCT01514734]	Phase 4	9 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to Low recruitment rate)
A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension. [NCT01749904]	Phase 3	420 participants (Actual)	Interventional	2013-01-31	Completed
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance [NCT01677507]	Phase 4	135 participants (Actual)	Interventional	2012-08-31	Completed
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) [NCT02730871]	Phase 4	173 participants (Actual)	Interventional	2016-06-24	Terminated(stopped due to Enrollment Challenges)
[NCT02097719]	Phase 4	100 participants (Actual)	Interventional	2014-05-31	Completed
The Role of Topical Timolol 0.5% in Wound Healing and Scar Improvement Following Atrophic Acne Scar Microneedling [NCT05597813]		30 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy [NCT01978600]	Phase 4	89 participants (Actual)	Interventional	2013-10-31	Completed
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalm [NCT02558374]	Phase 3	708 participants (Actual)	Interventional	2015-09-30	Completed
The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension [NCT02325518]	Phase 4	218 participants (Actual)	Interventional	2014-12-31	Completed
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker [NCT02003391]	Phase 4	157 participants (Actual)	Interventional	2013-12-31	Completed
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevat [NCT02207491]	Phase 3	411 participants (Actual)	Interventional	2014-07-31	Completed
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America [NCT01518244]	Phase 4	50 participants (Actual)	Interventional	2011-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00379834 (1) [back to overview]	Diurnal Intraocular Pressure Control
NCT00449956 (3) [back to overview]	Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks
NCT00449956 (3) [back to overview]	Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks
NCT00449956 (3) [back to overview]	Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks
NCT00471068 (1) [back to overview]	Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment
NCT00471380 (1) [back to overview]	Intra Ocular Pressure (IOP)
NCT00508469 (1) [back to overview]	Adherence
NCT00545064 (4) [back to overview]	Change in Glaucoma Symptom Scale (GSS)-SYMP-6 Score
NCT00545064 (4) [back to overview]	Change in Intra-ocular Pressure (IOP) for Worse Eye From Baseline to Week 4 and From Baseline to Week 8, in Patients Receiving Preservative-free Dorzolamide-timolol
NCT00545064 (4) [back to overview]	Patient's Global Satisfaction
NCT00545064 (4) [back to overview]	Physician's Global Satisfaction
NCT00572936 (8) [back to overview]	Uvescleral Outflow
NCT00572936 (8) [back to overview]	Aqueous Flow
NCT00572936 (8) [back to overview]	Episcleral Venous Pressure
NCT00572936 (8) [back to overview]	Anterior Chamber Volume
NCT00572936 (8) [back to overview]	Outflow Facility
NCT00572936 (8) [back to overview]	Intraocular Pressure
NCT00572936 (8) [back to overview]	Central Corneal Thickness
NCT00572936 (8) [back to overview]	Blood Pressure
NCT00716859 (10) [back to overview]	Mean IOP at Week 4
NCT00716859 (10) [back to overview]	Reduction From Baseline in Mean IOP at Week 4
NCT00716859 (10) [back to overview]	Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)
NCT00716859 (10) [back to overview]	Reduction From Baseline in Mean IOP at Week 12 (Observed)
NCT00716859 (10) [back to overview]	Reduction From Baseline in Mean IOP at Week 1
NCT00716859 (10) [back to overview]	Percentage of Participants With Greater Than or Equal to (≥) 15% IOP Reduction From Baseline at Both Weeks 4 and 12
NCT00716859 (10) [back to overview]	Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience
NCT00716859 (10) [back to overview]	Mean IOP at Week 12
NCT00716859 (10) [back to overview]	Mean IOP at Week 1
NCT00716859 (10) [back to overview]	Mean IOP at Baseline
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 10 AM at Week 6
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 10 AM at Week 12
NCT00735449 (5) [back to overview]	Number of Subjects With Adverse Events
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 8 AM at Week 6
NCT00735449 (5) [back to overview]	Mean Intraocular Pressure (IOP) at 8 AM at Week 12
NCT00763061 (4) [back to overview]	Week 12 - Mean IOP At 4 PM
NCT00763061 (4) [back to overview]	Mean IOP Change From Baseline at 9 AM
NCT00763061 (4) [back to overview]	Mean IOP Change at 4 PM
NCT00763061 (4) [back to overview]	Mean Intraocular Pressure (IOP) at 9 AM
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks
NCT00800540 (12) [back to overview]	Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Diastolic Blood Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6
NCT00804648 (12) [back to overview]	Visual Acuity
NCT00804648 (12) [back to overview]	Stinging on Instillation
NCT00804648 (12) [back to overview]	Corneal Staining Grade
NCT00804648 (12) [back to overview]	Corneal Staining Count
NCT00804648 (12) [back to overview]	Conjunctival Staining - Temporal Grade
NCT00804648 (12) [back to overview]	Conjunctival Staining - Nasal Count
NCT00804648 (12) [back to overview]	Intraoclular Pressure
NCT00804648 (12) [back to overview]	Tear Film Break-up Time
NCT00804648 (12) [back to overview]	Conjunctival Staining - Nasal Grade
NCT00804648 (12) [back to overview]	Conjunctival Hyperemia
NCT00804648 (12) [back to overview]	Basic Schirmer's
NCT00804648 (12) [back to overview]	Conjunctival Staining - Temporal Count
NCT00811564 (1) [back to overview]	Intraocular Pressure (IOP) at Week 12
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Temporal Short Posterior Ciliary Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Central Retinal Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Ophthalmic Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (End Diastolic Velocity) as Measured by Color Doppler Imaging in the Temporal Short Posterior Ciliary Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Central Retinal Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery
NCT00811850 (8) [back to overview]	Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Ophthalmic Artery
NCT00823043 (4) [back to overview]	Subject Reported Burning/Stinging
NCT00823043 (4) [back to overview]	Subject Reported Light Sensitivity
NCT00823043 (4) [back to overview]	Subject Reported Tearing
NCT00823043 (4) [back to overview]	Subject Reported Blurred Vision
NCT00824824 (1) [back to overview]	Presence of Retinal Vascular Dysregulation (RVD)
NCT00832377 (4) [back to overview]	Mean Change in Trough IOP Measured Right Before Study Drug Administration at Week 12 Compared to Baseline IOP.
NCT00832377 (4) [back to overview]	Mean Change in the Peak Intraocular Pressure (IOP) Measured Two Hours After Study Drug Administration at Week 12 Compared to Baseline IOP.
NCT00832377 (4) [back to overview]	Mean Change in IOP 8 Hours After the Study Drug Administration at Week 12 Compared to Baseline IOP
NCT00832377 (4) [back to overview]	Baseline IOP
NCT00869141 (3) [back to overview]	Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma
NCT00869141 (3) [back to overview]	Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma
NCT00869141 (3) [back to overview]	Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase
NCT00906087 (3) [back to overview]	Intraocular Pressure in Sitting and Supine Positions.
NCT00906087 (3) [back to overview]	Blood Pressure in Sitting to Supine Positions
NCT00906087 (3) [back to overview]	Myocilin Mutation Arg272Gly in Subjects
NCT01026831 (2) [back to overview]	Baseline IOP
NCT01026831 (2) [back to overview]	Mean Intraocular Pressure (IOP) Change From Baseline at All 9 Time Points During the Study (0800, 1000 and 1600 Hrs at Weeks 2, 6, and 12)
NCT01062971 (2) [back to overview]	Number of Adverse Events
NCT01062971 (2) [back to overview]	Intraocular Pressure (IOP)
NCT01068964 (1) [back to overview]	The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4
NCT01145898 (14) [back to overview]	3-year Change in OPP
NCT01145898 (14) [back to overview]	6-month Change inOphthalmic Artery (OA) End Diastolic Velocity (EDV)
NCT01145898 (14) [back to overview]	6-month Change in Ophthalmic Artery (OA) Vascular Resistance (RI)
NCT01145898 (14) [back to overview]	6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV)
NCT01145898 (14) [back to overview]	6-month Change in Ocular Perfusion Pressures (OPP)
NCT01145898 (14) [back to overview]	6-month Change in Central Retinal Artery (CRA) Vascular Resistance (RI)
NCT01145898 (14) [back to overview]	6-month Change in Central Retinal Artery (CRA) Peak Systolic Velocity (PSV)
NCT01145898 (14) [back to overview]	3-year Change in CRA EDV
NCT01145898 (14) [back to overview]	3-year Change in CRA PSV
NCT01145898 (14) [back to overview]	3-year Change in CRA RI
NCT01145898 (14) [back to overview]	3-year Change in OA EDV
NCT01145898 (14) [back to overview]	3-year Change in OA PSV
NCT01145898 (14) [back to overview]	3-year Change in OA RI
NCT01145898 (14) [back to overview]	6-month Change in Central Retinal Artery (CRA) End Diastolic Velocity (EDV)
NCT01147601 (1) [back to overview]	Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos.
NCT01170884 (1) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 12
NCT01175902 (6) [back to overview]	Intraocular Pressure (IOP), Period 2
NCT01175902 (6) [back to overview]	OPP, Period 2
NCT01175902 (6) [back to overview]	Ocular Perfusion Pressure (OPP), Period 1
NCT01175902 (6) [back to overview]	Blood Pressure (BP), Period 2
NCT01175902 (6) [back to overview]	Intraocular Pressure (IOP), Period 1
NCT01175902 (6) [back to overview]	Blood Pressure (BP), Period 1
NCT01177098 (6) [back to overview]	Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12
NCT01177098 (6) [back to overview]	Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2
NCT01177098 (6) [back to overview]	Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6
NCT01177098 (6) [back to overview]	Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12
NCT01177098 (6) [back to overview]	Change From Baseline in Average Eye IOP at Each Hour Evaluated at Week 12
NCT01177098 (6) [back to overview]	Change From Baseline in Worse Eye IOP at Each Hour Evaluated at Week 12
NCT01191008 (3) [back to overview]	Number of Participants WithTreatment-Related Adverse Events
NCT01191008 (3) [back to overview]	Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert
NCT01191008 (3) [back to overview]	Clinical Effectiveness Rate
NCT01215786 (3) [back to overview]	Mean Concentration of AGN-207281 in Plasma at Day 7
NCT01215786 (3) [back to overview]	Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14
NCT01215786 (3) [back to overview]	Mean Concentration of AGN-207281 in Plasma at Day 14
NCT01216943 (1) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Analysis of Covariance (ANCOVA)
NCT01217606 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Mixed-Effect Model for Repeated Measure
NCT01229462 (1) [back to overview]	Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4
NCT01241240 (3) [back to overview]	Mean Worse Eye IOP
NCT01241240 (3) [back to overview]	Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12
NCT01241240 (3) [back to overview]	Change From Baseline in Mean Worse Eye IOP
NCT01243567 (5) [back to overview]	Absolute Difference Between Patient's Lowest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading
NCT01243567 (5) [back to overview]	Change From Baseline in Average Intraocular Pressure (IOP)
NCT01243567 (5) [back to overview]	Change From Baseline IOP
NCT01243567 (5) [back to overview]	Percentage of Patients Reaching a Predefined Target Pressure Threshold
NCT01243567 (5) [back to overview]	Absolute Difference Between Patient's Highest IOP Reading at Baseline (Day 0) and the Corresponding IOP Reading
NCT01254604 (4) [back to overview]	Number of Participants With an Adverse Event (AE)
NCT01254604 (4) [back to overview]	Number of Participants With ≥25% Reduction in IOP From Baseline to Week 4 - Study Eye
NCT01254604 (4) [back to overview]	Number of Participants Who Discontinued Study Drug Due to an AE
NCT01254604 (4) [back to overview]	Mean Diurnal IOP Change From Baseline at Week 4 - Study Eye
NCT01257698 (1) [back to overview]	Duration of Intraocular Gas
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP Per Prostaglandin Group at Week 12
NCT01263444 (4) [back to overview]	Percentage of Patients Reaching the Target IOP (≤ 18 mmHg)
NCT01263444 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP at Week 4
NCT01327599 (5) [back to overview]	Percentage of Subjects Who Reach Target IOP of ≤ 18 mmHg in Subjects Using Ganfort® at Baseline
NCT01327599 (5) [back to overview]	Mean Change From Baseline in IOP at Week 4 in Subjects Using Ganfort® at Baseline
NCT01327599 (5) [back to overview]	Mean Change From Baseline in Ocular Hyperemia Score at Week 12 in Subjects Using Ganfort® at Baseline
NCT01327599 (5) [back to overview]	Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Week 12 in Subjects Using Ganfort® at Baseline
NCT01327599 (5) [back to overview]	Mean Change From Baseline in IOP at Week 12 in Subjects Using Ganfort® at Baseline
NCT01336569 (1) [back to overview]	Mean Intraocular Pressure (IOP) Change at the Final Visit From Baseline (Prior Beta-blocker Monotherapy)
NCT01340014 (2) [back to overview]	Preferred Treatment
NCT01340014 (2) [back to overview]	Ocular Discomfort
NCT01342081 (1) [back to overview]	Change From Baseline in Mean Diurnal IOP(Intraocular Pressure) at End of Study
NCT01342094 (1) [back to overview]	Change From Baseline in Mean Diurnal IOP (Intraocular Pressure) at End of Study
NCT01357616 (4) [back to overview]	Mean IOP Change From Baseline at 11 AM
NCT01357616 (4) [back to overview]	Mean Diurnal IOP Change From Baseline at Week 8
NCT01357616 (4) [back to overview]	Mean IOP Change From Baseline at 9 AM
NCT01357616 (4) [back to overview]	Mean IOP Change From Baseline (5 PM) at Week 8
NCT01415401 (2) [back to overview]	Change in IOP at the Final Visit From Prior Brimonidine 0.2%/Timolol 0.5% Fixed Combination (COMBIGAN®) Therapy (i.e. From Baseline)
NCT01415401 (2) [back to overview]	Percentage of Subjects Who Reach Target IOP (≤ 18 mmHg)
NCT01484951 (2) [back to overview]	Change in Intraocular Pressure (IOP) at the Final Visit From Prior Beta-blocker Monotherapy (Timolol 0.5% Only)
NCT01484951 (2) [back to overview]	Percentage of Patients With Target IOP (≤18 mmHg), Regardless of Prior Therapy
NCT01514734 (1) [back to overview]	Change in Intraocular Pressure (IOP) at 8 Weeks From Baseline (Prior Therapy).
NCT01518244 (2) [back to overview]	Percentage of Subjects Who Reach Target IOP (≤18 mmHg) at Week 8
NCT01518244 (2) [back to overview]	Mean Change in Intraocular Pressure (IOP) From Baseline (Prior Therapy) at Week 8
NCT01547598 (5) [back to overview]	Change From Baseline in Mean IOP at Week 12
NCT01547598 (5) [back to overview]	Mean Diurnal Intraocular Pressure (IOP)
NCT01547598 (5) [back to overview]	Change From Baseline in Mean IOP at Week 6
NCT01547598 (5) [back to overview]	Percentage of Participants With ≥15% Reduction in Mean Diurnal IOP From Baseline
NCT01547598 (5) [back to overview]	Percentage of Participants With Mean Diurnal IOP Less Than 18 mmHg
NCT01628601 (5) [back to overview]	Change From Baseline in Intraocular Pressure (IOP)
NCT01628601 (5) [back to overview]	Physician Assessment of Tolerability Using a 4-Point Scale
NCT01628601 (5) [back to overview]	Physician Assessment of Adherence to GANfort®
NCT01628601 (5) [back to overview]	Patients Continuing With GANfort® After 18 Weeks
NCT01628601 (5) [back to overview]	Patient Assessment of Tolerability Using a 4-Point Scale
NCT01652664 (1) [back to overview]	Mean Change From Baseline in IOP at Month 3
NCT01677507 (3) [back to overview]	Variation in Episcleral Venous Pressure.
NCT01677507 (3) [back to overview]	Variation in Aqueous Flow Between Individuals.
NCT01677507 (3) [back to overview]	Variation in Eye Pressure Between Individuals.
NCT01707381 (3) [back to overview]	24 Hour IOP
NCT01707381 (3) [back to overview]	IOP Area Under the Curve Over 24 Hours
NCT01707381 (3) [back to overview]	24-hour Ocular Perfusion Pressure
NCT01749904 (4) [back to overview]	Response Rate - IOP Reduction ≥ 25%
NCT01749904 (4) [back to overview]	Response Rate - IOP ≤ 18 mm Hg
NCT01749904 (4) [back to overview]	Number of Participants With Ocular and Systemic Adverse Events
NCT01749904 (4) [back to overview]	Mean IOP
NCT01749930 (4) [back to overview]	Number of Participants With Ocular and Systemic Adverse Events
NCT01749930 (4) [back to overview]	IOP Reduction ≥ 25%
NCT01749930 (4) [back to overview]	IOP ≤ 18 mm Hg
NCT01749930 (4) [back to overview]	Mean IOP
NCT01752049 (1) [back to overview]	Change in Lesion Area of Treated Telangiectasia.
NCT01843920 (1) [back to overview]	Complete Resolution of Intraocular Gas Bubble
NCT01881126 (1) [back to overview]	Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
NCT01915940 (6) [back to overview]	Change From Baseline in Intra-Ocular Pressure (IOP) at Week 12
NCT01915940 (6) [back to overview]	Change From Baseline in Intra-Ocular Pressure (IOP) at Week 2
NCT01915940 (6) [back to overview]	Change From Baseline in IOP at Month 6
NCT01915940 (6) [back to overview]	Change From Baseline in IOP at Month 5
NCT01915940 (6) [back to overview]	Change From Baseline in IOP at Month 4
NCT01915940 (6) [back to overview]	Change From Baseline in Intra-Ocular Pressure (IOP) at Week 6
NCT01976624 (2) [back to overview]	Change From Baseline in Intraocular Pressure (IOP)
NCT01976624 (2) [back to overview]	Number of Participants With Adverse Events and Adverse Drug Reactions
NCT01978600 (3) [back to overview]	Mean 24-hour IOP at Week 4
NCT01978600 (3) [back to overview]	Mean Diurnal IOP at Week 4
NCT01978600 (3) [back to overview]	Mean Nocturnal IOP at Week 4
NCT01987752 (2) [back to overview]	Percentage of Participants Reporting Adverse Events
NCT01987752 (2) [back to overview]	Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)
NCT01999348 (7) [back to overview]	Percentage of Patients Who Discontinued Treatment
NCT01999348 (7) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
NCT01999348 (7) [back to overview]	Physician Assessment of IOP-Lowering Effect in the Study Eye Using a 3-Point Scale
NCT01999348 (7) [back to overview]	Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale
NCT01999348 (7) [back to overview]	Physician Assessment of Tolerability on a 4-Point Scale
NCT01999348 (7) [back to overview]	Patient Assessment of Tolerability on a 4-Point Scale
NCT01999348 (7) [back to overview]	Percentage of Patients Prescribed by the Physician to Continue Treatment
NCT02003391 (3) [back to overview]	Percentage Change From Baseline in IOP (8AM) at Week 4 in the Study Eye
NCT02003391 (3) [back to overview]	Mean Change From Baseline in IOP (8AM) at Week 4 in the Study Eye
NCT02003391 (3) [back to overview]	Least Squares Mean Intraocular Pressure (IOP) at 8AM in the Study Eye
NCT02097719 (1) [back to overview]	Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
NCT02207491 (2) [back to overview]	Intraocular Pressure (IOP)
NCT02207491 (2) [back to overview]	Extent of Exposure
NCT02207621 (2) [back to overview]	Intraocular Pressure (IOP)
NCT02207621 (2) [back to overview]	Extent of Exposure
NCT02246764 (1) [back to overview]	Extent of Exposure
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 12 (Hour 2)
NCT02247804 (8) [back to overview]	Change From Baseline in IOP in the Study Eye at Week 12 (Hours 0 and 2)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 12 (Hour 0)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 2 (Hour 2)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 2 (Hour 0)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 6 (Hour 0)
NCT02247804 (8) [back to overview]	IOP in the Study Eye at Week 6 (Hour 2)
NCT02247804 (8) [back to overview]	Change From Baseline in IOP in the Study Eye
NCT02250612 (3) [back to overview]	Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
NCT02250612 (3) [back to overview]	Change From Baseline in the Glaucoma Quality of Life Questionnaire (GQL-15) Scores Within Each Treatment Arm
NCT02250612 (3) [back to overview]	Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 6 (Hour 2)
NCT02250651 (8) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) in the Study Eye to Week 12 (Hours 0 and 2)
NCT02250651 (8) [back to overview]	Change From Baseline in IOP in the Study Eye
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 6 (Hour 0)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 12 (Hour 2)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 2 (Hour 2)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 12 (Hour 0)
NCT02250651 (8) [back to overview]	IOP in the Study Eye at Week 2 (Hour 0)
NCT02278614 (1) [back to overview]	Non-inferiority of T2347 Compared With Xalacom® on Change in Mean IOP at 9.00 am (± 1 Hour) Between the Baseline (Day 0) and Day 84 in the Worse Eye
NCT02325518 (2) [back to overview]	Least Squares Mean Change From Baseline in IOP at 9 AM
NCT02325518 (2) [back to overview]	Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AM
NCT02358369 (13) [back to overview]	Dilated Fundus Exam: Cup-to-Disc-Ratio
NCT02358369 (13) [back to overview]	Percentage of Participants With Clinically Significant Change From Baseline in Slit-Lamp Examination Findings at Week 12
NCT02358369 (13) [back to overview]	Change From Baseline in Automated Visual Field at Week 12
NCT02358369 (13) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) at Week 8
NCT02358369 (13) [back to overview]	Change From Baseline in IOP at Week 12
NCT02358369 (13) [back to overview]	Change From Baseline in IOP at Week 6
NCT02358369 (13) [back to overview]	Change From Baseline in IOP in Period C
NCT02358369 (13) [back to overview]	Percentage of Participants by Change From Baseline in Best-corrected Visual Acuity (BCVA) Categories at Week 12
NCT02358369 (13) [back to overview]	Percentage of Participants by Change From Baseline in Best-corrected Visual Acuity (BCVA) Categories at Week 8
NCT02358369 (13) [back to overview]	Change From Baseline in IOP at Week 2
NCT02358369 (13) [back to overview]	Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity in Period A/B
NCT02358369 (13) [back to overview]	Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity in Period C
NCT02358369 (13) [back to overview]	Percentage of Participants by Dilated Fundus Exam Pathology Grade at Week 12
NCT02558374 (2) [back to overview]	IOP (Intraocular Pressure)
NCT02558374 (2) [back to overview]	Extent of Exposure
NCT02571972 (4) [back to overview]	Maximum Pigment Epithelial Detachment Height
NCT02571972 (4) [back to overview]	Maximum Subretinal Fluid Height
NCT02571972 (4) [back to overview]	Mean Central Subfield Thickness (CST)
NCT02571972 (4) [back to overview]	Visual Acuity
NCT02630719 (1) [back to overview]	Timolol Eye Drops in the Treatment of Acute Migraine Headache
NCT02730871 (5) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02730871 (5) [back to overview]	Mean Change From Baseline in IOP (09:00, 11:00) at Week 6
NCT02730871 (5) [back to overview]	Mean Percentage Change From Baseline in IOP (09:00, 11:00) at Week 6
NCT02730871 (5) [back to overview]	Mean Change From Baseline in Diurnal Intraocular Pressure (IOP) (Mean of Changes at 09:00 and 11:00 Time Points) at Week 6
NCT02730871 (5) [back to overview]	Mean Diurnal IOP at Week 6
NCT02742649 (7) [back to overview]	IOP on Day 28
NCT02742649 (7) [back to overview]	Intraocular Pressure (IOP) on Day 8
NCT02742649 (7) [back to overview]	IOP During Open Label Period
NCT02742649 (7) [back to overview]	IOP on Day 16
NCT02742649 (7) [back to overview]	Number of Participants With Ocular and Non-Ocular Adverse Events
NCT02742649 (7) [back to overview]	IOP on Day 70
NCT02742649 (7) [back to overview]	IOP on Day 49
NCT02754596 (2) [back to overview]	Severe Adverse Events
NCT02754596 (2) [back to overview]	IOP (mmHg) Change From Baseline at Week 12
NCT02913612 (9) [back to overview]	Change in Hemangioma Quality of Life (IH-QoL) Assessment for Infants
NCT02913612 (9) [back to overview]	Change in Hemangioma Dynamic Complication Scale (HDCS)
NCT02913612 (9) [back to overview]	Number of Participants With Partial Response in Hemangioma Color as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls
NCT02913612 (9) [back to overview]	Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls
NCT02913612 (9) [back to overview]	Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm
NCT02913612 (9) [back to overview]	Comparison of Partial Response of Hemangioma Color From Baseline to 180 Days, Within Each Treatment Arm
NCT02913612 (9) [back to overview]	Number of Participants Who Reach Partial Response, Assessed by Hemangioma Color
NCT02913612 (9) [back to overview]	Number of Participants Who Reach Partial Response, Assessed by Volume
NCT02913612 (9) [back to overview]	Number of Serious Adverse Events and Adverse Events of Special Interest in Infants Treated With Topical Timolol Maleate
NCT03034772 (5) [back to overview]	Change in Visual Acuity
NCT03034772 (5) [back to overview]	Change in Mean Maximum Subretinal Fluid (SRF) Height
NCT03034772 (5) [back to overview]	Change in Mean Maximum Pigment Epithelial Detachment (PED) Height
NCT03034772 (5) [back to overview]	Change in Mean Intraocular Pressure (IOP)
NCT03034772 (5) [back to overview]	Change in Mean Central Subfield Thickness (CST)
NCT03257813 (8) [back to overview]	Number of Eyes With Foreign Body Sensation
NCT03257813 (8) [back to overview]	Number of Eyes With Tearing
NCT03257813 (8) [back to overview]	Visual Acuity (VA)
NCT03257813 (8) [back to overview]	Conjunctival Hyperemia
NCT03257813 (8) [back to overview]	Chemosis
NCT03257813 (8) [back to overview]	Adverse Events
NCT03257813 (8) [back to overview]	Intraocular Pressure (IOP)
NCT03257813 (8) [back to overview]	Eye Burning
NCT03323164 (6) [back to overview]	Comparison of Percent Changes in Optic Nerve Head Flow Index in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Comparison of Percent Changes in Optic Nerve Head Vessel Density in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Comparison of Percent Changes in Peripapillary Vessel Density in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Comparison of Percent Changes in Peripapillary Flow Index in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography
NCT03323164 (6) [back to overview]	Changes in Flow Index in Treatment Groups Assessed by OCT Angiography
NCT03691649 (8) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 1 (Third Key Secondary Endpoint)
NCT03691649 (8) [back to overview]	Intraocular Pressure (IOP) at Week 1 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)
NCT03691649 (8) [back to overview]	Intraocular Pressure (IOP) at Week 6 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)
NCT03691649 (8) [back to overview]	Intraocular Pressure at Month 3
NCT03691649 (8) [back to overview]	Intraocular Pressure at Week 1
NCT03691649 (8) [back to overview]	Intraocular Pressure at Week 6
NCT03691649 (8) [back to overview]	Intraocular Pressure (IOP) at Month 3 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)
NCT03691649 (8) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Month 3 (First Key Secondary Endpoint)
NCT03691662 (8) [back to overview]	Intraocular Pressure (IOP) at Week 6
NCT03691662 (8) [back to overview]	Intraocular Pressure (IOP) at Week 1 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)
NCT03691662 (8) [back to overview]	Intraocular Pressure (IOP) at Week 1
NCT03691662 (8) [back to overview]	Intraocular Pressure (IOP) at Month 3 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)
NCT03691662 (8) [back to overview]	Intraocular Pressure (IOP) at Month 3
NCT03691662 (8) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 1 (Third Key Secondary Endpoint)
NCT03691662 (8) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Month 3 (First Key Secondary Endpoint)
NCT03691662 (8) [back to overview]	Intraocular Pressure (IOP) at Week 6 With Baseline Mean Diurnal IOP Less Than 25 mmHg (Second Key Secondary Endpoint)
NCT03836664 (3) [back to overview]	Number of Participants Satisfied With Intervention
NCT03836664 (3) [back to overview]	Adverse Reaction From Using Timolol Eye Drops
NCT03836664 (3) [back to overview]	Headache Severity
NCT03966365 (7) [back to overview]	Changes in Intraocular Pressure
NCT03966365 (7) [back to overview]	Eye Comfort Index
NCT03966365 (7) [back to overview]	Number of Adverse Events
NCT03966365 (7) [back to overview]	Participants With Chemosis
NCT03966365 (7) [back to overview]	Visual Ability
NCT03966365 (7) [back to overview]	Number of Eyes With Epithelial Defects by Grade
NCT03966365 (7) [back to overview]	Participants With Conjunctival Hyperemia (CH) by Grade
NCT04139018 (1) [back to overview]	Change in Assisted Epistaxis Severity Scale (aESS) Score From Baseline at 8 Week Follow-up
NCT04149899 (2) [back to overview]	Part 2: Mean Change From Baseline in Intraocular Pressure (IOP) at Day 14 - Study Eye
NCT04149899 (2) [back to overview]	Part 2: Mean IOP at Day 14 - Study Eye
NCT04742283 (4) [back to overview]	Mean Diurnal Intraocular Pressure at Month 3
NCT04742283 (4) [back to overview]	Intraocular Pressure at Month 3
NCT04742283 (4) [back to overview]	Intraocular Pressure at Week 6
NCT04742283 (4) [back to overview]	Intraocular Pressure at Week 2

Diurnal Intraocular Pressure Control

Change from baseline in mean diurnal IOP (measured every two hours from 8AM to 8PM) averaged across on-treatment study visits (week 1, months 1, 6, 12) (NCT00379834)
Timeframe: 12 months

Intervention	millimeters of mercury (Mean)
Cosopt	-4.4

Intervention	mmHg (Least Squares Mean)
MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	-2.50
Timolol 0.5%	-1.82
Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	-2.78

Intervention	Percent Change (Least Squares Mean)
MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	23.47
Timolol 0.5%	17.17
Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	26.75

Intervention	Percent Change (Least Squares Mean)
MK0507A (Dorzolamide 1.0% / Timolol 0.5% Combination)	-11.99
Timolol 0.5%	-8.74
Concomitant (Dorzolamide 1.0% / Timolol 0.5%)	-13.46

Intervention	mm Hg (millimeters mercury)*week (Mean)
	Week 8	Week 16	Week 24
Crossover Group ABB	179.20	188.82	201.50
Crossover Group BAA	191.89	196.26	191.93

Intervention	percentage of adherent patients (Number)
Travalert With Travoprost/Timolol Fixed Combination	63
Travalert With Travoprost and Timolol	43

Intervention	Units on a Scale (Mean)
Preservative-free Dorzolamide-timolol (COSOPT®) Week 4	1.7
Preservative-free Dorzolamide-timolol (COSOPT®) Week 8	3.2

Intervention	mm Hg (Mean)
Preservative-free Dorzolamide-timolol (COSOPT®) Week 4	-11.7
Preservative-free Dorzolamide-timolol (COSOPT®) Week 8	-11.5

Intervention	Participants (Number)
	Very Satisfied	Satisfied	Neither Satisfied or Dissatisfied	Dissatisfied	Very Dissatisfied	Missing
Preservative-free COSOPT® at Week 8	79	65	11	6	3	6

Intervention	µL/min per mm Hg (Mean)
	day time fluorophotometry	daytime tonography	night tonography
Dorzolamide	0.14	0.58	0.12
Latanoprost	0.43	0.90	0.26
Timolol	-0.16	0.70	0.50

Intervention	μL/min (Mean)
	day time	night time
Dorzolamide	1.75	1.1
Latanoprost	2.09	1.1
Timolol	1.57	1.1

Intervention	mmHg (Mean)
	Daytime	Night time
Dorzolamide	20.2	17.6
Latanoprost	17.6	17.0
Timolol	16.4	17.1

Intervention	mmHg (Mean)
	systolic day time	systolic night time	diastolic day time	diastolic night time
Dorzolamide	139	138	83	82
Latanoprost	136	143	78	83
Timolol	138	136	81	79

Intervention	cm/s (centimeters per second) (Mean)
	9:00 am	1:00 pm	5:00 pm	9:00 pm	12:00 am	3:00 am	6:00 am
AZARGA	-0.01	0.02	0.01	0.01	-0.01	0.01	0.01
COMBIGAN	-0.01	0.02	0.01	0.01	0.02	0.03	0.03

Intervention	number of letters (Mean)
Timolol Hemihydrate 0.5%	52.3
Timolol Maleate 0.5%	52.5
Timolol Maleate Gel Forming Solution 0.5%	51.4

Intervention	Number of spots (Mean)
Timolol Hemihydrate 0.5%	10.5
Timolol Maleate 0.5%	10.4
Timolol Maleate Gel Forming Solution 0.5%	8.3

Intervention	number of spots (Mean)
Timolol Hemihydrate 0.5%	11.0
Timolol Maleate 0.5%	10.3
Timolol Maleate Gel Forming Solution 0.5%	12.9

Intervention	mm of mercury (Mean)
Timolol Hemihydrate 0.5%	16.3
Timolol Maleate 0.5%	16.2
Timolol Maleate Gel Forming Solution 0.5%	16.2

Intervention	mm of moisture (Mean)
Timolol Hemihydrate 0.5%	17.7
Timolol Maleate 0.5%	14.8
Timolol Maleate Gel Forming Solution 0.5%	15.4

Intervention	Millimeters of mercury (mm Hg) (Mean)
Fixed Combination of Brimonidine Tartrate 0.2%/Timolol Maleate	17.75
Latanoprost 0.005% Ophthalmic Solution	17.90

Intervention	mmHg in 1 year postop (Mean)
Hypertensive Phase Group	15.1
Non-hypertensive Phase Group	11.4

Intervention	mmHg (Mean)
	Sitting right eye	Sitting left eye	Supine right eye	Supine left eye
Cosopt	18.5	19.4	22.2	22.8

timolol

Description

Cross-References

Synonyms (90)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (1)

Protein Targets (43)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (98)

Molecular Functions (49)

Ceullar Components (30)

Bioassays (263)

Research

Studies (3,612)

Study Types

Clinical Trials (266)

Trial Overview

Trial Outcomes

Diurnal Intraocular Pressure Control

Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks

Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks

Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks

Intaocular Pressure (IOP) Mean Change After 6 Weeks of Treatment

Intra Ocular Pressure (IOP)

Adherence

Change in Glaucoma Symptom Scale (GSS)-SYMP-6 Score

Change in Intra-ocular Pressure (IOP) for Worse Eye From Baseline to Week 4 and From Baseline to Week 8, in Patients Receiving Preservative-free Dorzolamide-timolol

Patient's Global Satisfaction

Physician's Global Satisfaction

Uvescleral Outflow

Aqueous Flow

Episcleral Venous Pressure

Anterior Chamber Volume

Outflow Facility

Intraocular Pressure

Central Corneal Thickness

Blood Pressure

Mean IOP at Week 4

Reduction From Baseline in Mean IOP at Week 4

Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)

Reduction From Baseline in Mean IOP at Week 12 (Observed)

Reduction From Baseline in Mean IOP at Week 1

Percentage of Participants With Greater Than or Equal to (≥) 15% IOP Reduction From Baseline at Both Weeks 4 and 12

Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience

Mean IOP at Week 12

Mean IOP at Week 1

Mean IOP at Baseline

Mean Intraocular Pressure (IOP) at 10 AM at Week 6

Mean Intraocular Pressure (IOP) at 10 AM at Week 12

Number of Subjects With Adverse Events

Mean Intraocular Pressure (IOP) at 8 AM at Week 6

Mean Intraocular Pressure (IOP) at 8 AM at Week 12

Week 12 - Mean IOP At 4 PM

Mean IOP Change From Baseline at 9 AM

Mean IOP Change at 4 PM

Mean Intraocular Pressure (IOP) at 9 AM

Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks

Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6

Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6

Mean Change From Baseline in Diastolic Blood Pressure at Week 6

Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6

Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6

Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6

Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6

Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6

Mean Change From Baseline in Systolic Blood Pressure at Week 6

Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6

Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6

Visual Acuity

Stinging on Instillation

Corneal Staining Grade

Corneal Staining Count

Intervention	mmHg (Mean)
	Sitting systolic blood pressure	Supine systolic blood pressure	Sitting diastolic blood pressure	Supine diastolic blood pressure
Cosopt	139.6	133.8	86.8	89.3

Intervention	mmHg (Least Squares Mean)
	Baseline 0800 timepoint (n=299; n=313)	Baseline 1000 timepoint (n=299; n=313)	Baseline 1600 timepoint (n=296; n=312)
Tafluprost	26.1	24.8	23.8
Timolol Maleate	26.0	24.6	23.5

Intervention	mmHg (Least Squares Mean)
	Week 2 - 0800 (n=280; n=295)	Week 2 - 1000 (n=293; n=305)	Week 2 - 1600 (n=289; n=302)	Week 6 - 0800 (n=294; n=308)	Week 6 - 1000 (n=298; n=312)	Week 6 - 1600 (n=295; n=310)	Week 12 - 0800 (n=296; n=308)	Week 12 - 1000 (n=298; n=312)	Week 12 - 1600 (n=295; n=310)
Tafluprost	-7.1	-6.8	-6.2	-7.3	-7.0	-6.3	-7.4	-7.0	-6.2
Timolol Maleate	-6.8	-6.1	-5.3	-7.4	-6.6	-5.5	-7.5	-6.6	-5.7

Intervention	mmHg (Mean)
	baseline	Final
A (Triple Therapy)	24.1	13.9
B (Doble Therapy)	23.6	16.9

Intervention	Millimeters of mercury (mmHg) (Mean)
	Baseline	Change from Baseline at Week 4
0.03% Bimatoprost and 0.5% Timolol in Separate Bottles	24.87	-8.93
0.03% Bimatoprost/0.5% Timolol in Same Bottle	25.20	-9.38

Intervention	mmHg (Mean)
	IOP at 8am	IOP at 10am	IOP at 12pm	IOP at 16pm	IOP at 20pm
Dorzolamide/Timolol, Period 2	12.36	12.36	12.72	13.04	13.13
Latanoprost, Period 2	13.13	12.81	12.54	12.81	13.40

Intervention	mmHg (Mean)
	OPP at 8am	OPP at 10am	OPP at 12pm	OPP at 16pm	OPP at 20pm
Dorzolamide/Timolol, Period 2	46.71	46.07	45.90	44.99	46.70
Latanoprost, Period 2	48.36	48.04	48.47	47.81	47.10

Intervention	mmHg (Mean)
	systolic BP at 8am	systolic BP at 10am	systolic BP at 12pm	systolic BP at 16pm	systolic BP at 20pm	diastolic BP at 8am	diastolic BP at 10am	diastolic BP at 12pm	diastolic BP at 16pm	diastolic BP at 20pm
Dorzolamide/Timolol, Period 2	118.41	117.95	119.05	118.45	119.82	73.72	72.50	72.40	71.36	74.72
Latanoprost, Period 2	123.14	123.59	122.41	124.50	123.23	76.45	74.86	75.54	73.45	73.81

Intervention	mm Hg (Mean)
	Week 12_Hour 0	Week 12_Hour 2	Week 12_Hour 8
Bimatoprost/Timolol Fixed Combination Ophthalmic Solution	16.56	16.37	16.09
Bimatoprost/Timolol Formulation A	16.29	16.18	15.85

Intervention	mm Hg (Mean)
	Week 2_Hour 0	Week 2_Hour 2	Week 2_Hour 8
Bimatoprost/Timolol Fixed Combination Ophthalmic Solution	16.49	16.23	15.83
Bimatoprost/Timolol Formulation A	16.23	16.05	15.49